<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004885.pub2" GROUP_ID="HAEMATOL" ID="509603122910240643" MERGED_FROM="" MODIFIED="2008-11-06 10:58:53 +0100" MODIFIED_BY="Nicole Skoetz" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-06 10:58:53 +0100" NOTES_MODIFIED_BY="Nicole Skoetz" REVIEW_NO="001" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-11-06 10:58:53 +0100" MODIFIED_BY="Nicole Skoetz">
<TITLE>Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation</TITLE>
<CONTACT>
<PERSON ID="18252" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Susanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Quellmann</LAST_NAME>
<SUFFIX/>
<POSITION>Pharmacist, MSc, PhD</POSITION>
<EMAIL_1>s.quellmann@email.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 710 ext: 77025</PHONE_1>
<PHONE_2/>
<FAX_1>+49 221 710 77024</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-06 10:46:29 +0100" MODIFIED_BY="Nicole Skoetz">
<PERSON ID="18252" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Susanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Quellmann</LAST_NAME>
<SUFFIX/>
<POSITION>Pharmacist, MSc, PhD</POSITION>
<EMAIL_1>s.quellmann@email.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 710 ext: 77025</PHONE_1>
<PHONE_2/>
<FAX_1>+49 221 710 77024</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5936" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Guido</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schwarzer</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>sc@imbi.uni-freiburg.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical Biometry and Statistics</DEPARTMENT>
<ORGANISATION>German Cochrane Center</ORGANISATION>
<ADDRESS_1>University Medical Center</ADDRESS_1>
<ADDRESS_2>Stefan-Meier-Str. 26</ADDRESS_2>
<CITY>Freiburg</CITY>
<ZIP>D-79104</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 761 203 6668</PHONE_1>
<PHONE_2/>
<FAX_1>+49 761 203 6680</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="527F159982E26AA201BA4B54166A4141" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kai</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hübel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>kai.huebel@uni-koeln.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49-221-478 ext: 4407</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13760" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alexander</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Greb</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>alexandergreb@freenet.de</EMAIL_1>
<EMAIL_2>info@chmg.de</EMAIL_2>
<URL/>
<MOBILE_PHONE>+49 170 8605061</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION/>
<ADDRESS_1>Carl Schurz Strasse 8</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50935</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 221 5103138</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8933" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Andreas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Engert</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Senior Consultant</POSITION>
<EMAIL_1>a.engert@uni-koeln.de</EMAIL_1>
<EMAIL_2>baerbel.baecker@uk-koeln.de</EMAIL_2>
<URL>www.chmg.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 478 5933</PHONE_1>
<PHONE_2>+49 221 478 5966</PHONE_2>
<FAX_1>+49 221 478 3778</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19365" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Julia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bohlius</LAST_NAME>
<SUFFIX>MPH</SUFFIX>
<POSITION/>
<EMAIL_1>julia.bohlius@uk-koeln.de</EMAIL_1>
<EMAIL_2>jbohlius@ispm.unibe.ch</EMAIL_2>
<URL>www.chmg.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Haematological Malignancies Group, Department I of Internal Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Cologne</ORGANISATION>
<ADDRESS_1>Kerpener Str. 62</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cologne</CITY>
<ZIP>50924</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 221 710770 25</PHONE_1>
<PHONE_2>+49 221 478 0</PHONE_2>
<FAX_1>+49 221 710770 24</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-08-13 14:49:41 +0200" MODIFIED_BY="Nicole Skoetz" NOTES="&lt;p&gt;Minor update: 9/1/07&lt;/p&gt;" NOTES_MODIFIED="2008-08-13 14:49:41 +0200" NOTES_MODIFIED_BY="Nicole Skoetz">
<UP_TO_DATE>
<DATE DAY="28" MONTH="1" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="2" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-06 10:58:53 +0100" MODIFIED_BY="Nicole Skoetz">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-06 10:58:46 +0100" MODIFIED_BY="Nicole Skoetz">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Typo correction</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-06 10:58:53 +0100" MODIFIED_BY="Nicole Skoetz">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-06 10:58:53 +0100" MODIFIED_BY="Nicole Skoetz">
<DATE DAY="14" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-05-14 15:05:52 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-05-14 15:05:52 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-05-14 15:05:52 +0200" MODIFIED_BY="[Empty name]">
<NAME>Köln Fortune</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>Funding programme &#8220;Köln Fortune&#8221; , Medical Faculty University of Cologne</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-05-14 15:05:06 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-05-14 15:05:06 +0200" MODIFIED_BY="[Empty name]">
<NAME>BMBF</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>The Editorial Base is funded by Federal Ministry of Education and Research (BMBF) No : 01GH0501</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-06 10:54:40 +0100" MODIFIED_BY="Nicole Skoetz">
<SUMMARY MODIFIED="2008-11-06 10:52:21 +0100" MODIFIED_BY="Nicole Skoetz">
<TITLE MODIFIED="2008-04-24 21:21:56 +0200" MODIFIED_BY="[Empty name]">Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-06 10:52:21 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Some types of blood cancer can be treated by transplanting stem cells from the patient's blood relatives or siblings. Unfortunately, transplanted stem cells (also called the 'graft') can sometimes induce an inflammatory reaction in the patient (or the 'host'). This reaction is called 'graft-versus-host disease' (GvHD), and once it occurs it is difficult to treat. GvHD can adversely affect the patient's quality of life and often causes death. Drug therapies have been developed to prevent GvHD. Even so, many patients still suffer this complication. Preventive therapy against GvHD must be optimised. Since corticosteroids are the first-line treatment used after GvHD occurs, it is a hypothesis that if used in prophylaxis regimens, corticosteroids can decrease the occurrence of GvHD and improve patient survival rates.</P>
<P>Five RCTs involving 604 people were included in this review. Analyses of these studies showed that the incidence of moderate forms of GvHD can be reduced by prophylactic corticosteroid regimens. However, there is no evidence that the incidence of life-threatening forms or patient mortality can be reduced. Effects on quality of life could not be estimated because this information was not systematically collected during these studies. Further studies are needed to determine if the timing of steroid administration influences the outcomes of GvHD.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-14 14:55:56 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-05-14 11:35:50 +0200" MODIFIED_BY="[Empty name]">
<P>Despite ongoing progress, acute and chronic GvHD still represent major drawbacks in the context of allogeneic myeloablative haematopoietic stem cell transplantation (HSCT) due to their high morbidity and mortality. Corticosteroids are used as first-line treatment of acute and chronic GvHD. However, their role for preventing GvHD is unclear as the published study results are controversial. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-05-14 12:04:55 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of corticosteroids used for the prophylaxis of GvHD in adults following allogeneic myeloablative HSCT. in improving overall survival, disease-free survival, relapse incidence, non-relapse mortality, acute GvHD grade I to IV, II to IV and III to IV, chronic GvHD, incidence of infectious complications, other adverse effects and cause of deaths.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-05-14 11:36:05 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Haematological Malignancies Group trials register, CENTRAL (<I>The Cochrane Library </I>Issue 2, 2004), MEDLINE (January 1999 to February 2006), EMBASE (January 1999 to 2004), LILACS covering publications until 2004, as well as handsearched conference proceedings, including citations until 2005.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCT) comparing the addition of corticosteroids to a GvHD prophylaxis regimen in adult patients having undergone allogeneic myeloablative HSCT were included into the review. All types and stages of the underlying disease as well as all types of possible HLA-matching were considered.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Trial eligibility and quality assessment, data extraction and analysis were done in duplicate.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-05-14 14:55:56 +0200" MODIFIED_BY="[Empty name]">
<P>Five RCTs involving 604 people were included. The pooled results revealed that the addition of corticosteroids reduces statistically significant the risk for acute GvHD grade I to IV (HR 0.58; 95% CI 0.45 to 0.76) and II to IV (HR 0.69; 95% CI 0.51 to 0.92). No evidence was found that it has any clinical relevance on overall survival (HR 0.99; 95% CI 0.79 to 1.25) or disease-free survival (HR 0.95; 95% CI 0.74 to 1.23). As well, no statistically significant influence was found for acute GvHD grade III to IV (HR 0.78; 95% CI 0.52 to 1.15), chronic GvHD (HR 1.21;95% CI 0.89 to 1.65]), relapse incidence (HR 0.82; 95% CI 0.57 to 1.18) or non-relapse mortality (HR 0.88;95% CI 0.61 to 1.26). No clear evidence was found that the rate of infectious complications (under the concomitant use of antiviral or antibacterial medication or both) increases with the addition of corticosteroids. With respect to the other outcomes no significant differences could be detected.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-05-14 14:55:33 +0200" MODIFIED_BY="[Empty name]">
<P>The addition of corticosteroids reduces the incidences of acute GvHD grade I to IV and II to IV. This reduction, however, did not show any effect on overall survival and disease-free survival. Further randomised controlled studies are needed to evaluate if the timing of steroid administration has a significant influence on the outcome; data on quality of life should be assessed systematically.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-06 10:54:40 +0100" MODIFIED_BY="Nicole Skoetz">
<BACKGROUND MODIFIED="2008-11-06 10:52:30 +0100" MODIFIED_BY="Nicole Skoetz">
<P>The transplantation of allogeneic haematopoietic stem cells (HSCT) preceded by the use of a myeloablative conditioning regimen (consisting of high doses of chemotherapeutic agents with or without total body irradiation (TBI)) provides a reasonable therapeutic approach for a variety of malignant or inherited diseases of the lympho-haematopoietic system, e.g. acute or chronic leukaemia, severe aplastic anaemia or thalassaemia (<LINK REF="REF-Bensinger-2004" TYPE="REFERENCE">Bensinger 2004</LINK>; <LINK REF="REF-Cutler-2005" TYPE="REFERENCE">Cutler 2005</LINK>; <LINK REF="REF-Deeg-2006a" TYPE="REFERENCE">Deeg 2006a</LINK>; <LINK REF="REF-Diaconescu-2005" TYPE="REFERENCE">Diaconescu 2005</LINK>; <LINK REF="REF-Horowitz-2004" TYPE="REFERENCE">Horowitz 2004</LINK>; <LINK REF="REF-Sawyers-1999" TYPE="REFERENCE">Sawyers 1999</LINK>). In this context the occurrence of graft-versus-host disease (GvHD) (previously named secondary disease, runt disease or wasting syndrome) remains one of the major drawbacks limiting its wider application: it is considered as the main cause for transplant-related morbidity - with major impact on patients' quality of life - and mortality (<LINK REF="REF-Billingham-1966" TYPE="REFERENCE">Billingham 1966</LINK>; <LINK REF="REF-Chao-2006" TYPE="REFERENCE">Chao 2006</LINK>; <LINK REF="REF-Deeg-2006b" TYPE="REFERENCE">Deeg 2006b</LINK>; <LINK REF="REF-Ferrara-2004" TYPE="REFERENCE">Ferrara 2004</LINK>; <LINK REF="REF-Ferrara-2006" TYPE="REFERENCE">Ferrara 2006</LINK>; <LINK REF="REF-Sullivan-2004" TYPE="REFERENCE">Sullivan 2004</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). GvHD can be described as an excessive unintended inflammatory reaction caused by donor lymphocytes interacting in a milieu that facilitates inflammation. With respect to the kinetic and different pathobiological pathways GvHD has been recognised as two separate entities, an acute and a chronic form (<LINK REF="REF-Ferrara-2004" TYPE="REFERENCE">Ferrara 2004</LINK>).</P>
<P>By definition, acute GvHD develops within the first 100 days after allogeneic HSCT and is characterised by a triad of symptoms: dermatitis, hepatitis and gastroenteritis (<LINK REF="REF-Ferrara-2004" TYPE="REFERENCE">Ferrara 2004</LINK>). The pathophysiology of acute GvHD consists - according to the current standard of knowledge - of three steps (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Ferrara-2006" TYPE="REFERENCE">Ferrara 2006</LINK>; <LINK REF="REF-Ferrara-2007" TYPE="REFERENCE">Ferrara 2007</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>):<BR/>(I) Before donor cells are infused the pre-transplant conditioning regimen causes tissue damage and activates host antigen-presenting cells (APC) to release inflammatory cytokines, mainly IL-1 and TNF-&#945;. TBI in particular is considered to cause epithelial injury to the gastrointestinal mucosa allowing microbial products such as lipopolysaccharides reach into systemic circulation, which amplifies further release of inflammatory cytokines.<BR/>(II) After stem cell infusion donor T cells recognise disparate human leukocyte antigens (HLA) on host tissue cells. Host APCs presenting antigens on the surface lead to activation and proliferation of donor T cells. Activated Th-1-cells (T helper cells type 1 subset) commence to secret additional inflammatory cytokines such as IL-2 and IFN-g.<BR/>(III) In the effector phase, target tissues are destructed by cytotoxic T lymphocytes and natural killer cells due to synergistic interactions of the components generated in the former steps.</P>
<P>The median incidence of clinically significant grades of acute GvHD (grade II to IV) is about 40%, but ranges - according to risk factors - from 10% to 80%, the treatment-related mortality can exceed 90% for grade IV (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Cahn-2005" TYPE="REFERENCE">Cahn 2005</LINK>; <LINK REF="REF-Gratwohl-1995" TYPE="REFERENCE">Gratwohl 1995</LINK>; <LINK REF="REF-Przepiorka-1995" TYPE="REFERENCE">Przepiorka 1995</LINK>; <LINK REF="REF-Rowlings-1997" TYPE="REFERENCE">Rowlings 1997</LINK>; <LINK REF="REF-Sullivan-2004" TYPE="REFERENCE">Sullivan 2004</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). Patients experiencing acute GvHD grade I seem to have the most favourable prognosis, which is credited to the graft-versus-leukaemia (GvL) effect (<LINK REF="REF-Glucksberg-1974" TYPE="REFERENCE">Glucksberg 1974</LINK>; <LINK REF="REF-Gratwohl-1995" TYPE="REFERENCE">Gratwohl 1995</LINK>; <LINK REF="REF-Ringden-1996" TYPE="REFERENCE">Ringden 1996</LINK>). GvL is an immune reaction of the graft against malignant cells - mediated by allo-reactive T cells of the donor recognising disparate antigens on the cells of the recipient - and implies a curative potential decreasing the number of deaths due to relapses (<LINK REF="REF-Burroughs-2005" TYPE="REFERENCE">Burroughs 2005</LINK>; <LINK REF="REF-Feinstein-2001" TYPE="REFERENCE">Feinstein 2001</LINK>; <LINK REF="REF-Ringden-1996" TYPE="REFERENCE">Ringden 1996</LINK>; <LINK REF="REF-Sandmaier-2004" TYPE="REFERENCE">Sandmaier 2004</LINK>;<LINK REF="REF-Toze-2005" TYPE="REFERENCE">Toze 2005</LINK>). The most powerful risk factor for the development of acute GvHD is a mismatch between donor and recipient at the major histocompatibility complex (MHC): the MHC contains genes which encode HLA involved in the presentation of peptides (<LINK REF="REF-Carreras-2006" TYPE="REFERENCE">Carreras 2006</LINK>; <LINK REF="REF-Deeg-2006b" TYPE="REFERENCE">Deeg 2006b</LINK>; <LINK REF="REF-Vogelsang-2003" TYPE="REFERENCE">Vogelsang 2003</LINK>). With the level of HLA-mismatch the incidence of acute GvHD increases, especially at the HLA-DRB1 allele (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Ferrara-2005" TYPE="REFERENCE">Ferrara 2005</LINK>). However, even in HLA-matched siblings acute GvHD remains a severe problem due to minor histocompatibility antigen (mHA) mismatches (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Chao-2006" TYPE="REFERENCE">Chao 2006</LINK>; <LINK REF="REF-Przepiorka-2000" TYPE="REFERENCE">Przepiorka 2000</LINK>). Other risk factors are sex mismatch, especially between female donors and male recipients, and increased age of donors or recipients or both; also donor parity and cytomegalovirus positivity have been associated with an increased risk (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Carreras-2006" TYPE="REFERENCE">Carreras 2006</LINK>; <LINK REF="REF-Deeg-2006b" TYPE="REFERENCE">Deeg 2006b</LINK>; <LINK REF="REF-Gale-1987" TYPE="REFERENCE">Gale 1987</LINK>). Also the immunomodulation is considered as an influencing factor: an increased dose of TBI is associated with an increased risk of acute GvHD (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Goldberg-2005" TYPE="REFERENCE">Goldberg 2005</LINK>; <LINK REF="REF-Perez_x002d_Simon-2005" TYPE="REFERENCE">Perez-Simon 2005</LINK>). Furthermore the source of haematopoietic stem cells matters: a recent meta-analysis revealed that acute GvHD grade III-IV occurred more often after peripheral blood stem cell transplantation (PBSCT) than after bone marrow transplantation (BMT) (<LINK REF="REF-Stem-Cell-Trialists_x0027_-Collaborative-Group-2005" TYPE="REFERENCE">Stem Cell Trialists' Collaborative Group 2005</LINK>). This finding is presumably due to the 1 to 2 log higher number of T cells in peripheral blood stem cell products (<LINK REF="REF-Cutler-2005" TYPE="REFERENCE">Cutler 2005</LINK>). According to the recent annual activity survey of the European Group for Blood and Marrow Transplantation (EBMT), the majority of allogeneic HSCT in Europe is now derived from peripheral blood stem cells (65% versus 35%) (<LINK REF="REF-Gratwohl-2005b" TYPE="REFERENCE">Gratwohl 2005b</LINK>).</P>
<P>Chronic GvHD represents one of the most common late challenges of allogeneic HSCT {<LINK REF="REF-Horwitz-2006" TYPE="REFERENCE">Horwitz 2006</LINK>). It can emerge in patients with or without previous acute GvHD and occurs - by definition - more than 100 days after HSCT; however, it also can actually occur before day 100 (<LINK REF="REF-Ferrara-2004" TYPE="REFERENCE">Ferrara 2004</LINK>; <LINK REF="REF-Ferrara-2007" TYPE="REFERENCE">Ferrara 2007</LINK>). Chronic GvHD is characterised by a multi-organ involvement and features similar to autoimmune diseases (<LINK REF="REF-Ferrara-2004" TYPE="REFERENCE">Ferrara 2004</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). In contrast to acute GvHD the exact pathogenesis has not been clarified yet, but differs from that of acute GvHD (<LINK REF="REF-Ferrara-2004" TYPE="REFERENCE">Ferrara 2004</LINK>). Approximately 50% of the patients experience some degree of chronic GvHD, its incidence ranges from 30% to 80% (<LINK REF="REF-Horwitz-2006" TYPE="REFERENCE">Horwitz 2006</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). The mortality rate of chronic GvHD is closely correlated to a progressive type of onset, an intensive skin involvement (&gt; 50% body surface) and persistent thrombocytopenia (&lt; 100,000/µL): among non-relapse related deaths chronic GvHD is the leading cause of deaths (approximately 54%) more than two years after transplantation (<LINK REF="REF-Horwitz-2006" TYPE="REFERENCE">Horwitz 2006</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>; <LINK REF="REF-Vogelsang-2003" TYPE="REFERENCE">Vogelsang 2003</LINK>; <LINK REF="REF-Wingard-2002" TYPE="REFERENCE">Wingard 2002</LINK>). The commonly used staging system distinguishes between a limited and an extensive form, depending on the involvement of skin and inner organs (<LINK REF="REF-Horwitz-2006" TYPE="REFERENCE">Horwitz 2006</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). From the patients affected 90% suffer of the extensive form and their 10-year survival is less than 5% (<LINK REF="REF-Horwitz-2006" TYPE="REFERENCE">Horwitz 2006</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). In contrast, patients suffering from the limited form show a 10-year survival of approximately 80% (<LINK REF="REF-Horwitz-2006" TYPE="REFERENCE">Horwitz 2006</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). As chronic GvHD is associated with immunodeficiency, patients die mainly due to infections (<LINK REF="REF-Horwitz-2006" TYPE="REFERENCE">Horwitz 2006</LINK>; <LINK REF="REF-Vogelsang-2003" TYPE="REFERENCE">Vogelsang 2003</LINK>; <LINK REF="REF-Wingard-2002" TYPE="REFERENCE">Wingard 2002</LINK>). The most important risk factor for the development of chronic GvHD represents previous acute GvHD: patients with a history of acute GvHD have a 10 times higher risk of developing chronic GvHD (<LINK REF="REF-Atkinson-1990" TYPE="REFERENCE">Atkinson 1990</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). Other determinants are increased age of donors and recipients and higher degrees of histoincompatibility (<LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). In addition, the use of peripheral blood stem cells has been identified as an important risk factor for developing extensive chronic GvHD (<LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>; <LINK REF="REF-Stem-Cell-Trialists_x0027_-Collaborative-Group-2005" TYPE="REFERENCE">Stem Cell Trialists' Collaborative Group 2005</LINK>).</P>
<P>Taking into account the impact of GvHD on patients' survival and quality of life, the effective prophylaxis of GvHD is of vital importance since it has been shown to be more promising than the treatment (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Chao-2006" TYPE="REFERENCE">Chao 2006</LINK>). Removing T cells by in vitro treatment of the donor marrow is one of the most effective way to reduce the incidence and the severity of acute GvHD (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Chao-2006" TYPE="REFERENCE">Chao 2006</LINK>; <LINK REF="REF-Ferrara-2005" TYPE="REFERENCE">Ferrara 2005</LINK>; <LINK REF="REF-Sullivan-2004" TYPE="REFERENCE">Sullivan 2004</LINK>; <LINK REF="REF-Vargas_x002d_Diez-2005" TYPE="REFERENCE">Vargas-Diez 2005</LINK>). Unfortunately, non-specific T cell depletion increases the rates of graft failure, infections and relapses due to the absence of the beneficial GvL effect, resulting in an equivalent overall survival; thus, the selective depletion of T cells is currently under clinical investigation (<LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Chao-2006" TYPE="REFERENCE">Chao 2006</LINK>; <LINK REF="REF-Simpson-2001" TYPE="REFERENCE">Simpson 2001</LINK>). Currently, the most common applied approach for GvHD prevention is the prophylactic use of immunosuppressive agents given post-transplant blocking the T cell activation in vivo (<LINK REF="REF-Chao-2006" TYPE="REFERENCE">Chao 2006</LINK>; <LINK REF="REF-Vogelsang-2003" TYPE="REFERENCE">Vogelsang 2003</LINK>). Various non-specific immunosuppressive drugs, specific T cell immunosuppressive drugs and drugs with distinct mechanism including the use of antibodies or cytokines trying to interfere at step I, II or III of the pathophysiology cascade are in use or rather under investigation (<LINK REF="REF-Chao-2006" TYPE="REFERENCE">Chao 2006</LINK>; <LINK REF="REF-Ferrara-2006" TYPE="REFERENCE">Ferrara 2006</LINK>).</P>
<P>The current standard regimen for preventing GvHD combines cyclosporine A (CSP) for six months (3 mg/kg/day on day -1 through day 10, then oral application tapered off until day +180) with a short-course of methotrexate (MTX) (15 mg/m<SUP>2</SUP> on day 1; 10 mg/m<SUP>2</SUP> on days 3, 6 and 11), as it has been shown that these drug combinations are more effective than the single agents (<LINK REF="REF-Storb-1986a" TYPE="REFERENCE">Storb 1986a</LINK>; <LINK REF="REF-Storb-1986b" TYPE="REFERENCE">Storb 1986b</LINK>). Also combinations with "mini-methotrexate" (5 mg/m<SUP>2</SUP> on days 1, 3, 6, 11) or "very-short methotrexate" (omitting the fourth dose on day 11) are used or under clinical investigation (<LINK REF="REF-Atkinson-1995" TYPE="REFERENCE">Atkinson 1995</LINK>; <LINK REF="REF-Bensinger-2006" TYPE="REFERENCE">Bensinger 2006</LINK>; <LINK REF="REF-Bolanos_x002d_Meade-2004" TYPE="REFERENCE">Bolanos-Meade 2004</LINK>; <LINK REF="REF-Chao-2004" TYPE="REFERENCE">Chao 2004</LINK>; <LINK REF="REF-Przepiorka-2000" TYPE="REFERENCE">Przepiorka 2000</LINK>): A recent individual patient data meta analysis revealed that in patients receiving PBSCT - compared to those receiving BMT - four doses of MTX cause a statistically significant survival advantage. The authors hypothesised that this finding might be due to the additional immunosuppression among BMT recipients resulting in a reduced anti-leukaemic effect (<LINK REF="REF-Bensinger-2006" TYPE="REFERENCE">Bensinger 2006</LINK>). However, it still seems to be uncertain whether the addition of corticosteroids provides an advantage by potentially decreasing the incidence of GvHD as - on the other hand - corticosteroids may augment the risk for infections and consequently may increase mortality. Various studies have tried to assess if the addition of corticosteroids is beneficial; however, as the results of single studies are ambiguous "the role [of steroids] in the prevention of GvHD is controversial" according to the EBMT Handbook (<LINK REF="REF-Chao-2004" TYPE="REFERENCE">Chao 2004</LINK>; <LINK REF="REF-Benesch-2004" TYPE="REFERENCE">Benesch 2004</LINK>; <LINK REF="REF-Devergie-2004" TYPE="REFERENCE">Devergie 2004</LINK>; <LINK REF="REF-Sullivan-2004" TYPE="REFERENCE">Sullivan 2004</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-05-14 12:13:43 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of corticosteroids used for the prevention of GvHD after allogeneic myeloablative HSCT in improving overall survival, disease-free survival, relapse incidence, non-relapse mortality, acute GvHD grade I to IV, II to IV and III to IV, chronic GvHD, incidence of infectious complications, other adverse effects and cause of deaths.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-06 10:52:37 +0100" MODIFIED_BY="Nicole Skoetz">
<SELECTION_CRITERIA MODIFIED="2008-11-06 10:52:37 +0100" MODIFIED_BY="Nicole Skoetz">
<CRIT_STUDIES>
<P>Randomised controlled trials with or without blinding were included in this review. Studies with quasi-randomisation, e.g. treatment allocation by case record number or by day of admission, were not included, as these studies are considered to potentially introduce selection bias and thus leading to unreliable results (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients undergoing allogeneic HSCT either by BMT or PBSCT after myeloablative conditioning therapy were included. Studies restricted to paediatric patients were excluded. Hence, a limit of 80% was arbitrarily set for the patients being adults (age &gt; 18 years) participating in the study. All types and stages of the underlying disease as well as all types of possible HLA-matching (HLA-identical sibling, all extents of HLA-mismatched related and HLA-matched and -mismatched unrelated donor) were considered.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-05-14 11:59:48 +0200" MODIFIED_BY="[Empty name]">
<P>In order to define the role of commonly used corticosteroids (e.g. methylprednisolone, prednisone) any kind of drug therapy administered for GvHD prophylaxis in both study arms was included on the condition that the two study arms differed only with respect to an additional use of corticosteroids. Thus, the prevention therapy had to be of one of the following types:</P>
<OL>
<LI> Single drug versus same single drug plus steroid</LI>
<LI> Multiple drug regimen versus same multiple drug regimen plus steroid</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-06 10:52:37 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Following outcomes adopted by the statistical guidelines of EBMT were considered to be relevant (<LINK REF="REF-Labopin-2005" TYPE="REFERENCE">Labopin 2005</LINK>; <LINK REF="REF-Wheatley-2004" TYPE="REFERENCE">Wheatley 2004</LINK>); if studies reported similar outcomes, the results were included if possible.</P>
<SUBSECTION>
<HEADING LEVEL="4">I. Primary outcome measures</HEADING>
<UL>
<LI>Overall survival (OS), defined as the probability of survival irrespective of disease state at any point in time</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">II. Secondary outcome measures</HEADING>
<UL>
<LI>Disease-free survival (DFS), defined as the probability of being alive and free of disease at any point in time</LI>
<LI>Relapse incidence (RI), defined as the probability of having had a relapse before time t</LI>
<LI>Non-relapse mortality (NRM), defined as the probability of dying without previous occurrence of a relapse</LI>
<LI>Acute GvHD (grades I-IV, II-IV and III-IV), defined as occurrence of acute GvHD grades I-IV, II-IV and III-IV within the first 100 days post-transplant</LI>
<LI>Chronic GvHD, defined as occurrence of chronic GvHD after day 100 post-transplant</LI>
<LI>Incidence of infectious complications, analysed according to type and number of infections due to bacterial, fungal or viral causes post-transplant</LI>
<LI>Other adverse events, analysed according to type and number of other adverse events post-transplant</LI>
<LI>Causes of death, analysed according to number and causes of deaths post-transplant</LI>
</UL>
<P>
<BR/>To avoid selection bias, time-to-event outcomes should be defined from the time of randomisation (except for the outcome chronic GvHD as only patients surviving at least 100 days posttransplant are at risk to develop it (<LINK REF="REF-Labopin-2005" TYPE="REFERENCE">Labopin 2005</LINK>)).</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-06 10:49:21 +0100" MODIFIED_BY="Nicole Skoetz">
<SUBSECTION>
<HEADING LEVEL="3">I. Electronic databases</HEADING>
<P>We searched the following databases.</P>
<UL>
<LI>Cochrane Haematological Malignancies Group trials register (July 2004)</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), <I>The Cochrane Library</I> (Issue 2, 2004)</LI>
<LI>MEDLINE (January 1999 to 19 February, 2006)</LI>
<LI>EMBASE (January 1999 to July 2004)</LI>
<LI>LILACS (Latin American and Caribbean Health Science Literature Database) (January 1982 to July 2004)</LI>
</UL>
<P>The search in the databases MEDLINE, EMBASE, LILACS consisted of two parts: a methodological strategy to retrieve randomised controlled trials that was added to the topic-specific strategy. The topic-specific search strategy aimed at identifying all studies which have been conducted for the prevention of GvHD.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">II. Conference proceedings</HEADING>
<P>The conference proceedings of the American Society of Clinical Oncology (ASCO) and of the American Society of Hematology (ASH) were searched manually for the period 1975-1994 and electronically for the period 1995-2005.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">III. Electronic search in databases of ongoing trials</HEADING>
<P>We searched the following databases for ongoing trials:<BR/>
</P>
<UL>
<LI>metaRegister of Controlled Trials [mRCT], searched 29 December 2004: http://www.controlled-trials.com</LI>
<LI>National Cancer Institute of Canada, Clinical Trials Group, searched 29 December 2004: http://www.ctg.queensu.ca/trials/default.html</LI>
<LI>National Cancer Institute, USA, searched 29 December 2004: http://www.cancer.gov/clinicaltrials/finding/</LI>
<LI>National Health and Medical Research Council (NHMRC), Clinical Trials Center (CTC), affiliated with the University of Sydney, searched 31 December 2004: http://www.ctc.usyd.edu.au/trials/trials.htm</LI>
<LI>Trials Central, Brown Medical School, USA, searched 31 December 2004: http://www.trialscentral.org/ClinicalTrials.aspx</LI>
</UL>
<P>On the 21 February 2006 all websites were still available on the internet.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">IV. Additional search methods</HEADING>
<P>We checked the references of relevant articles and actual treatment guidelines manually for additional references. We also approached the following experts, investigators, haemato-oncological study groups in the field of stem cell transplantations and various transplantation centres around the world identified as active in this field through published material, for unpublished data or overlooked studies.<BR/>
</P>
<UL>
<LI>European Group for Blood and Marrow Transplantation (EBMT) (http://wws.ebmt.org/) contacted via email to info@ebmt.org 31 December 2004 (answered 6 January 2005)</LI>
<LI>European Organisation for Research and Treatment of Cancer (EORTC) (http://ww.eortc.be), Brussels, Belgium, contacted via email to fme@eortc.be, dee@eortc.be and mfe@eortc.be 31 December 2004 (answered 17 January 2005)</LI>
<LI>Fred Hutchinson Cancer Research Center (FHCRC) (http://www.fhcrc.org/), Seattle, USA, contacted via email to rstorb@fhcrc.org 21 September 2004 (answered 21 September 2005) and to fappelba@fhcrc.org 31 December 2004 (answered 15 January 2005)</LI>
<LI>Eastern Cooperative Oncology Group (ECOG), USA, contacted via website http://www.ecog.org/general/contactus.html 31 December 2004 (no answer)</LI>
<LI>French Comprehensive Cancer Centres Federation, France (FNCLCC), contacted via email to bonichon@bergonie.org 31 December 2004 (no answer)</LI>
<LI>Southwest Oncology Group, San Antonio, USA, contacted via website http://swog.org/Visitors/ContactUs.asp 31 December 2004 (no answer)</LI>
</UL>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-14 14:36:36 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Trials selection</HEADING>
<P>Two review authors (SQ, JB) independently screened identified references . If title or abstract did not provide sufficient information, we obtained full-text versions. All studies that appeared to meet the criteria were assessed with an eligibility form. The form consisted of the following questions:</P>
<OL>
<LI>Is the study described as randomised?</LI>
<LI>Were a minimum of 80% of the participants adults (age &gt; 18 years)?</LI>
<LI>Did the patients undergo a myeloablative conditioning therapy before transplantation?</LI>
<LI>Did one arm of patients receive corticosteroids for GvHD prophylaxis?</LI>
<LI>Does a control group exist that differs to the study group only with respect to an additional use of corticosteroids (that is, same background therapy)?</LI>
</OL>
<P>In order to be eligible for the systematic review, studies had to meet all inclusion criteria stated above. If full-text versions did not provide sufficient information we contacted the responsible author for further details. All disagreements between the two review authors (SQ, JB) were resolved by discussion. We identified any duplicate trial reports and updates of prior publications at this stage.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Quality assessment</HEADING>
<P>To assess the quality of eligible studies, we obtained full-text version of all studies if available. Two review authors (SQ, JB) independently assessed the trials for their internal validity, that is, methodological quality. Due to the problematic use of summary scores from quality scales the influence of the key components was assessed individually by applying a quality assessment form containing parameters of the Consolidated Standards of Reporting Trials (CONSORT) statement (<LINK REF="REF-Juni-1999" TYPE="REFERENCE">Juni 1999</LINK>; <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>; <LINK REF="REF-Verhagen-1998" TYPE="REFERENCE">Verhagen 1998</LINK>):</P>
<OL>
<LI>Was the allocation truly random?</LI>
<LI>Was the treatment allocation concealed?</LI>
<LI>Were the patients blinded to the treatment?</LI>
<LI>Were the clinicians blinded to the treatment?</LI>
<LI>Were the outcome assessors blinded to the treatment?</LI>
<LI>Were the number of withdrawals, drop-outs and losses to follow up stated for each group?</LI>
<LI>Did the analysis include an intention-to-treat-analysis?</LI>
</OL>
<P>If questions 1 or 2 were not met, the trial was excluded in order to avoid selection bias. If these questions could not be answered reliably, the studies were included into the review assuming a correct randomisation respective an adequate concealment of allocation. However, these items were classified as not reported and subgroup analyses were performed for these criteria. If question 3, 4 or 5 were not met, the studies were categorised as no for these items, but included into the review. We performed respective subgroup analyses. If a study was stated as double-blind without further description of the method of blinding or the placebo, an adequate blinding of patients and clinicians were assumed. If a placebo was used without mentioning a double-blind design, an adequate blinding of the patients (single-blind design) was assumed. If no placebo was used or if no use of placebo was stated or if the study was stated as unblinded, the study was classified as unblinded. If the questions could not be answered for certain, the studies were categorised with no for these items, but included into the review. We performed respective subgroup analyses.. Question 6 was only answered with yes, if detailed information about the number of withdrawals, drop-outs and lost to follow up were stated separately for each treatment arm. If this information were missing, the studies were categorised with no for this item, but included into the review and respective subgroup analyses were performed. If less than 10% of the patients within each study arm were excluded from the analysis (except for the outcome chronic GvHD as this outcome is restricted to patients surviving at least 100 days post-transplant), question 7 was answered with yes. If the question was not met or could not be answered for certain, the studies were categorised with no for this item, but included into the review. We performed respective subgroup analyses.</P>
<P>Any disagreement between the two review authors (SQ, JB) was resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Data extraction</HEADING>
<P>For data extraction, two review authors (SQ, JB) independently extracted the data of the included studies using a standardised data extraction sheet covering the following items:</P>
<OL>
<LI>General information: title, authors, source, contact address, country, year of publication, setting, funding</LI>
<LI>Trial characteristics: design, method of randomisation, concealment of allocation, blinding of patients, blinding of clinicians, blinding of outcome assessors, method of GvHD-diagnosis (clinical or histopathological)</LI>
<LI>Patients: inclusion and exclusion criteria, underlying disease demanding HSCT, type of conditioning regimen, type of stem cell source, type and extent of HLA-matching (i.e. HLA-identical sibling, all extents of HLA-mismatched related and HLA-matched and mismatched unrelated donor), sample size, baseline characteristics (e.g. median age), withdrawals, losses to follow up</LI>
<LI>Interventions: type of drug regimens, dose, day of initiation and duration of treatments</LI>
<LI>Outcomes: as specified above</LI>
</OL>
<P>In addition, we contacted the authors to provide unpublished data if available. Any disagreements between the review authors (SQ, JB) were resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Data analysis</HEADING>
<P>For the data analyses, RevMan Analyses software was used (Version date 7 July 2005). Additional analyses that could not be done with RevMan Analyses software were performed with SPSS<SUP>®</SUP> (Version 11.0 for Windows).</P>
<P>We analysed dichotomous data, such as cause of death, by calculating the relative risk (RR) for each trial along with a 95% confidence interval (CI).</P>
<P>To analyse continuous data, that are at least approximately normally distributed, we required data of means and standard deviations of each trial to calculate the effect size (mean difference) along with a 95% CI; for skewed data, methods for meta-analysis are still lacking.</P>
<P>We analysed outcomes with time-to-event data as hazard ratios (HR) - representing a measure for the relative survival in two groups - and presented with a 95% CI. We calculated the HRs of the single trials on the basis of individual patient data (IPD) or - if these were not available - extracted from the publication using the method of Parmar et al. (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>), e.g. using log-rank P-values or Kaplan-Meier survival curves. For time-to-event data with competing risks, that is, events that preclude the occurrence of the failure type of interest, Parmar's method was applied as well, and treatment comparisons used log-rank of Kaplan-Meier survival curves, or Cox regression analysis, with patients failing from a competing risk treated as lost to follow up at this time (censored). These are the appropriate tests to use. However, Kaplan-Meier survival curves may not the best estimates when calculating the proportion of patients who suffer the event of interest, as they overestimate it; cumulative incidence estimates are more appropriate for describing this (<LINK REF="REF-Gooley-2001" TYPE="REFERENCE">Gooley 2001</LINK>; <LINK REF="REF-Pepe-1993" TYPE="REFERENCE">Pepe 1993</LINK>). The criteria defining the time-to-event outcomes are displayed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, adopted by the statistical guidelines for EBMT (<LINK REF="REF-Labopin-2005" TYPE="REFERENCE">Labopin 2005</LINK>).<BR/>
<BR/>If appropriate, results from independent studies were meta-analysed: the individual HRs were weighted according to the method of Peto founded on the hypothesis of a fixed-effect model. To facilitate interpretation of meta-analyses results, we calculated the numbers needed to treat to benefit (NNTB), that is, the number of patients who must receive steroids in addition during a specific period of time to experience a beneficial outcome.</P>
<P>In meta-analyses with at least four trials, we explored potential publication bias by generating a funnel plot and statistically tested by using a linear regression test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). Heterogeneity of treatment effects between trials was assessed by using a chi-squared test. To describe the extent of heterogeneity within the meta-analysis the significance level was set at P &lt; 0.1 rather than the conventional level of P &lt; 0.05 as this test has low power if a small number of studies are included. If the value of &#967;<SUP>2</SUP> was above the significance level ( &#967;<SUP>2 </SUP>= 2.70 for P &lt; 0.1 one-sided), we performed sensitivity analyses . To detect statistically significant differences between subgroups the standard significance level of P &lt; 0.05 was chosen. As this test for assessing heterogeneity does not quantify the effect of heterogeneity, in addition an alternative approach - the quantity I<SUP>2</SUP> - to measure inconsistency between the studies was applied (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). A value of 0% indicates no observed heterogeneity, larger values indicate increasing heterogeneity; values greater than 50% may be considered to represent substantial heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Subgroup analysis</HEADING>
<P>We analysed potential sources of heterogeneity using the following subgroup analyses:<BR/>
</P>
<UL>
<LI>Type of randomisation (truly randomised versus not reported)</LI>
<LI>Concealment of allocation (adequate versus not reported)</LI>
<LI>Blinding (patients and clinicians blinded versus versus open-label)</LI>
<LI>Statement of withdrawals and losses to follow-up in each group (stated versus not stated)</LI>
<LI>MTX part of GvHD prophylaxis regimen (MTX included versus not included)</LI>
<LI>Timing of steroid administration (overlapping with MTX administration versus not overlapping)</LI>
<LI>Risk status of patients (only high risk patients versus no differentiation between high and low risk patient; definition of low risk: patiens with acute leukaemia in first remission or CML in first chronic phase; definition of high risk patients: all others)</LI>
</UL>
<P>The following criteria were considered a priori as other potential sources for heterogeneity among the included studies, but could not be evaluated in form of subgroup analyses as the identified studies did not differ with respect to these aspects:<BR/>
</P>
<UL>
<LI>Type of underlying disease demanding HSCT</LI>
<LI>Type of conditioning regimen</LI>
<LI>Type of stem cell source (BMT versus PBSCT)</LI>
<LI>Type of prophylaxis regimen</LI>
<LI>HLA-matching criteria: HLA-identical sibling, HLA-mismatched related donors (in dependence of the mismatching-extent), HLA-matched and HLA-mismatched unrelated donors (in dependence of the mismatching-extent)</LI>
<LI>Intention-to-treat analysis versus per-protocol analysis</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Sensitivity analysis</HEADING>
<P>We performed sensitivity analyses for the following criteria.<BR/>
</P>
<UL>
<LI>Non-concordance with the a priori defined inclusion criteria (excluding the study of Chao 2000</LI>
<LI>Duration of median follow up and study size</LI>
<LI>Data derived from Kaplan-Meier (in case of different data origin)</LI>
</UL>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-06 10:53:53 +0100" MODIFIED_BY="Nicole Skoetz">
<STUDY_DESCRIPTION MODIFIED="2008-11-06 10:52:59 +0100" MODIFIED_BY="Nicole Skoetz">
<SUBSECTION>
<HEADING LEVEL="3">Identified studies</HEADING>
<P>We retrieved 1700 references searching the CHMG trials register, CENTRAL, MEDLINE, EMBASE, and LILACS in July 2004. Handsearching of outlined conference proceedings revealed nine additional abstracts of trials. Thirty six references seemed to meet the eligibility criteria and were - if available - obtained as full-text paper to complete the study eligibility form. The report followed the Quality of Reporting Meta-analyses (QUOROM) statement as displayed in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>(<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>). A rerun of the electronic search in MEDLINE 19th February 2006 did not reveal any additional relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies</HEADING>
<P>Six abstracts were identified as duplicates of trials published in full-text, four trials were non-randomised studies (<LINK REF="STD-Elfenbein-1986" TYPE="STUDY">Elfenbein 1986</LINK>; <LINK REF="STD-Hamazaki-2000" TYPE="STUDY">Hamazaki 2000</LINK>; <LINK REF="STD-Leelasiri-1995" TYPE="STUDY">Leelasiri 1995</LINK>; <LINK REF="STD-Michallet-1999" TYPE="STUDY">Michallet 1999</LINK>) and three did not focus upon the prevention of GvHD (<LINK REF="STD-Buckner-1991" TYPE="STUDY">Buckner 1991</LINK>; <LINK REF="STD-Lowenberg-1986" TYPE="STUDY">Lowenberg 1986</LINK>; <LINK REF="STD-Michallet-1995" TYPE="STUDY">Michallet 1995</LINK>). Twelve trials comparing different GvHD-prophylaxis regimens had to be excluded as the participants were not randomised to the use of corticosteroids (<LINK REF="STD-Basara-1999" TYPE="STUDY">Basara 1999</LINK>; <LINK REF="STD-Bauser-1998" TYPE="STUDY">Bauser 1998</LINK>; <LINK REF="STD-Helenglass-1987" TYPE="STUDY">Helenglass 1987</LINK>; <LINK REF="STD-Kraut-2000" TYPE="STUDY">Kraut 2000</LINK>; <LINK REF="STD-Linck-2004" TYPE="STUDY">Linck 2004</LINK>; <LINK REF="STD-Mohty-2002" TYPE="STUDY">Mohty 2002</LINK>; <LINK REF="STD-Przepiorka-1998" TYPE="STUDY">Przepiorka 1998</LINK>; <LINK REF="STD-Ramsay-1981" TYPE="STUDY">Ramsay 1981</LINK>; <LINK REF="STD-Ruutu-2002" TYPE="STUDY">Ruutu 2002</LINK>; <LINK REF="STD-Schmidt-1989" TYPE="STUDY">Schmidt 1989</LINK>; <LINK REF="STD-Sullivan-1993" TYPE="STUDY">Sullivan 1993</LINK>; <LINK REF="STD-Tollemar-1989" TYPE="STUDY">Tollemar 1989</LINK>). One trial published in form of an abstract did not seem to be randomised ("A control group of 23 participants matched for age, disease and conditioning regime was also studied."). We contacted the authors, who did not reply; since no full-text publication was found to demonstrate the contrary, the study was excluded (<LINK REF="STD-Nandi-1987" TYPE="STUDY">Nandi 1987</LINK>). One study with 13 participants randomised to receive or not to receive corticosteroids was excluded, because the study was focused on the pharmacokinetics of tacrolimus and no separate outcome analysis of the randomised groups was available (<LINK REF="STD-Nash-1995" TYPE="STUDY">Nash 1995</LINK>). One trial of a Brazilian study group identified in LILACS seemed to meet the inclusion criteria; however, the abstract did not provide sufficient data to include the study in the meta-analysis (<LINK REF="STD-Macedo-1997" TYPE="STUDY">Macedo 1997</LINK>). Thus, we contacted the authors , but received no reply, and a full-text publication was not identified. One reference was a retrospective analysis of infection data (<LINK REF="STD-Sayer-1994" TYPE="STUDY">Sayer 1994</LINK>) complementary to a study which was reported separately (<LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>). Two references were identified as long-term follow ups of already included studies (<LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK>; <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>No current trial studying the role of corticosteroids in the prevention of GvHD could be identified, neither in the databases of ongoing trials nor by contacting experts, haemato-oncological study groups and transplantation centres around the world.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>Five randomised controlled trials (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>; <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK>; <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) were included in the review. For the studies of Deeg et al. and Ruutu et al. long-term follow ups were available (<LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK>; <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK>). The data of infections of the study of Storb et al. were analysed in a retrospective manner and published separately (<LINK REF="STD-Sayer-1994" TYPE="STUDY">Sayer 1994</LINK>). All studies were published in English. They comprised 604 participants. We contacted the authors and asked them to provide additional unpublished data if available. However, none of them contributed supplementary data as requested, this may be because all the studies were conducted n the 80s or 90s and thus, access to data turned out to be difficult.</P>
<P>All studies included participants with mixed entities of haematological malignancies. None of the studies evaluated non-myeloablative conditioning regimens; all participants received chemotherapy (mainly CY, alone or in addition either with BU or fractionated TBI or both). All but one study used bone marrow of HLA-identical siblings as a source for stem cells. Except for the prophylactic use of antiinfective agents and folin acid given to the participants in the study of <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> no other routinely use of any co-intervention, e.g. the use of haematopoietic growth factors, was stated. The detailed drug regimens used in the included trials for preventing GvHD are displayed in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. The treatment of GvHD once it has occured is shown in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. Ruutu et al. stated that the outcomes overall survival and disease-free survival were calculated from time of randomisation to respective outcome; all other studies did not provide further informations if the applied time-to-event outcomes were defined from the date of randomisation or the date of transplantation.</P>
<P>The median follow-up time of the trials was 2.6 years ranging from 0.8 up to 10.0 years in one long-term follow up. The median age in the individual studies ranged from 28 to 42. However, all studies included participants younger than 18, but only in the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> this proportion was higher than 20%: one treatment arm consisted of 23% paediatric participants and thus, less than 80% were adults. In addition, in this study the GvHD-prophylaxis regimens in both study arms were not completely identical (only the control group received the fourth dose of MTX on day 11). Nevertheless, on the basis of expert opinions the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> was also included into the review for the following reasons, but respective sensitivity analyses were performed (<LINK REF="REF-Bohlius-2005" TYPE="REFERENCE">Bohlius 2005</LINK>; <LINK REF="REF-Elfenbein-2005" TYPE="REFERENCE">Elfenbein 2005</LINK>; <LINK REF="REF-Wheatley-2005" TYPE="REFERENCE">Wheatley 2005</LINK>):<BR/>
</P>
<UL>
<LI>The limit of 80% being adults in a treatment arm was arbitrarily set before initiating the study in order to exclude studies with the main focus on paediatric participants. Thus, it was not meant as a tool to exclude studies which might be useful for a meta-analysis in this context.</LI>
<LI>The day 11 dose of the short-course of MTX (called "very-short methotrexate") is often omitted because of toxicity to the mouth and to the GI tract. Thus, omitting this dose reflects clinical practice.</LI>
<LI>A similar proportion of participants in both study arms missed the dose on day 11: 64% of the steroid group and 57% of the control group only received this final dose (MTX or placebo).</LI>
</UL>
<P>
<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> evaluated the addition of methylprednisolone (iv) respective prednisolone (po) (0.5 mg/kg bid on alternate days, respectively; initiating at the day of transplantation) to the 2-drug-combination of CSP (3 mg/kg iv days 1 to 4, then augmented to 6.25 mg/kg po bid) and MTX (7.5 mg/m<SUP>2</SUP> on day 1, 3, 6 and 11) in 41 participants; after 30 days, the administration of steroids was stopped. The median follow up was 0.8 years. Both study arms seemed to be well-balanced in terms of the underlying diseases (control arm: ALL = 2, ANL = 8 CML = 9, lymphoma = 1; steroid arm: ALL = 4, ANL = 8, CML = 9). However, in terms of the risk status of the participants (participants deemed as low-risk participants: acute leukaemia in first remission or CML in first chronic phase; all others deemed as high-risk participants) the control and treatment arm seemed to be unbalanced (40% high risk participants in control arm, 62% in treatment arm) as well as in terms of the risk factor sex mismatch (50% in control arm, 19% in treatment arm), although a stratified randomisation for the latter was stated. The study was supported in part by grants from a governmental fund as well as from the Australian Bone Marrow Transplant Foundation. Grading of acute GvHD was based on clinical and histological criteria previously described by <LINK REF="REF-Glucksberg-1974" TYPE="REFERENCE">Glucksberg 1974</LINK>. No information about power calculation were provided.<BR/>
<BR/>The study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> included 186 participants and evaluated the addition of methylprednisolone (iv) respective prednisone (po) to the 2-drug-combination of CSP and MTX: the administration of steroids was initiated on day seven post-transplant (0.25 mg/kg iv bi-daily) and then tapered off until day 180 (final dose: 0.1 mg/kg po qd). The administration of CSP was started two days pre-transplant (5 mg/kg iv), then tapered through day 35 (3.75 mg/kg iv), augmented through day 83 (5 mg/kg po bid) and then tapered off until day 180 (final dose: 2 mg/kg po bid). MTX was given on day 1 (15 mg/m<SUP>2</SUP>), 3, 6 and 11 (10 mg/m<SUP>2</SUP>, respectively). However, only the control group received the MTX-dose on day 11; the steroid group received a placebo instead. The median follow-up was 2.1 years in the steroid group and 2.3 years in the control group. In terms of the underlying diseases (control arm: ALL = 21, AML = 31, CML = 44; steroid arm: ALL = 19, AML = 28, CML = 43), the risk factor sex mismatch (47% in control arm, 50% in treatment arm) and the risk status of the participants (23% high risk participants in control arm, 28% in treatment arm), the study was stated by the authors as well-balanced. The funding of the study was not reported. Grading of acute GvHD was based on the criteria previously described by <LINK REF="REF-Glucksberg-1974" TYPE="REFERENCE">Glucksberg 1974</LINK>; all skin GvHD were biopsy-proven, biopsies of liver and gut were performed as clinically indicated. Patient accrual goal was based on a 15% incidence of acute GvHD in the steroid group compared with 30% in the control group; at second interim analysis the study was closed as it suggested that further accrual would not achieve the initially projected end point.<BR/>
<BR/>The study of Deeg et al. (<LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK>; <LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK>) evaluated the addition of methylprednisolone (iv and po) to CSP in 122 participants: the dosage regimen of CSP was identical to that used by Chao et al. except for the day of initiation which was in this study on day 1 pre-transplant. Methylprednisolone was given to the treatment group starting on day 7 (0.25 mg/kg iv bid) through day 14, then increased until day 28 (0.5 mg/kg po bid) and after that tapered off until day 72 (final dose: 0.1 mg/kg per day). The median follow-up was 3.4 years respective 6.1 years in the long-term follow up. All participants were deemed as high risk participants, data to sex mismatch were not reported; however, the authors stated that the study arms were well balanced with respect to this risk factor as well as to the underlying diseases (control group: ALL = 15, ANL = 9, CML = 2, lymphoma = 21, MDS = 11, other = 2; steroid group: ALL = 13, ANL = 9, CML = 2, lymphoma = 20, MDS = 15, other = 3). The study was supported by grants from the National Institutes of Health, USA. Assessment and grading of acute GvHD was based on criteria previously described by <LINK REF="REF-Przepiorka-1995" TYPE="REFERENCE">Przepiorka 1995</LINK>. A power calculation was stated for aGvHD II-IV (&#945; = 0.05 and &#946; = 0.90, expected incidence in control group 50%, in steroid group 25%).</P>
<P>Ruutu et al. (<LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>; <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK>) included 108 participants in their study and evaluated the addition of methylprednisolone (po) to CSP and MTX: Methylprednisolone was administered to the treatment group starting on day 14 post-transplant for seven days (0.25 mg/kg po bid), then increased through day 34 (0.5 mg/kg po bid) and then tapered off until day 110 (final dose: 0.06 mg/kg po qd on alternate days). CSP was given to all participants initiating on day 1 pre-transplant (3 mg/kg iv), which was switched on day 14 to an oral application (1.5 mg/kg po bid) and between day 366 and 407 tapered off; MTX was given on day 1 (15 mg/m<SUP>2</SUP>), 3, 6 and 11 (10 mg/m<SUP>2</SUP>, respectively). Six hours after each dose the same milligram dose of calcium folinate was given iv. The median follow up was 6.4 years respective 10.0 years in the long-term follow up. In terms of the underlying diseases (control group: ALL = 10, AML = 21, CML = 13, MDS = 6, MM = 4, NHL = 1; steroid group: ALL = 5, AML = 22, CML = 15, CLL = 2, MDS = 3, MM = 4, NHL = 2) the study was stated as well-balanced as well as to the risk factor sex mismatch (46% in control arm, 49% in treatment arm) and the risk status of the participants (33% high risk participants in control arm, 38% in treatment arm). The study was supported by the Sigrid Jusélius Foundation and the Blood Disease Research Foundation, Finland. Grading of acute GvHD was based on the criteria previously described by <LINK REF="REF-Glucksberg-1974" TYPE="REFERENCE">Glucksberg 1974</LINK> and <LINK REF="REF-Thomas-1975" TYPE="REFERENCE">Thomas 1975</LINK>; skin GvHD was clinically diagnosed, involvement of gut and liver was biopsy-proven. No information about power calculation were provided.</P>
<P>In the study <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> the addition of prednisone to CSP and MTX was evaluated in 147 participants, of which 25 received bone marrow of HLA-non-identical relatives differing no more than one HLA-locus. However, as the randomisation was stratified for the HLA-matching criteria, no imbalance between the two study groups was detected according to this aspect. Prednisone was given to the treatment group from day of transplantation through day 21 (0.5 mg/kg po bid), then with decreased dose until day 35 (0.25 mg/kg po bid), when it was stopped. CSP was initiated on day 1 pre-transplant (1.5 mg/kg iv bid), augmented until day 60 (6.25 mg/kg po bid) as soon as the participants recovered from conditioning regimen-induced gastrointestinal toxicity, and tapered off until day 180 by 5% each week. Participants without signs of acute GvHD were randomised to stop CSP entirely on day 60 post-transplant. The MTX-regimen was identical to that of Chao et al. (<LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>) and Ruutu et al (<LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>) (administered on day 1: 15 mg/m<SUP>2</SUP>, on days 3, 6 and 11 10 mg/m<SUP>2</SUP>, respectively). The median follow up was 2.3 years in the steroid group and 2.6 years in the control group. In terms of the underlying diseases (control group: ANL = 32, CML = 30, MDS = 6, AA = 6; steroid group: ANL = 31, CML = 27, MDS = 8, AA = 7), risk factor sex mismatch (42% in control arm, 40% in treatment arm) and the risk status of the participants (35 or 36% high risk participants in control arm, 37 or 38% in treatment arm [of one patient with CML in 2nd chronic phase the allocation was not stated]), the study groups seemed to be well balanced. The study was supported by grants from the National Cancer Institute and National Heart, Lung and Blood Institute, USA. Assessment and grading of acute GvHD was based on the criteria previously described by <LINK REF="REF-Thomas-1975" TYPE="REFERENCE">Thomas 1975</LINK>. A total accrual of 340 participants was planned, but the study was terminated early on the basis of results from an interim analysis (designed to detect a 17% reduction in the incidence of acute GvHD).<BR/>
</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-05-14 11:37:07 +0200" MODIFIED_BY="[Empty name]">
<P>All studies were reported as randomised. One study described the generation of allocation sequences, which was adequate (<LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>); the remaining studies did not report the randomisation technique. Two studies described the method of concealment of allocation (<LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>; <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>), which was adequate. One study was described as being blinded to participants and clinicians (<LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>), one study was stated to be an open-label study (<LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK>). For the other three studies no information about blinding or the use of a placebo was stated and thus, they were classified as unblinded (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>). No study reported about blinding of the assessors and thus, all studies were considered not to be blinded to the assessors. Detailed information about withdrawals, dropouts and losses to follow up in each study arm were available in two studies (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>), the remaining studies did not report these numbers separately for each study arm. Details of the quality assessment are shown in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-06 10:53:53 +0100" MODIFIED_BY="Nicole Skoetz">
<SUBSECTION>
<HEADING LEVEL="3">Overall survival</HEADING>
<P>All five studies comprising 604 participants were analysed. The pooled HR was 0.99 (95% CI 0.79 to 1.25). Based on the data available, there is no evidence that the addition of steroids improves overall survival.</P>
<P>To include the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> data were taken from a table containing individual patient data. With the software SPSS, a Kaplan-Meier analysis was performed and a corresponding log-rank P-value calculated. We extracted the data of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> from the published Kaplan-Meier survival curve given along with a log-rank P-value. <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> reported a HR along with a 95% CI for this outcome. To include the study of <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> and the long-term follow up of the study of <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK> the respective HRs were calculated based on the published numbers of surviving participants or deaths, respectively, along with the reported corresponding log-rank P-values. The median follow up of the studies ranged from 0.8 to 10.0 years, the latter including a maximum follow up of 12.7 years. The long-term follow up of the study of <LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK> did not report sufficient data to be included into the meta-analysis: the probability for overall survival was stated with 26% for the steroid group and 23% for the control group after a median follow-up of 6.1 years.</P>
<P>The linear regression analysis of the funnel plot did not reveal a statistically significant asymmetry (P = 0.7925). There was no statistically significant heterogeneity among the trials ( &#967;<SUP>2 </SUP>= 4.85, df = 4, P = 0.30; I<SUP>2 </SUP>= 17.5%). Statistically significant differences between subgroups were found for the subgroup statement of withdrawals and losses to follow up in each group (P = 0.0468): those studies which did not state these data separately for each treatment arm resulted in a more favourable outcome for the steroid group (HR 0.86; 95% CI 0.65 to 1.13), three studies, N = 377). In contrast, the HR of the studies which stated these information showed an increased risk for the steroid group (HR 1.45;95% CI 0.93 to 2.25), two studies, N = 227).<BR/>
<BR/>Sensitivity analyses were performed for the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> (not in complete concordance with the a priori defined inclusion criteria) and the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> (median follow up &lt; 1 year, study size &lt; 100 participants): in both analyses, the 95% CIs were clearly overlapping.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Disease-free survival</HEADING>
<P>All studies reported data for outcomes termed event-free survival, leukaemia-free survival or relapse-free survival, but did not provide the applied definitions. Thus, it is not certain if the studies are congruent in their definition.<BR/>Analysing all five studies comprising 604 participants the pooled HR was 0.95 (95% CI 0.74 to 1.23). Accordingly, on the condition that the applied outcome definitions are consistent across the studies, there is no evidence that the addition of steroids improves disease-free survival.</P>
<P>For the studies of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>, <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK>, <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> respective HRs were calculated based on the number of relapses and causes of deaths reported in the individual publications. To include the long-term follow-up data of <LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK> the HR was calculated based on the number of participants surviving in remission given along with a reported corresponding log-rank P-value. The data of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> were extracted from the published Kaplan-Meier survival curve given along with a log-rank P-value. The median follow up of the studies ranged from 2.1 to 6.1 years, the latter including a maximum follow up of 8.0 years. The long-term follow-up results of <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK> could not be included into the analysis due to insufficiently reported data.<BR/>
<BR/>The linear regression analysis of the funnel plot did not reveal a statistically significant asymmetry (P = 0.4097). There was no statistically significant heterogeneity among the trials (&#967;<SUP>2 </SUP>= 6.62, df = 4, P = 0.16; I<SUP>2 </SUP>= 39.6%). Statistically significant differences between subgroups were found for the subgroup statement of withdrawals and losses to follow-up in each group (P = 0.0166), and thus, it was identical to that seen for overall survival. Those studies which did not state these data separately for each treatment arm resulted in a more favourable outcome for the steroid group (HR 0.77; 95% CI 0.56 to1.05], three studies, N = 377). In contrast, the HR of the studies which stated these information showed an increased risk for the steroid group (HR 1.49; 95% CI 0.95 to 2.31, two studies, N = 227).</P>
<P>Sensitivity analyses were performed for the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> (not in complete concordance with the a priori defined inclusion criteria) and the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> (median follow up &lt; 1 year, study size &lt; 100 participants): in both analyses, the 95% CIs were clearly overlapping. In addition, a sensitivity analysis was performed with respect to the type of data: excluding those studies with data not derived from Kaplan-Meier (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) did not alter the 95% CIs considerably.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Relapse incidence</HEADING>
<P>All five studies comprising 604 participants could be included in the analysis. The pooled HR was 0.82 (95% CI 0.57 to1.18). Based on the data available, there is no evidence that the addition of steroids improves relapse incidence.</P>
<P>To include the studies of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> and <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> as long-term follow-up data of the study of <LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK> the respective HRs were calculated based on number of relapses given along with the respective log-rank P-value. The respective HRs of the studies of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> and <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> were derived from the reported number of relapses. The median follow up of the studies ranged from 0.8 to 6.4 years, the latter including a maximum follow up of 9.1 years. The long-term follow-up of <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK> could not be included into the analysis due to insufficiently reported data.</P>
<P>The linear regression analysis of the funnel plot did not reveal a statistically significant asymmetry (P = 0.4179). There was no statistically significant heterogeneity among the trials (&#967;<SUP>2 </SUP>= 4.81, df = 4, P = 0.31; I<SUP>2 </SUP>= 16.8%). Subgroup analyses did not show any statistically significant differences.</P>
<P>Sensitivity analyses were performed for the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> (not in complete concordance with the a priori defined inclusion criteria) and the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> (median follow up &lt; 1 year, study size &lt; 100 participants): in both analyses, the 95% CIs were clearly overlapping. In addition, a sensitivity analysis was performed with respect to the type of data: excluding those studies with data not derived from Kaplan-Meier (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) did not alter the 95% CIs considerably.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Non-relapse mortality</HEADING>
<P>Only <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> analysed this outcome, but did not state an exact definition. The other studies did not analyse NRM. However, three studies reported number and causes of deaths. Hence, the quantity of non-relapse related deaths could be assessed and respective HRs calculated. Four studies comprising 418 participants could be analysed (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK>; <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) The pooled HR was 0.88 (95% CI 0.61 to 1.26). Thus, based on the available data, there is no evidence that the addition of steroids improves non-relapse related deaths.</P>
<P>To include the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> data were taken from a table containing individual patient data. With the software SPSS, a Kaplan-Meier analysis was performed and a corresponding log-rank P-value calculated. <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> reported a HR along with a 95% CI for NRM. The respective HRs of the studies of <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> and <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> were calculated based on listed number and causes of deaths. The median follow up of the included studies ranged from 0.8 to 6.4 years, the latter including a maximum follow up of 9.1 years. The long-term follow ups of the studies of <LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK> and <LINK REF="STD-Ruutu-2003" TYPE="STUDY">Ruutu 2003</LINK> did not contain updated information concerning NRM and thus, were not included into the analysis.</P>
<P>The linear regression analysis of the funnel plot did not reveal a statistically significant asymmetry (P = 0.8913). There was no statistically significant heterogeneity among the trials (&#967;<SUP>2</SUP>=1.97, df = 3, P = 0.58; I<SUP>2 </SUP>= 0%). Subgroup analyses were not performed as the value of &#967;<SUP>2 </SUP>was below the significance level ( &#967;<SUP>2</SUP>=2.70 for P &gt; 0.1 two-sided).</P>
<P>A sensitivity analysis was performed for the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> (median follow up &lt; 1 year, study size &lt; 100 participants): the 95% CIs were clearly overlapping. In addition, a sensitivity analysis was performed with respect to the type of data: excluding those studies with data not derived from Kaplan-Meier (<LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>; <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>) did not alter the 95% CIs considerably.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Acute GvHD grade I to IV</HEADING>
<P>All five studies comprising 604 participants reported data of acute GvHD grade I to IV. The pooled HR was 0.58 (95% CI 0.45 to 0.76), the risk to develop acute GvHD grade I to IV was reduced by 42%. Thus, the meta-analysis reveals that the addition of steroids reduces statistically significant the risk to develop acute GvHD grade I to IV; expressed as NNT, 10 (95% CI 6 to 48) participants had to receive corticosteroids in addition to prevent one additional case of acute GvHD grade I to IV.</P>
<P>
<LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> reported a HR along with a 95% CI for acute GvHD grade I to IV. To include the data of the other four studies the respective HRs were calculated based on the listed number of participants affected by acute GvHD grade I to IV, for the study of <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> a corresponding log-rank P-value was stated in addition.</P>
<P>The linear regression analysis of the funnel plot did not reveal a statistically significant asymmetry (P = 0.3563). Heterogeneity tests revealed statistically significant heterogeneity among the trials (&#967;<SUP>2 </SUP>= 12.20, df = 4, P = 0.02; I<SUP>2</SUP>= 67.2%). Statistically significant differences between subgroups were found for the subgroups type of randomisation (P = 0.0376) and timing of steroid administration (P = 0.0086). Pooling the individual HRs of the studies which did not report the way of randomisation resulted in a more favourable outcome for the steroid group (HR 0.51; 95% CI 0.38 to 0.69), four studies, N = 457). In contrast, the HR of the only truly randomised described study <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> showed an increased risk for the steroid group (HR 1.09 (95% CI 0.57 to 2.07), one study, N = 147). For studies in which the administration of steroids was not overlapping with that of MTX (respective no MTX given at all), the participants showed less acute GvHD grade I to IV (HR 0.49; 95% CI 0.36 to 0.66), three studies, N = 416). Participants who received simultaneous administration of steroids and MTX had a higher risk for acute GvHD grade I to IV than the respective control groups (HR 1.19; 95% CI 0.65 to 2.15), two studies, N = 188).</P>
<P>Sensitivity analyses were performed for the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> (not in complete concordance with the a priori defined inclusion criteria) and the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> (study size &lt; 100 participants): in both analyses, the 95% CIs were clearly overlapping. In addition, a sensitivity analysis was performed with respect to the type of data: excluding those studies with data not derived from Kaplan-Meier (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) did not alter the 95% CIs considerably.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Acute GvHD grade II to IV</HEADING>
<P>All five studies comprising 604 participants reported data of acute GvHD grade II to IV. The pooled HR was 0.69 (95% CI 0.51 to 0.92), so the risk to develop acute GvHD grade II to IV was reduced by 31%. Thus, the meta-analysis reveals that the addition of steroids reduces statistically significant the risk to develop acute GvHD grade II to IV; expressed as NNTB, 20 (95% CI 8 to &#8734;) participants had to receive corticosteroids in addition to prevent one additional case of acute GvHD grade II to IV.</P>
<P>
<LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> reported a HR along with a 95% CI for acute GvHD grade II to IV. To include the data of the other four studies the respective HRs were calculated based on the listed number of participants affected by acute GvHD grade II to IV, for the studies of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> and <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> respectively the corresponding log-rank P-value were also stated.</P>
<P>The linear regression analysis of the funnel plot did not reveal a statistically significant asymmetry (P = 0.8053). Heterogeneity tests revealed statistically significant heterogeneity among the trials (&#967;<SUP>2 </SUP>= 9.31, df = 4, P = 0.05; I<SUP>2 </SUP>= 5 7.0%). Statistically significant differences between subgroups were identified for the subgroups type of randomisation (P = 0.0147) and timing of steroid administration (P = 0.0139). Thus, the subgroup analyses confirm the results observed for the outcome acute GvHD I to IV. The pooled results of studies with no detailed reporting of randomisation indicated a favour for the steroid arm (HR 0.58; 95% CI 0.42 to 0.80), four studies, N = 457) whereas in the only as truly randomised described study of <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> the steroid arm had an unfavourable outcome (HR 1.43; 95% CI 0.74 to 2.76), one study, N = 147). For studies in which the administration of steroids was not overlapping with that of MTX (respective no MTX given at all, the participants showed less acute GvHD grade II to IV (HR 0.57; 95% CI 0.41 to 0.79), three studies, N = 416). Participants who received simultaneous administration of steroids and MTX had a higher risk for acute GvHD grade II to IV than the respective control groups (HR 1.38; 95% CI 0.74 to 2.57), two studies, N = 188).</P>
<P>Sensitivity analyses were performed for the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> (not in complete concordance with the a priori defined inclusion criteria) and the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> (study size &lt; 100 participants): in both analyses, the 95% CIs were clearly overlapping. In addition, a sensitivity analysis was performed with respect to the type of data: excluding those studies with data not derived from Kaplan-Meier (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) did not alter the 95% CIs considerably.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Acute GvHD grade III to IV</HEADING>
<P>All five studies comprising of 604 participants reported data of acute GvHD grade III to IV. The pooled HR was 0.78 (95% CI 0.52 to 1.15). Thus, there is no evidence that the addition of steroids improves the incidence of acute GvHD grade III to IV.</P>
<P>
<LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> reported a HR along with a 95% CI for acute GvHD grade III to IV. To include the data of the other four studies the respective HRs were calculated based on the listed number of participants affected by acute GvHD grade III-IV, for the study of Ruutu et al. a corresponding log-rank P-value was stated in addition.</P>
<P>The linear regression analysis of the funnel plot did not reveal a statistically significant asymmetry (P = 0.7975). There was no statistically significant heterogeneity among the trials (&#967;<SUP>2 </SUP>= 3.45, df = 4, P = 0.49; I<SUP>2 </SUP>= 0%). Subgroup analyses did not show any statistically significant difference.</P>
<P>Sensitivity analyses were performed for the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> (not in complete concordance with the a priori defined inclusion criteria) and the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> (study size &lt; 100 participants): in both analyses, the 95% CIs were clearly overlapping. In addition, a sensitivity analysis was performed with respect to the type of data: excluding those studies with data not derived from Kaplan-Meier (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) did not alter the 95% CIs considerably</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Chronic GvHD</HEADING>
<P>All five studies reported data to chronic GvHD, however, only <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> and <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> reported data for a restricted subset of participants (<I>see</I> definitions of outcome measures in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The remaining three studies did not state any restriction of the population. Hence, of all studies two subsets (studies restricted to participants surviving 100 days and studies with no restriction of the analysed population) were built. Of the studies with the restricted population the pooled HR was 1.14 (95% CI 0.72 to 1.81] (analysis based on two studies with 215 participants) while the pooled HR of the studies with no restriction was 1.27 (95% CI 0.84 to 1.93] (analysis based on three studies with 349 participants). Thus, for both subsets there is no evidence that the addition of steroids improves the incidence of chronic GvHD.</P>
<P>
<LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> reported a HR along with a 95% CI for chronic GvHD. <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> stated the number of participants affected by chronic GvHD along with a corresponding log-rank P-value. To include the data of the other three studies the respective HRs were calculated based only on the listed number of participants affected by chronic GvHD. The median follow up of the studies ranged from 0.8 to 6.4 years, the latter including a maximum follow up of 9.1 years. The long-term follow up results of <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK>and <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> could not be included into the analysis due to insufficiently reported data. Between both subsets there was no statistically significant heterogeneity (&#967;<SUP>2 </SUP>= 0.12, df = 1, P = 0.7315). However, statistically significant heterogeneity was observed within the subset with restricted population (&#967;<SUP>2 </SUP>= 8.10, df = 1, P = 0.004; I<SUP>2 </SUP>= 87.7%). Hence, it seemed reasonable to neglect the distinct population restrictions and to pool across all studies; the pooled HR was 1.21 (95% CI 0.89 to 1.65] (analysis based on five studies with 564 participants).<BR/>
<BR/>The linear regression analysis of the funnel plot did not reveal a statistically significant asymmetry (P = 0.7902). Heterogeneity tests confirmed statistically significant heterogeneity among all trials (&#967;<SUP>2 </SUP>= 12.80, df = 4, P = 0.01; I<SUP>2 </SUP>= 68.8%). Statistically significant differences between subgroups were found for the subgroups type of randomisation (P = 0.0238), concealment of allocation (P = 0.0027) and MTX part of GvHD prophylaxis regimen respective risk status of participants, as these subgroups are identical (P = 0.0406). No qualitative difference was seen between the result of the only as randomised described study of <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> and the pooled result of studies with no detailed reporting of randomisation: in both subgroups participants in the steroid group showed a more unfavourable outcome. However, in the subgroup with single study this risk was higher (HR 2.61; 95% CI 1.25 to 5.45], one study, N = 113) than in the subgroup consisting of the remaining studies (HR 1.02; 95% CI 0.73 to 1.44), four studies, N = 451). With respect to concealment of allocation, participants in the steroid group had a lower risk for developing chronic GvHD, if they were adequately concealed (HR 0.79; 95% CI 0.52 to 1.20], two studies N = 288); the pooled result of the studies, which did not report the way of concealment, showed an unfavourable outcome for participants in the steroid group (HR 2.07; 95% CI 1.30 to 3.31], three studies, N = 276). Statistically significant differences were found for the subgroups MTX part of GvHD prophylaxis regimen, which are identical to the subgroups risk status of participants. However, these differences were not caused by different directions of the outcome, but rather by the magnitude as the pooled results of both subgroups indicated a higher risk for chronic GvHD in the steroid group: if no MTX was given respective only high risk participants included, this risk was higher (HR 2.33; 95% CI 1.16 to 4.69), one study, N = 122) compared to those participants, who had received MTX respective were deemed as low risk participants (HR 1.03; 95% CI 0.73 to 1.46], four studies, N = 442).</P>
<P>Sensitivity analyses were performed for the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> (not in complete concordance with the a priori defined inclusion criteria) and the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> (median follow up &lt; 1 year, study size &lt; 100 participants): in both analyses, the 95% CIs were clearly overlapping. In addition, a sensitivity analysis was performed with respect to the type of data: excluding those studies with data not derived from Kaplan-Meier (<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>; <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) did not alter the 95% CIs considerably.</P>
<P>On top, <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> and <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> reported number of participants affected by the limited and extensive form of chronic GvHD. Tthe pooled HR for the limited form was 0.62 (95% CI 0.32 to 1.18) while for the extensive form the pooled HR was 1.05 (95% CI 0.62 to 1.78). Thus, there is no evidence that the addition of steroids improves the incidence neither of the limited nor the extensive form of chronic GvHD. For both outcomes there was no statistically significant heterogeneity between the trials ( &#967;<SUP>2 </SUP>= 0.24, df = 1, P = 0.62; I<SUP>2</SUP> = 0% for the limited form; &#967;<SUP>2 </SUP>= 0.92, df = 1, P = 0.34; I<SUP>2 </SUP>= 0% for the extensive form).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Incidence of infectious complications</HEADING>
<P>All studies provided data about the incidence of infections and prophylactic use of antiviral and antibacterial agents (<LINK REF="STD-Sayer-1994" TYPE="STUDY">Sayer 1994</LINK> reported these data separately for the study of <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>). However, due to the heterogeneity of the reported data no meta-analysis could be performed, details are listed in <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
<P>In conclusion, <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK>, <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> and <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> did not detect statistically significant differences between both treatment arms with respect to the analysed type of infections. Of note, <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> performed an additional analysis in order to take into account the use of steroids once GvHD has occurred by censoring participants at the time of treatment for GvHD: they could not identify a significant difference. <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> found statistically significant fewer rates of pneumonia and remarkably, but non-significant lower rates for other categories in the steroid group, while <LINK REF="STD-Sayer-1994" TYPE="STUDY">Sayer 1994</LINK> found considerably higher incidences of infections respective infectious episodes in the steroid group of the study of <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>.</P>
<P>Due to these inconsistent findings in the studies, a final judgment about the influence of steroids to the number of infections can hardly be given. However, in our review there is no clear evidence that steroids - under concomitant prophylactic use of antiviral or antibacterial medication or both - increase the number of infections in general.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>All studies gave details about adverse events. However, quality and quantity of the information given differed substantially among the studies. Thus, a pooling of data was not realisable.</P>
<P>
<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> did not list any adverse events explicitly, but mentioned severe oropharyngeal mucositis as a reason for omitting MTX doses: in the steroid group 5 of 80 MTX doses were not administered whereas 7 of 72 were not given in the control group.</P>
<P>As treatment toxicities <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> analysed duration of mucositis (measured in terms of days of morphine drip), peak levels of serum creatinine, bilirubin, alkaline phosphatase, aspartat transaminase and alanin transaminase. They detected a statistically significant higher median peak alkaline phosphatase level in the control group (P = 0.002) and a higher median alanine transaminase in the steroid group (P = 0.01). Assessing the reasons for removal from the study they found a higher but not statistically significant incidence of alveolar haemorrhage in the control group (8 in control group versus 3 in steroid group; P = 0.22).</P>
<P>
<LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> stated in their long-term follow up that more participants in the steroid group than in the control group had developed chronic pulmonary disease (four versus one patient). Also more participants in the steroid group developed aseptic necrosis than in the control group (five participants involving one to three joints versus three involving one to four joints) requiring replacement surgery in two participants in each treatment arm. At the time of last contact 4 participants of the steroid group still required immunosuppressive therapy compared with one patient in the control group.</P>
<P>Due to severe mucositis or liver toxicity the day +11 dose of MTX was not given in the study of <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> to seven participants in the steroid group and 17 participants in the control group. In the long-term follow up of the study the authors reported that two participants in the steroid group and one in the control group had developed a secondary malignancy.</P>
<P>
<LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> found significant higher bilirubin levels in the steroid group (P = 0.02) and a slightly, but not significant higher need for dialysis in the control group (three in steroid group, nine in control group: P = 0.13). Other adverse events were comparable in both groups including oral mucositis, doubling creatinine over baseline or creatinine over 2 mg/mL (one third of participants in each treatment arm) and the incidence of hypertension (47 participants in the steroid group versus 41 in the control group). The compliance with MTX and CSP also was comparable in both groups; however, there was a trend for lower doses of both drugs in the control group.</P>
<P>Due to the heterogeneity of the reported adverse events no conclusion can be drawn if the addition of steroids influences the incidence of certain adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Days spent in hospital</HEADING>
<P>Only <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> and <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> analysed the outcome days spent in hospital. However, a meta-analysis could not be performed, because means and standard deviations, which are indispensable for pooling the data, were not reported.</P>
<P>In the study of <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> participants randomised to the steroid group were hospitalised statistically significant for a shorter period (median 39 days versus 45 days; P = 0.03). However, after one year this difference was no longer significant (53 days versus 64 days; P = 0.13). The median follow up of this study was 0.8 years. <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> could not identify a significant difference between the two treatment groups (median 63 versus 57 days including pre-transplant conditioning regimen; P = 0.77; the median follow up among surviving participants were 871 days in steroid group and 931 days in control group).</P>
<P>Due to the sparse data no conclusion can be drawn whether the addition of steroids alters the period spent in hospital after stem cell transplantation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Engraftment</HEADING>
<P>All studies reported results for engraftment. However, due to the heterogeneity of the definitions reported for engraftment, no meta-analysis could be performed. <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> gives an overview about measures and results for engraftment. These data indicate that the addition of steroids might decrease the time to engraftment in terms of recruitment of granulocytes. However, no definite conclusions can be drawn.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>None of the studies assessed the quality of life of their transplanted participants in a systematic way. Only in the long-term follow up of the study of <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> some information is given: in both treatment arms the median Karnofsky performance score was 100 at the time of last contact. However, the lowest scores were seen in the steroid group (range steroid group 60 to 100 versus 80 to 100 in control group).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cause of death</HEADING>
<P>All studies except <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK> reported individual causes of deaths, which are listed in <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>. The long-term follow ups of the studies of <LINK REF="STD-Deeg-1997" TYPE="STUDY">Deeg 1997</LINK> and <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> did not contain updated information for this outcome. Thus, the median follow up of the studies ranged from 0.8 to 6.4 years, the latter including a maximum follow up of 9.1 years.</P>
<P>Relapse was the leading cause of death in both treatment arms in the study of <LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> as well as in the study of <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>. The pooled RR for death due to relapse consisting of four studies with 418 participants was 0.83 (95% CI 0.57 to 1.21). In the study of <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> relapse was leading cause of death only in the control group, whereas in the steroid group infections were more frequent considered responsible for death. However, the authors of this study did not separate deaths due to GvHD from those due to infections as the other studies did. Thus, the number of reported deaths due to infections might be higher compared to the other studies. The pooled RR for deaths due to infections consisting of four studies with 418 participants was 1.35 (95% CI 0.87 to 2.10); the pooled RR for deaths due to GvHD consisting of three studies with 271 participants was 1.00 (5% CI 0.48 to 2.11).<BR/>
<LINK REF="STD-Atkinson-1991" TYPE="STUDY">Atkinson 1991</LINK> and <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> also reported data on death due to veno-occlusive disease (VOD): the pooled RR consisting of two studies with 174 participants was 0.22 (95% CI 0.04 to 1.21).</P>
<P>To conclude, based on the data from the five included studies, individuals are not more likely to die from any one particular cause of death compared to another.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-06 10:54:40 +0100" MODIFIED_BY="Nicole Skoetz">
<P>This study represents the first systematic review assessing the role of corticosteroids (methylprednisolone, prednisone and prednisolone) for preventing GvHD after allogeneic myeloablative stem cell transplantation. According to the EBMT Handbook, an actual guideline for haematopoietic stem cell transplantation, methylprednisolone is used as first line treatment of GvHD; however, "its role in the prevention of GvHD is controversial" as several combinations with corticosteroids have been reported without substantial benefit (<LINK REF="REF-Devergie-2004" TYPE="REFERENCE">Devergie 2004</LINK>). So far, no systematic assessment of the studies evaluating the addition of corticosteroids to the prophylaxis regimen for GvHD has been conducted.</P>
<P>The main findings are as follows:<BR/>i) The addition of corticosteroids reduces statistically significant the risk for acute GvHD grade I to IV and grade II to IV.<BR/>ii) There is no evidence that addition of corticosteroids improves overall survival, disease-free survival, relapse incidence, non-relapse mortality or the incidence of chronic GvHD or acute GvHD grade III to IV.<BR/>iii) No clear evidence was found that the incidence of infectious complications - under the concomitant use of antiviral and/or antibacterial prophylactic medication - increases with the addition of corticosteroids.<BR/>iv) Concerning time to engraftment and days spent in hospital the addition of corticosteroids seems to be beneficial.<BR/>v) With respect to the outcomes other adverse events, quality of life, and causes of deaths, no obvious differences were detected.</P>
<P>However, to interpret these findings the following limitations should be taken into account:<BR/>a) If GvHD occurred, first-line therapy for all participants included the administration of corticosteroids exceeding the dosage used for preventing GvHD (for details <I>see </I>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). This might present a major problem since steroids were likely used earlier in the control groups thus masking the effect of the GvHD prevention strategy on the outcomes.<BR/>b) Only one study stated that two of the assessed time-to-event outcomes (OS and DFS) were calculated from time of randomisation (and not - misleadingly - from day of transplantation): thus, selection bias as a potential threat to the validity of the other individual study results can not clearly be excluded.<BR/>c) The results are based on a small number of studies (N = 5) and participants (N = 604), which might not sufficiently increase the power of the individual studies to detect small effects.</P>
<P>The reliability of all pooled results was tested by a priori defined subgroup and sensitivity analyses: statistically significant heterogeneity was found for acute GvHD grade I to IV, II to IV and chronic GvHD. However, results of subgroup analyses need to be interpreted with caution as subgroup comparisons are entirely observational and thus, have the same limitations as any other observational study.</P>
<SUBSECTION>
<HEADING LEVEL="2">Acute GvHD</HEADING>
<P>For acute GvHD grade I to IV and II to IV a statistically significant decreased risk was observed. The same, but not statistically significant tendency was seen for acute GvHD grade III to IV. This might be explained by the size of the study population: a number of 604 participants might be too small to show statistically different incidences for grade III to IV as - according to a data analysis of the EBMT and IBMTR based on 5809 participants - the frequency of grade III is supposed to range between 10 and 24% and for grade IV between 5 and 16% (<LINK REF="REF-Przepiorka-1995" TYPE="REFERENCE">Przepiorka 1995</LINK>). As in general, participants experiencing grade I have a more favourable prognosis - credited to the beneficial antileukaemic - compared to those with grade IV, which is life threatening, a reduction of particularly high grades of GvHD seems to be desirable. Therefore, ideal prevention strategies do not aim at erasing acute GvHD completely, but at finding the best balance between acute GvHD and the beneficial GvL effect. Considering this, the observed significant reduction of GvHD grade I to IV and II to IV, which is desirable in terms of a better quality of life, should not be interpreted without considering the results of the other (long-term) outcomes, especially OS, DFS and RI.</P>
<P>For acute GvHD grade I to IV and II to IV, substantial heterogeneity among the included studies was observed. The criteria of the a priori defined subgroup and sensitivity analyses found to be statistically significant were identical for both outcomes (type of randomisation; timing of the administration of steroids). Also <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> suspected that the timing of the steroid administration might have an influence for the outcome: the cumulative incidence of acute GvHD grade II to IV among participants receiving "late prednisone", that is, not overlapping with MTX, was lower than that seen in the group of HLA-identical recipients, who had received prednisone beginning on the day of transplantation. Furthermore, participants having received "late prednisone" did not show any case of acute GvHD grade IV, which is of special interest as explained above. The authors discussed various hypotheses potentially be responsible for this finding: one conceivable explanation they stated was that 'early' prophylactic prednisone interferes with the initial proliferation of donor lymphocytes activated by alloantigens. Thus, MTX's way of action as an antimetabolite for preventing acute GvHD might be reduced while still causing toxicity. According to another explanation, which is based on observational experimental animals, prednisone might be involved in down-regulating graft-versus-host responses: host lymphoid cells are held responsible for a reduced incidence of acute GvHD in recipients with mixed chimerism. These cells, however, might be eliminated by the administration of prednisone. In contrast to the findings of <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> are the results of the study by <LINK REF="STD-Macedo-1997" TYPE="STUDY">Macedo 1997</LINK> (also with steroids not overlapping with that of MTX) which could not be included into the meta-analysis as the data provided in the abstract were insufficiently reported and no full-text was available: they conclude that the addition of "high-dose steroids" did not decrease the incidence of GvHD, but instead had a negative impact on survival and increasing infection related mortality (<LINK REF="STD-Macedo-1997" TYPE="STUDY">Macedo 1997</LINK>).</P>
<P>Considering the results in this review for acute GvHD in the context of the contrary results observed in other (partly non-randomised) studies not included in this systematic review, the influence of the timing of steroid administration in dependence of the MTX administration on the various grades of GvHD needs to be evaluated in further randomised controlled clinical studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Chronic GvHD</HEADING>
<P>The analysis of chronic GvHD turned out to be difficult as the analyses of the individual studies based on different populations: to analyse chronic GvHD the statistical guidelines for EBMT recommend to restrict the population to those participants who have survived at least until day 100 post-transplant as only those are considered to be at risk (<LINK REF="REF-Labopin-2005" TYPE="REFERENCE">Labopin 2005</LINK>). However, only two studies analysed their data following this recommendation. Thus, in order to pool the individual study results two subsets of studies (studies restricted to participants surviving 100 days and studies with no restriction of the analysed population) were compiled: there was no evidence for both subsets that the addition of corticosteroids improves the incidence of chronic GvHD. Instead, both results showed an - non-significant - increased risk to develop chronic GvHD.</P>
<P>Due to the high heterogeneity observed in both subsets a pooling over all individual studies, covering 564 participants, was performed. This (second) result also indicated a tendency towards a negative impact of the addition of corticosteroids; however, this result was not statistically significant either. Still significant was the observed heterogeneity among all trials (type of randomisation; concealment of allocation; MTX part of prophylaxis regimen respective risk status of the participants). However, it should be considered that these 'subsequent' subgroup results cannot be weighted as the results of other subgroup analyses as they were performed after pooling the two different types of analysed populations. The pooled results of all, but one subgroup with statistically significant differences for chronic GvHD indicated the same (unfavourable) outcome for the participants in the steroid arm. Considering this, it raises the hypothesis that these subgroup significancies might be artefacts and thus, makes it hard to tell if they reflect real causes for the different outcomes in the study.</P>
<P>Two studies reported, in addition, data for the different appearances of GvHD, the limited and the extensive form: the risk to experience the limited form of chronic GvHD, which has - in general - a more favourable outcome than the extensive form, seems to be decreased by the addition of corticosteroids. However, this result was not statistically significant. For the extensive form of chronic GvHD, the addition of corticosteroids did not seem to have any influence. The explanatory power of these findings, however, is limited as only two studies consisting of 288 participants could be analysed. Nevertheless, comparing these results with those found for acute GvHD, certain parallels can be drawn: the less life-threatening appearances of GvHD (acute GvHD grade I-IV and II-IV respective chronic GvHD limited form) seem to be reduced by the addition of corticosteroids. However, for the unfavourable forms (acute GvHD grade III-IV respective extensive form of chronic GvHD) no similarities could be observed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Overall survival and disease-free survival</HEADING>
<P>The results for the outcome OS, which was considered as the primary outcome, as well as for the outcome DFS indicate that there are no clinically relevant differences. The conclusion which can be drawn from the analysis of DFS is, however, limited: the individual studies used various terms for this outcome (event-free survival, leukaemia-free survival, relapse-free survival) without stating the definitions used. Thus, the pooled result for DFS is only valid under the condition of congruent definitions. In the analysis of OS, the long-term follow up of <LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK> could not be included into the meta-analysis due to incomplete data: the authors report that - after a median follow up of 6.1 years - 23% participants in the control arm and 26% in the steroid arm were surviving, which indicates a slight tendency in favour of the addition of corticosteroids. The pooled result for OS (and DFS), however, shows that the advantage of decreased incidences of acute GvHD grade I-IV and II-IV cannot be transpolated to an advantage concerning the overall survival of the participants. This might be explained by the facts mentioned above: a sole reduction of low grades of acute GvHD might not increase the survival rate as a) especially higher grades have a negative impact on survival and b) the beneficial GvL effect might be eliminated. The latter argument should be reflected in particular in the relapse rates, as less GvL effects is supposed to enhance the relapse rates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Relapse incidence</HEADING>
<P>The meta-analysis of the individual relapse incidences showed a not statistically significant tendency towards favouring the addition of corticosteroids. This finding is surprising, as a significant reduction of low grades of acute GvHD - as found in this review - is supposed to cause a reduction of the beneficial antileukaemic effect resulting in an increased relapse rate. The result of this meta-analysis, however, shows a - not significant - tendency towards better relapse rates and hence, might indicate that the addition of corticosteroids could be able to decrease (low grades of) acute GvHD without influencing the GvL effect in the same extent. Nevertheless, as the pooled result is not statistically significant, the only conclusion which can be drawn is that no benefit for the addition of corticosteroids could be shown in this review for the outcome relapse incidence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Non-relapse mortality</HEADING>
<P>The pooled result for the outcome non-relapse mortality showed the same but less distinctive tendency as seen for the outcome RI. However, the explanatory power of this meta-analysis is not only limited by the non-significance of the result, but also by the fact that the cause of death is very subjective, and thus, likely to be biased. In addition, only one single study had analysed this outcome and reported a respective HR; to include the other studies, the respective HRs were calculated on the reported number and causes of deaths presented in the respective publications. Thus, it can be argued that participants who had relapsed and died because of different reasons (for example, pneumonia) are wrongly included into this analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Infections</HEADING>
<P>The incidence of infectious complications is of special interest as a) infections still remain an important cause of morbidity and mortality after allogeneic HSCT (<LINK REF="REF-Cordonnier-2004" TYPE="REFERENCE">Cordonnier 2004</LINK>; <LINK REF="REF-Gratwohl-2005a" TYPE="REFERENCE">Gratwohl 2005a</LINK>) and b) corticosteroids are non-specific immunosuppressive agents setting the stage more than others for infectious complications (<LINK REF="REF-Chao-2004" TYPE="REFERENCE">Chao 2004</LINK>). Depending on the immune reconstitution of the patient, the pattern of infections can be divided into three periods: 1) in the aplastic phase, in which infection-related mortality is mainly due to severe bacterial sepsis, pneumonia and fungal infections, 2) in the period from initial engraftment until the third or fourth month post-transplant, which is characterised by a cell-mediated immune deficiency and 3) in the late post-transplantation period, in which immune reconstitution is mainly influenced by the presence and severity of chronic GvHD (<LINK REF="REF-Cordonnier-2004" TYPE="REFERENCE">Cordonnier 2004</LINK>). All studies provided data on the outcome infections. Only two studies (<LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK>; <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>) found statistically significant differences for the prophylactic use of corticosteroids, which were - interestingly - oppositional to each other. Unfortunately, due to different patterns of infections the results of these studies cannot be compared in a direct manner. However, it should be considered that both studies differed according to the timing of steroid administration: while <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> initiated the steroid administration on day 14 post-transplant through day 110, <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> only administered corticosteroids from the day of transplantation until day 35 post-transplant. Thus, it can be hypothesized, if an "early" addition of corticosteroids in the most critical, the aplastic phase for developing infections, might be counterproductive. Considering the different definitions of outcomes in the individual studies, the different settings and the partly contrary results according to this outcome, a final judgment about the influence of corticosteroids on the infection rate can hardly be given: a significant decrease of GvHD achieved by the use of corticosteroids on the one hand (as seen in this review for lower grades), while (potentially) causing an increase in even life-threatening infections on the other hand would not justify the general addition of corticosteroids to a GvHD-prophylaxis regimen. Instead, it might represent an explanation if OS does not decrease or even increase. On the other side, corticosteroids are used as first-line treatment for acute and chronic GvHD, which might contribute to high rates of infections even if no corticosteroids are incorporated into the prophylaxis regimen. Therefore, the incidence of infectious complications is difficult to interpret. Thus, these findings reveal that further randomised controlled studies are needed to assess the influence of corticosteroids - also in dependence of the timing - on the incidence of infections after allogeneic HSCT, under the concomitant use of identical antibacterial, antiviral or antifungal prophylactic medications or both.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Causes of deaths</HEADING>
<P>No statistically significant difference was seen for any particular cause of death. According to a retrospective study of <LINK REF="REF-Socie-1999" TYPE="REFERENCE">Socie 1999</LINK> who analysed the mortality rates and causes of deaths of 6691 participants of the IBMTR, relapse represents a leading cause of death for participants who had undergone HSCT due to leukaemia. This finding can be also be seen in this review: in three of four studies, which mainly consisted of participants suffering from leukaemia, more people died due to relapse than due to any other cause. Interestingly, the pooled RR for death due to relapse reveals a slight, but not statistically significant advantage for the addition of corticosteroids (RR 0.83; 95% CI 0.57 to 1.21); analysis based on four studies including 418 participants). This corresponds to the (not significant) lower HR for relapse under the use of corticosteroids reported above (HR 0.82; 95% CI 0.57 to 1.18); analysis based on five studies including 604 participants). The pooled result for death due to infection shows a - presumed - tendency towards a worse outcome for the steroid group (RR=1.35, 95% CI 0.87,2.10]; analysis based on four studies with 418 participants). In conclusion, no obvious difference with respect to any particular cause of death was detected; however, as the differentiation between deaths due to GvHD and deaths due to infection was not stated explicitly and not handled uniformly in the individual studies, it cannot be confirmed irrevocably that corticosteroids do not increase the risk to die from infections.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Engraftment</HEADING>
<P>As noted above, the time to engraftment represents a critical phase for each patient as they are defenseless against pathogen agents until neutrophil recovery (<LINK REF="REF-Cordonnier-2004" TYPE="REFERENCE">Cordonnier 2004</LINK>). Thus, time to engraftment is an important outcome which was analysed by all included studies. However, a uniformly used definition of engraftment seems to be a matter of discussion as the applied definitions of the individual studies: three studies reporting further details for this outcome applied (slightly) different definitions for engraftment and found a small, but statistically significant benefit for the steroid group in terms of faster recovery of neutrophil respective granulocytes counts. The phenomenon, that glucocorticoids in general have a positive and rather unexpected impact on neutrophils has already been reported previously: several mechanism such as increased release from bone marrow or prolongation in the peripheral half life are thought to be responsible (<LINK REF="REF-Cox-1995" TYPE="REFERENCE">Cox 1995</LINK>; <LINK REF="REF-Hansen-1995" TYPE="REFERENCE">Hansen 1995</LINK>). In the context of allogeneic myeloablative HSCT, <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> supposed that the faster neutrophil recovery under the use of glucocorticoids is due to demargination, a shift from the marginated to the circulating pool. Considering the impact of the aplastic phase for the susceptibility of infections, each day less of aplasia could represent a survival benefit. However, a higher number of neutrophils does not explicitly imply a better immune constitution, as glucocorticoids interfere with the release of chemotactic factors, and thus impair the neutrophils' ability to react to pathogens (<LINK REF="REF-Barnes-1998" TYPE="REFERENCE">Barnes 1998</LINK>). Hence, this review shows that the addition of corticosteroids decreases the time to engraftment in terms of neutrophil respective granulocytes counts. If this fact translates directly into a faster immune recovery, and thus implies fewer infectious deaths under the concomitant use of corticosteroids, this needs to be evaluated in further studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Duration of hospital stay</HEADING>
<P>This outcome should be considered complimentary to the outcomes incidence of infections and time to engraftment discussed above: a fast engraftment and a low rate of infections should minimise the time spent in hospital. According to <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> participants in the steroid group spent statistically significant fewer days in hospital right after transplantation (median 39 days versus 45 days, P = 0.03). After a year, a difference was still observed (53 versus 64 days), which was, however, no longer statistically significant. In this same study, statistically significant fewer participants suffered from pneumonia and had a statistically significant faster engraftment (<I>see </I>above). Therefore, this result supports the hypothesis that these three outcomes are closely related. The other study which analysed this outcome was <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK>: they could not find a statistically significant difference between both groups although the steroid group tended to stay longer hospitalised (63 versus 57 days, P = 0.77). Looking back on the rate of infections and the time to engraftment in this study, the picture is more inconsistent as the recovery of granulocytes counts was statistically significantly faster in the steroid group. However, the prophylactic use of methylprednisolone was identified as a risk factor for first septicaemia, bacteraemia or fungaemia during the first 65 days after transplantation. Therefore it again might be hypothesised that the timing of the steroid administration plays a distinctive role because the studies of <LINK REF="STD-Ruutu-2000" TYPE="STUDY">Ruutu 2000</LINK> and <LINK REF="STD-Storb-1990" TYPE="STUDY">Storb 1990</LINK> differed with respect to that issue.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Adverse events</HEADING>
<P>The information given in the individual differed substantially with respect to quality and quantity. A meta-analysis could not be performed. Statistically significant different incidences of adverse events were only reported for the blood levels of alkaline phosphatase, alanine transaminase and bilirubin, each of these being higher in the steroid group (the latter, however, was not statistically significant in the study of <LINK REF="STD-Chao-2000" TYPE="STUDY">Chao 2000</LINK>). If those reactions should be reclassified as serious adverse events requiring a change in the drug administration, this was not stated by the authors. We cannot exclude the possibility that the addition of corticosteroids could be related to other serious adverse events with a major impact on survival or quality of life. Unfortunately, there is inadequate data and poor ly reporting or only partly statistically analysed data. This reflects a common problem: harms-related data often receive less attention compared with efficacy outcomes (<LINK REF="REF-Ioannidis-2002" TYPE="REFERENCE">Ioannidis 2002</LINK>; <LINK REF="REF-Medawar-2004" TYPE="REFERENCE">Medawar 2004</LINK>). In fact, due to this dilemma, the CONSORT statement has recently be extended by new recommendations about reporting harms-related issues (<LINK REF="REF-Ioannidis-2004" TYPE="REFERENCE">Ioannidis 2004</LINK>). Unfortunately, all studies included into this review were published prior to these recommendations and are lacking adequately reported data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Quality of life</HEADING>
<P>None of the studies assessed quality of life in a systematic way. This is unfortunate as not only 'hard outcomes' such as overall survival, disease-free survival or relapse-free survival should play a role in finding the best therapy, but also the subjective well-being of the participants. Only <LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK> reported this outcome in their long-term follow up, using the Karnofsky performance score which was 100 in both treatment arms at last contact with the lowest score seen in the steroid group (60 to 100). The original Karnofsky score was introduced 50 years ago as a tool to assess the performance status of the participants; in the adapted scoring system for bone marrow transplantation a score of 100% corresponds to a normal status with no complaints and no evidence of disease (<LINK REF="REF-Blume-2004" TYPE="REFERENCE">Blume 2004</LINK>). Considering this, the findings of <LINK REF="STD-Deeg-2000" TYPE="STUDY">Deeg 2000</LINK> are surprising, especially taking into account that they only included high risk participants into their study. On the other hand, a case-control study assessing the late effects of HSCT among 137 10-year survivors found that survivors and controls did not differ in terms of employment, marital satisfaction, psychological health and other items considered to be determinants for high quality of life (<LINK REF="REF-Syrjala-2005" TYPE="REFERENCE">Syrjala 2005</LINK>). Nevertheless, they also reported that survivors had a higher rate of medical needs and sexual problems, that is, items which also contribute to quality of life. Thus, basing on the data reported in the studies included into the review, no conclusion can be drawn concerning the quality of life under the addition of corticosteroids. Instead, this review reveals that further studies evaluating different prophylaxis regimens should include some measurement of quality of life.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-05-14 11:37:27 +0200" MODIFIED_BY="[Empty name]">
<P>There is strong evidence that the administration of corticosteroids to the prophylaxis regimen of GvHD reduces the incidences of acute GvHD grade I-IV and II-IV. However, there is no evidence that this is of any benefit regarding survival of the participants. For the incidence of infectious complications (under the concomitant use of antibacterial, antiviral and antifungal prophylactic medication), no clear evidence was found that these complications increase by incorporating corticosteroids to the prophylaxis regimen.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-05-07 01:11:31 +0200" MODIFIED_BY="[Empty name]">
<P>The subgroup analyses indicated that a 'late' administration of the steroid administration, i.e. not overlapping with MTX, seems to have a positive influence especially on acute GvHD (and potentially on infectious complications), which had already been observed by other authors. Whether the addition of corticosteroids to the prophylaxis regimen increases the quality of life could not be evaluated as these data were not systematically collected. Thus, further randomised controlled trials are needed evaluating the impact of the timing of the steroid administration as well as assessing the quality of life in a systematic manner. Even if no benefit on survival will be found, the addition of corticosteroids might be beneficial for the participants if their quality of life increases.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-13 14:51:39 +0200" MODIFIED_BY="Nicole Skoetz">
<P>Ronald Brand (statistician of the EBMT), Gail Higgins (Trials Search Co-ordinator), Kendra Hinnenthal (Academic librarian), Thilo Kober (Group Co-ordinator of the Cochrane Haematological Malignancies Group CHMG until March 2006), Olaf Weingart (Group Co-ordinator of the CHMG from April 2006 to December 2007), S.K. Srinivas (Pharmacist; native speaker)</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The review is not supported by the pharmaceutical industry or any other funding. Julia Bohlius and Alexander Greb are medical officers and reviewers, Kai Huebel is senior fellow in the stem cell transplantation unit of the clinics of the University of Cologne, Andreas Engert is co-ordinating editor of the CHMG.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-05-14 11:37:27 +0200" MODIFIED_BY="[Empty name]">
<P>SQ: conceiving the protocol, developing search strategy, undertaking searches, screening search results, selecting studies, obtaining and screening data on unpublished studies, appraising quality of papers, abstracting data from papers, analysis of data, interpretation of the findings, drafting and editing of the manuscript</P>
<P>JB: screening search results, selecting studies, screening data on unpublished studies, appraising quality of papers, abstracting data from papers, interpretation of the findings, content input</P>
<P>AG: providing general advice on the review</P>
<P>KH: providing a clinical perspective, content input</P>
<P>GS: providing statistical and methodological advice, analysis of data</P>
<P>AE: providing a clinical perspective, scientific advise, content input</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-05-14 11:37:27 +0200" MODIFIED_BY="[Empty name]">
<P>The quantity I<SUP>2</SUP> was not prospectively planned in the protocol (published in Issue 2, 2004 "Corticosteroids for preventing graft-versus-host disease") as it was not included into the software at that time. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-14 15:22:03 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-05-14 11:43:35 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-05-14 11:40:19 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Atkinson-1991" MODIFIED="2008-05-14 11:39:26 +0200" MODIFIED_BY="[Empty name]" NAME="Atkinson 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-14 11:39:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F, et al</AU>
<TI>A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>6</NO>
<PG>850-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chao-2000" MODIFIED="2008-05-14 11:39:36 +0200" MODIFIED_BY="[Empty name]" NAME="Chao 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-05-14 11:39:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS,et al</AU>
<TI>Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial</TI>
<SO>Biology of blood and marrow transplantation : Journal of the American Society for Blood and Marrow Transplantation</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>3</NO>
<PG>254-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deeg-1997" MODIFIED="2008-05-14 11:39:44 +0200" MODIFIED_BY="[Empty name]" NAME="Deeg 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-05-14 11:39:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, et al</AU>
<TI>Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>10</NO>
<PG>3880-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deeg-2000" MODIFIED="2008-05-14 11:39:54 +0200" MODIFIED_BY="[Empty name]" NAME="Deeg 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-05-14 11:39:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deeg H, Flowers M, Leisenring W, Appelbaum F, Martin P, Storb R</AU>
<TI>Cyclosporine (CSP) or CSP plus methylprednisolone for graft-versus-host disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: long-term follow-up of a randomized trial</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>3</NO>
<PG>1194-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="486"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruutu-2000" MODIFIED="2008-05-14 11:40:02 +0200" MODIFIED_BY="[Empty name]" NAME="Ruutu 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-05-14 11:40:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E</AU>
<TI>Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>7</NO>
<PG>2391-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruutu-2003" NAME="Ruutu 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ruutu T, Volin L, Juvonen E, Parkkali T, Elonen E, Nihtinen A</AU>
<TI>Cyclosporine, methotrexate and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: long-term follow-up of a randomized study [abstract]</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>S138</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Storb-1990" MODIFIED="2008-05-14 11:40:19 +0200" MODIFIED_BY="[Empty name]" NAME="Storb 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-05-14 11:40:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K, et al</AU>
<TI>What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?</TI>
<SO>Blood</SO>
<YR>1990</YR>
<VL>76</VL>
<NO>5</NO>
<PG>1037-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-05-14 11:43:35 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Basara-1999" MODIFIED="2008-05-14 11:40:28 +0200" MODIFIED_BY="[Empty name]" NAME="Basara 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-05-14 11:40:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Basara N, Blau W, Kiehl MG, Romer E, Bischoff M, Schmetzer B, et al</AU>
<TI>Mycophenolate mofetil in the treatment and prophylaxis of acute and chronic GVHD in bone marrow transplant patients [abstract]</TI>
<SO>Bone-Marrow-Transplantation</SO>
<YR>1999</YR>
<VL>23 Suppl 1</VL>
<PG>S89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bauser-1998" MODIFIED="2008-05-14 11:40:42 +0200" MODIFIED_BY="[Empty name]" NAME="Bauser 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-05-14 11:40:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bauser U, Kobbe G, Hunerliturkoglu A, Schneider P, Niederste-Hollenberg A, Rieth C, et al</AU>
<TI>Acute and chronic graft versus host disease in recipients of allogeneic peripheral blood stem cell transplantion</TI>
<SO>Annals of Hematology</SO>
<YR>1998</YR>
<VL>77 Suppl 2</VL>
<PG>S157</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buckner-1991" MODIFIED="2008-05-14 11:40:52 +0200" MODIFIED_BY="[Empty name]" NAME="Buckner 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-14 11:40:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Buckner CD, Clift RA, Appelbaum FR, Storb R, Petersen FB, Sanders JE, et al</AU>
<TI>Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia</TI>
<SO>Bone-Marrow-Transplantation</SO>
<YR>1991</YR>
<VL>7 Suppl 2</VL>
<PG>6-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elfenbein-1986" NAME="Elfenbein 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Elfenbein G, Goedert T, Graham-Pole J, Skoda-Smith S, Gross S, Weiner R</AU>
<TI>Is prophylaxis against acute graft versus host disease necessary if treatment is effective and survival is not impaired?</TI>
<SO>Proceedings of the American Society of Clinical Oncology [ASCO]</SO>
<YR>1986</YR>
<VL>5</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamazaki-2000" MODIFIED="2008-05-14 11:41:09 +0200" MODIFIED_BY="[Empty name]" NAME="Hamazaki 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-05-14 11:41:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamazaki T, Yagi K, Inoue M, Sakata N, Okamura T, Yasui M, et al</AU>
<TI>[Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors]</TI>
<SO>Jpn J Clin Hematol</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>5</NO>
<PG>430-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Helenglass-1987" NAME="Helenglass 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Helenglass G, Milliken S, Powles R</AU>
<TI>Factors influencing engraftment in cyclosporin (CYA) treated recipients of allogeneic bone marrow transplants (BMT) [abstract]</TI>
<SO>Blood</SO>
<YR>1987</YR>
<VL>70</VL>
<NO>5 Suppl 1</NO>
<PG>295a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraut-2000" MODIFIED="2008-05-14 11:41:25 +0200" MODIFIED_BY="[Empty name]" NAME="Kraut 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-05-14 11:41:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kraut L, Bunjes D, Bornhaeuser M, Stockschläder M, Ehninger G, Fauser A, et al</AU>
<TI>First results of a multicenter randomized trial on the mycophenolate mofetil in the prophylaxis of graft versus host disease [abstract]</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>Suppl 1</NO>
<PG>S151</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leelasiri-1995" MODIFIED="2008-05-14 11:41:34 +0200" MODIFIED_BY="[Empty name]" NAME="Leelasiri 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-05-14 11:41:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, et al</AU>
<TI>Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>3</NO>
<PG>401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linck-2004" MODIFIED="2008-05-14 11:41:40 +0200" MODIFIED_BY="[Empty name]" NAME="Linck 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-14 11:41:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Linck D, Schaefer-Eckart K, Kroeger M, Bornhaeuser M, Blau I, Wandt H, et al</AU>
<TI>Mycophenolate mofetil in combination with cyclosporine-A (CsA) +/- prednisolone - the new standard for GvHD prophylaxis? [abstract]</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2004</YR>
<VL>33</VL>
<NO>Suppl 1</NO>
<PG>S184</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lowenberg-1986" MODIFIED="2008-05-14 11:41:46 +0200" MODIFIED_BY="[Empty name]" NAME="Lowenberg 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-05-14 11:41:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lowenberg B, Sizoo W, Wagemaker G, Sintnicolaas K, Hendriks WD, Hagenbeek A</AU>
<TI>[Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in patients with leukemia]. [Dutch]</TI>
<SO>Nederlands tijdschrift voor geneeskunde</SO>
<YR>1986</YR>
<VL>130</VL>
<NO>19</NO>
<PG>872-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macedo-1997" MODIFIED="2008-05-14 11:41:52 +0200" MODIFIED_BY="[Empty name]" NAME="Macedo 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-05-14 11:41:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Macedo MCMA, PallottaFilho RS, Saboya R, Silva RL, Dzik C, Lotério H, et al</AU>
<TI>High-dose steroids, cyclosporine (CSA) and methotrexate (MTX) versus CSA and MTX as prophylaxis of graft-versus-host disease in HLA identical bone marrow transplantation</TI>
<SO>Blood</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michallet-1995" MODIFIED="2008-05-14 11:42:04 +0200" MODIFIED_BY="[Empty name]" NAME="Michallet 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-05-14 11:42:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Michallet M, Archimbaud E</AU>
<TI>Impact of graft versus host disease (GVHD) prophylactic and therapeutic management on survival and relapse post allogeneic transplant [abstract]</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15 Suppl 2</VL>
<PG>S144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michallet-1999" MODIFIED="2008-05-14 11:42:13 +0200" MODIFIED_BY="[Empty name]" NAME="Michallet 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-05-14 11:42:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, et al</AU>
<TI>Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>2</NO>
<PG>145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohty-2002" MODIFIED="2008-05-14 11:42:19 +0200" MODIFIED_BY="[Empty name]" NAME="Mohty 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-05-14 11:42:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, et al</AU>
<TI>Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>9</NO>
<PG>3128-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nandi-1987" MODIFIED="2008-05-14 11:42:29 +0200" MODIFIED_BY="[Empty name]" NAME="Nandi 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-05-14 11:42:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nandi A, Millar J, Millar B, Pollard C, Zuiable A, Treleaven J, et al</AU>
<TI>The effect of methyl prednisolone manipulation of bone marrow on engraftment and prevention of graft-versus-host disease [abstract]</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1987</YR>
<VL>2 Suppl 1</VL>
<PG>174</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1078"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nash-1995" MODIFIED="2008-05-14 11:42:36 +0200" MODIFIED_BY="[Empty name]" NAME="Nash 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-05-14 11:42:36 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19950720&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:42:36 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, et al .</AU>
<TI>Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study</TI>
<SO>Blood</SO>
<YR>1995</YR>
<VL>85</VL>
<NO>12</NO>
<PG>3746-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Przepiorka-1998" MODIFIED="2008-05-14 11:42:42 +0200" MODIFIED_BY="[Empty name]" NAME="Przepiorka 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-05-14 11:42:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Przepiorka D, Ippoliti C</AU>
<TI>Impact of prophylaxis regimen on the incidence of acute graft-versus-host disease after allogeneic blood stem cell transplantation [abstract]</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1998</YR>
<VL>21 Suppl 3</VL>
<PG>S107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramsay-1981" MODIFIED="2008-05-14 11:42:49 +0200" MODIFIED_BY="[Empty name]" NAME="Ramsay 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-05-14 11:42:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ramsay N, Kersey J, Robison L</AU>
<TI>Prevention of graft versus host disease (GVHD) in bone marrow transplantation (BMT) recipients: A randomized study</TI>
<SO>Proceedings of the American Association for Cancer Research</SO>
<YR>1981</YR>
<NO>Vol. 22</NO>
<PG>676</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruutu-2002" MODIFIED="2008-05-14 11:42:55 +0200" MODIFIED_BY="[Empty name]" NAME="Ruutu 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-05-14 11:42:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al</AU>
<TI>Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>6</NO>
<PG>1977-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sayer-1994" MODIFIED="2008-05-14 11:43:13 +0200" MODIFIED_BY="[Empty name]" NAME="Sayer 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-05-14 11:43:13 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical Trial; Journal Article; Randomized Controlled Trial&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:43:13 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sayer HG, Longton G, Bowden R, Pepe M, Storb R</AU>
<TI>Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>84</VL>
<NO>4</NO>
<PG>1328-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="967"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1989" MODIFIED="2008-05-14 11:43:22 +0200" MODIFIED_BY="[Empty name]" NAME="Schmidt 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-05-14 11:43:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schmidt GM, Snyder DS, Nademanee AP, ODonnel MR, Parker P, Stein A, et al</AU>
<TI>Prospective randomized study: cyclosporin A/prednisone/ methotrexate (CSA/PSE/MTX) versus CSA/PSE for the prevention of acute graft versus host disease (GVHD)</TI>
<SO>Blut</SO>
<YR>1989</YR>
<VL>59</VL>
<NO>3</NO>
<PG>218</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sullivan-1993" MODIFIED="2008-05-14 11:43:28 +0200" MODIFIED_BY="[Empty name]" NAME="Sullivan 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-05-14 11:43:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan KM, Gooley T, Nims J, Flowers M, Lin D, Anasetti C, et al</AU>
<TI>Comparison of cyclosporine (CSP), prednisone (Pred) or alternating-day CSP/Pred in patients with standard and high-risk chronic graft-versus-host disease (GvHD) [abstract]</TI>
<SO>Blood</SO>
<YR>1993</YR>
<VL>82</VL>
<NO>Suppl</NO>
<PG>845</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1137"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollemar-1989" MODIFIED="2008-05-14 11:43:35 +0200" MODIFIED_BY="[Empty name]" NAME="Tollemar 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-05-14 11:43:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollemar J, Ringden O, Backman L, Janossy G, Lonnqvist B, Markling L, et al</AU>
<TI>Results of four different protocols for prophylaxis against graft-versus-host disease</TI>
<SO>Transplantation Proceedings</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>1 Pt 3</NO>
<PG>3008-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-14 15:22:03 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-14 15:22:03 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Atkinson-1990" MODIFIED="2008-05-14 11:44:32 +0200" MODIFIED_BY="[Empty name]" NAME="Atkinson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, et al</AU>
<TI>Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation</TI>
<SO>Blood</SO>
<YR>1990</YR>
<VL>75</VL>
<NO>12</NO>
<PG>2459-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1183"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Atkinson-1995" MODIFIED="2008-05-14 11:44:39 +0200" MODIFIED_BY="[Empty name]" NAME="Atkinson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Atkinson K, Downs K</AU>
<TI>Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>6</NO>
<PG>755-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1192"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1998" MODIFIED="2008-05-14 11:44:45 +0200" MODIFIED_BY="[Empty name]" NAME="Barnes 1998" TYPE="JOURNAL_ARTICLE">
<AU>Barnes PJ</AU>
<TI>Anti-inflammatory actions of glucocorticoids: molecular mechanisms</TI>
<SO>Clinical Science</SO>
<YR>1998</YR>
<VL>94</VL>
<NO>6</NO>
<PG>557-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1239"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Benesch-2004" NAME="Benesch 2004" TYPE="BOOK_SECTION">
<AU>Benesch M, Deeg H</AU>
<TI>Acute graft-versus-host disease</TI>
<SO>Clinical bone marrow and blood stem cell transplantation</SO>
<YR>2004</YR>
<PG>1109-32</PG>
<EN>3rd</EN>
<ED>Atkinson K, Champlin R, Ritz J, Fibbe EW, Ljungman P, Brenner MK</ED>
<PB>Cambridge University Press</PB>
<CY>USA</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1190"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bensinger-2004" NAME="Bensinger 2004" TYPE="BOOK_SECTION">
<AU>Bensinger W, Spielberger R</AU>
<TI>Preparative Regimens and Modification of Regimen-Related Toxicities</TI>
<SO>Thomas' Hematopoietic Cell Transplantation</SO>
<YR>2004</YR>
<PG>158</PG>
<EN>3rd</EN>
<ED>Blume K, Forman J, Appelbaum FR</ED>
<PB>Blackwell Science</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1169"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bensinger-2006" MODIFIED="2008-05-14 11:45:17 +0200" MODIFIED_BY="[Empty name]" NAME="Bensinger 2006" NOTES="&lt;p&gt;DA - 20061004&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:45:17 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Bensinger W</AU>
<TI>Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>8</NO>
<PG>539-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Billingham-1966" MODIFIED="2008-05-14 11:45:23 +0200" MODIFIED_BY="[Empty name]" NAME="Billingham 1966" NOTES="&lt;p&gt;DA - 19681001&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:45:23 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Billingham R</AU>
<TI>The biology of graft-versus-host reactions</TI>
<SO>Harvey Lectures</SO>
<YR>1966</YR>
<VL>62</VL>
<PG>21-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1155"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blume-2004" NAME="Blume 2004" TYPE="BOOK_SECTION">
<AU>Blume KG, Amylon M</AU>
<TI>The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation</TI>
<SO>Thomas' Hematopoietic Cell Transplantation</SO>
<YR>2004</YR>
<PG>449-62</PG>
<EN>3rd</EN>
<ED>Blume KG, Forman J, Appelbaum FR</ED>
<PB>Blackwell Science</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1244"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bohlius-2005" NAME="Bohlius 2005" TYPE="CORRESPONDENCE">
<AU>Bohlius J</AU>
<TI>Expert opinion on in- or exclusion of a study</TI>
<SO>Personal communication</SO>
<YR>February 8 2005</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1163"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bolanos_x002d_Meade-2004" MODIFIED="2008-05-14 11:45:34 +0200" MODIFIED_BY="[Empty name]" NAME="Bolanos-Meade 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bolanos-Meade J, Vogelsang G</AU>
<TI>Acute graft-versus-host disease</TI>
<SO>Clinical Advances in Hematology &amp; Oncology : H&amp;O</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>10</NO>
<PG>672-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1156"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brand-2005" NAME="Brand 2005" TYPE="CORRESPONDENCE">
<AU>Brand R</AU>
<TI>Expert opinion on cumulative incidences</TI>
<SO>Personal communication</SO>
<YR>May 23, 2005</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1142"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burroughs-2005" MODIFIED="2008-05-14 11:45:56 +0200" MODIFIED_BY="[Empty name]" NAME="Burroughs 2005" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs L, Storb R</AU>
<TI>Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease</TI>
<SO>Current Opinion in Hematology</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>1</NO>
<PG>45-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1170"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cahn-2005" MODIFIED="2008-05-14 11:46:01 +0200" MODIFIED_BY="[Empty name]" NAME="Cahn 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cahn J, Klein J, Lee S, Milpied N, Blaise D, Antin J, et al</AU>
<TI>Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>4</NO>
<PG>1495-500</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1223"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carreras-2006" MODIFIED="2008-05-14 11:46:06 +0200" MODIFIED_BY="[Empty name]" NAME="Carreras 2006" TYPE="JOURNAL_ARTICLE">
<AU>Carreras E, Jimenez M, Gomez-Garcia V, de la CR, Martin C, Martinez F, et al</AU>
<TI>Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>1</NO>
<PG>33-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Castro-1997" MODIFIED="2008-05-14 11:47:04 +0200" MODIFIED_BY="[Empty name]" NAME="Castro 1997" NOTES="&lt;p&gt;DA - 19980615&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:47:04 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Castro AA, Clark OA, Atallah AN</AU>
<TI>Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS)</TI>
<SO>Sao Paulo Medical Journal/Revista Paulista de Medicina</SO>
<YR>1997</YR>
<VL>115</VL>
<NO>3</NO>
<PG>1423-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Castro-1999" MODIFIED="2008-05-14 11:47:10 +0200" MODIFIED_BY="[Empty name]" NAME="Castro 1999" NOTES="&lt;p&gt;DA - 20000229&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:47:10 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Castro AA, Clark OA, Atallah AN</AU>
<TI>Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): Update [Letter]</TI>
<SO>São Paulo Medical Journal / Revista Paulista de Medicina</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>3</NO>
<PG>138-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chao-2004" NAME="Chao 2004" TYPE="BOOK_SECTION">
<AU>Chao NJ</AU>
<TI>Pharmacology and the Use of Immunosuppressive Agents after Hematopoietic Cell Transplantation</TI>
<SO>Thomas' Hematopoietic Cell Transplantation</SO>
<YR>2004</YR>
<PG>209-20</PG>
<EN>3rd</EN>
<ED>Blume KG, Forman J, Appelbaum FR</ED>
<PB>Blackwell Science</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1186"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chao-2006" MODIFIED="2008-05-14 11:47:21 +0200" MODIFIED_BY="[Empty name]" NAME="Chao 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chao N, Chen B</AU>
<TI>Prophylaxis and treatment of acute graft-versus-host disease</TI>
<SO>Seminars in Hematology</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>1</NO>
<PG>32-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1185"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cordonnier-2004" NAME="Cordonnier 2004" TYPE="BOOK_SECTION">
<AU>Cordonnier C</AU>
<TI>Infections after HSCT</TI>
<SO>The EBMT Handbook - Haematopoietic Stem Cell Transplantation</SO>
<YR>2004</YR>
<PG>146-61</PG>
<ED>Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T</ED>
<PB>European School of Haematology</PB>
<CY>Paris</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1249"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cox-1995" MODIFIED="2008-05-14 11:47:37 +0200" MODIFIED_BY="[Empty name]" NAME="Cox 1995" NOTES="&lt;p&gt;Father Sean O'Sullivan Research Center, St Joseph's Hospital, McMaster University, Hamilton, Ontario, CanadaFAU - Cox, G&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:47:37 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Cox G</AU>
<TI>Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes</TI>
<SO>Journal of Immunology</SO>
<YR>1995</YR>
<VL>154</VL>
<NO>9</NO>
<PG>4719-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1241"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cutler-2005" MODIFIED="2008-05-14 11:47:43 +0200" MODIFIED_BY="[Empty name]" NAME="Cutler 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cutler C, Antin J</AU>
<TI>An overview of hematopoietic stem cell transplantation</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>4</NO>
<PG>517-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1179"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeg-2006a" MODIFIED="2008-05-14 11:47:49 +0200" MODIFIED_BY="[Empty name]" NAME="Deeg 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Deeg H</AU>
<TI>Transplant strategies for patients with myelodysplastic syndromes</TI>
<SO>Current Opinion in Hematology</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>2</NO>
<PG>61-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1175"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeg-2006b" MODIFIED="2008-05-14 11:47:53 +0200" MODIFIED_BY="[Empty name]" NAME="Deeg 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Deeg H, Antin J</AU>
<TI>The clinical spectrum of acute graft-versus-host disease</TI>
<SO>Seminars in Hematology</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>1</NO>
<PG>24-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks J, Altman D, Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>Systematic Reviews in Health Care - Meta-analysis in context</SO>
<YR>2001</YR>
<PG>285-312</PG>
<EN>2nd</EN>
<ED>Egger M, Smith GD, Altman D</ED>
<PB>BMJ Publ. Group</PB>
<CY>London</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Devergie-2004" NAME="Devergie 2004" TYPE="BOOK_SECTION">
<AU>Devergie A</AU>
<TI>Graft vs. host disease</TI>
<SO>The EBMT Handbook - Haematopoietic Stem Cell Transplantation</SO>
<YR>2004</YR>
<PG>163-77</PG>
<ED>Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T</ED>
<PB>European School of Haematology</PB>
<CY>Paris</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1248"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Diaconescu-2005" MODIFIED="2008-05-14 11:48:04 +0200" MODIFIED_BY="[Empty name]" NAME="Diaconescu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Diaconescu R, Storb R</AU>
<TI>Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care</TI>
<SO>Journal of Cancer Research and Clinical Oncology</SO>
<YR>2005</YR>
<VL>131</VL>
<NO>1</NO>
<PG>1-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1168"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2008-05-14 15:21:55 +0200" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-05-14 15:22:03 +0200" MODIFIED_BY="[Empty name]" NAME="Egger 1997" NOTES="&lt;p&gt;DA - 19971023&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 15:22:03 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elfenbein-2005" NAME="Elfenbein 2005" TYPE="CORRESPONDENCE">
<AU>Elfenbein G</AU>
<TI>Expert opinion on in- or exclusion of a study</TI>
<SO>Personal communication</SO>
<YR>January 28 2005</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1161"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Feinstein-2001" MODIFIED="2008-05-14 11:48:19 +0200" MODIFIED_BY="[Empty name]" NAME="Feinstein 2001" TYPE="JOURNAL_ARTICLE">
<AU>Feinstein L, Sandmaier B, Maloney D, McSweeney P, Maris M, Flowers C, et al</AU>
<TI>Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2001</YR>
<VL>938</VL>
<PG>328-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1172"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferrara-2004" NAME="Ferrara 2004" TYPE="BOOK_SECTION">
<AU>Ferrara JLM, Antin J</AU>
<TI>The Pathophysiology of Graft-vs-Host Disease</TI>
<SO>Thomas' Hematopoietic Cell Transplantation</SO>
<YR>2004</YR>
<PG>353-68</PG>
<EN>3rd</EN>
<ED>Blume KG, Forman J, Appelbaum FR</ED>
<PB>Blackwell Science</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1160"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferrara-2005" MODIFIED="2008-05-14 11:48:26 +0200" MODIFIED_BY="[Empty name]" NAME="Ferrara 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ferrara J, Yanik G</AU>
<TI>Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies</TI>
<SO>Clinical Advances of Hematology &amp; Oncology</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>5</NO>
<PG>415-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1151"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferrara-2006" MODIFIED="2008-05-14 11:48:35 +0200" MODIFIED_BY="[Empty name]" NAME="Ferrara 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ferrara J, Reddy P</AU>
<TI>Pathophysiology of graft-versus-host disease</TI>
<SO>Seminars in Hematology</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>1</NO>
<PG>3-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1191"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferrara-2007" MODIFIED="2008-05-14 11:48:40 +0200" MODIFIED_BY="[Empty name]" NAME="Ferrara 2007" NOTES="&lt;p&gt;DA - 20070305&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:48:40 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Ferrara JL</AU>
<TI>Novel strategies for the treatment and diagnosis of graft-versus-host-disease</TI>
<SO>Best Practice and Research. Clinical Haematology</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>1</NO>
<PG>91-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gale-1987" MODIFIED="2008-05-14 11:48:45 +0200" MODIFIED_BY="[Empty name]" NAME="Gale 1987" TYPE="JOURNAL_ARTICLE">
<AU>Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, et al</AU>
<TI>Risk factors for acute graft-versus-host disease</TI>
<SO>British Journal of Haematology</SO>
<YR>1987</YR>
<VL>67</VL>
<NO>4</NO>
<PG>397-406</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1177"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glucksberg-1974" MODIFIED="2008-05-14 11:48:53 +0200" MODIFIED_BY="[Empty name]" NAME="Glucksberg 1974" TYPE="JOURNAL_ARTICLE">
<AU>Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R, et al</AU>
<TI>Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors</TI>
<SO>Transplantation</SO>
<YR>1974</YR>
<VL>18</VL>
<NO>4</NO>
<PG>295-304</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1148"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldberg-2005" MODIFIED="2008-05-14 11:49:01 +0200" MODIFIED_BY="[Empty name]" NAME="Goldberg 2005" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg J, Jacobsohn D, Zahurak M, Vogelsang G</AU>
<TI>Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease</TI>
<SO>Biology of blood and marrow transplantation : Journal of the American Society for Blood and Marrow Transplantation</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>2</NO>
<PG>101-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gooley-2001" NAME="Gooley 2001" TYPE="BOOK_SECTION">
<AU>Gooley TA, Leisenring W, Crowley J, Storer BE</AU>
<TI>Why Kaplan-Meier Fails and Cumulative Incidence Succeeds When Estimating Failure Probabilities in the Presence of Competing Risks</TI>
<SO>Handbook of Statistics in Clinical Oncology</SO>
<YR>2001</YR>
<PG>513-23</PG>
<EN>1st</EN>
<ED>Cutler C</ED>
<PB>Dekker</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1141"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gratwohl-1995" MODIFIED="2008-05-14 11:49:06 +0200" MODIFIED_BY="[Empty name]" NAME="Gratwohl 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, et al</AU>
<TI>Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation</TI>
<SO>Blood</SO>
<YR>1995</YR>
<VL>86</VL>
<NO>2</NO>
<PG>813-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1164"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gratwohl-2005a" MODIFIED="2008-05-14 11:49:11 +0200" MODIFIED_BY="[Empty name]" NAME="Gratwohl 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, et al</AU>
<TI>Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>9</NO>
<PG>757-69</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1230"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gratwohl-2005b" MODIFIED="2008-05-14 11:49:17 +0200" MODIFIED_BY="[Empty name]" NAME="Gratwohl 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urbano-Ispizua A</AU>
<TI>Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>7</NO>
<PG>575-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1229"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hansen-1995" MODIFIED="2008-05-14 11:49:22 +0200" MODIFIED_BY="[Empty name]" NAME="Hansen 1995" NOTES="&lt;p&gt;Department of Hematology L, Herlev Hospital, University of Copenhagen, DenmarkFAU - Hansen, P B&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:49:22 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Hansen PB, Knudsen LM, Johnsen HE, Hansen NE</AU>
<TI>Stimulation tests for the bone marrow neutrophil pool in malignancies</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>3-4</NO>
<PG>237-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1240"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-05-14 11:49:26 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" NOTES="&lt;p&gt;DA - 20030905&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:49:26 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Horowitz-2004" NAME="Horowitz 2004" TYPE="BOOK_SECTION">
<AU>Horowitz M</AU>
<TI>Uses and Growth of Hematopoietic Cell Transplantation</TI>
<SO>Thomas' Hematopoietic Cell Transplantation</SO>
<YR>2004</YR>
<PG>9-15</PG>
<EN>3rd</EN>
<ED>Blume KG, Forman J, Appelbaum FR</ED>
<PB>Blackwell Science</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1167"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Horwitz-2006" MODIFIED="2008-05-14 11:49:37 +0200" MODIFIED_BY="[Empty name]" NAME="Horwitz 2006" TYPE="JOURNAL_ARTICLE">
<AU>Horwitz M, Sullivan K</AU>
<TI>Chronic graft-versus-host disease</TI>
<SO>Blood Reviews</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>1</NO>
<PG>15-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1222"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2002" MODIFIED="2008-05-14 11:49:42 +0200" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2002" NOTES="&lt;p&gt;DA - 20020312&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:49:42 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Lau J</AU>
<TI>Improving safety reporting from randomised trials</TI>
<SO>Drug Safety: an international of medical toxicology and drug experience</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>2</NO>
<PG>77-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" MODIFIED="2008-05-14 11:49:46 +0200" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2004" NOTES="&lt;p&gt;DA - 20041116&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:49:46 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<NO>10</NO>
<PG>781-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1245"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Juni-1999" MODIFIED="2008-05-14 11:49:53 +0200" MODIFIED_BY="[Empty name]" NAME="Juni 1999" NOTES="&lt;p&gt;DA - 19990929&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:49:53 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Witschi A, Bloch R, Egger M</AU>
<TI>The hazards of scoring the quality of clinical trials for meta-analysis</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>11</NO>
<PG>1054-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" MODIFIED="2008-05-14 11:50:01 +0200" MODIFIED_BY="[Empty name]" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman D, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Labopin-2005" NAME="Labopin 2005" TYPE="BOOK">
<AU>Labopin M, Iacobelli S</AU>
<SO>Statistical guidelines for EBMT</SO>
<YR>2005</YR>
<PB>EBMT</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1140"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2004" NAME="Lefebvre 2004" TYPE="CORRESPONDENCE">
<AU>Lefebvre C</AU>
<TI>EMBASE methodological search strategy for OVID</TI>
<SO>Personal communication</SO>
<YR>February 2 2004</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Medawar-2004" NAME="Medawar 2004" TYPE="JOURNAL_ARTICLE">
<AU>Medawar C, Herxheimer A</AU>
<TI>A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetin</TI>
<SO>Int J Risk Saf Med</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>5-19</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" MODIFIED="2008-05-14 11:50:30 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 1999" NOTES="&lt;p&gt;DA - 20000229&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:50:30 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2008-05-14 11:50:35 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 2001" NOTES="&lt;p&gt;DA - 20010417&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:50:35 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<NO>8</NO>
<PG>657-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2008-05-14 11:50:40 +0200" MODIFIED_BY="[Empty name]" NAME="Parmar 1998" NOTES="&lt;p&gt;DA - 19990324&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:50:40 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pepe-1993" MODIFIED="2008-05-14 11:50:45 +0200" MODIFIED_BY="[Empty name]" NAME="Pepe 1993" NOTES="&lt;p&gt;DA - 19930726&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:50:45 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R</AU>
<TI>Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods</TI>
<SO>British Journal of Haematology</SO>
<YR>1993</YR>
<VL>83</VL>
<NO>4</NO>
<PG>602-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="31"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Perez_x002d_Simon-2005" MODIFIED="2008-05-14 11:50:49 +0200" MODIFIED_BY="[Empty name]" NAME="Perez-Simon 2005" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Simon J, Diez-Campelo M, Martino R, Brunet S, Urbano A, Caballero M, et al</AU>
<TI>Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation</TI>
<SO>British journal of haematology</SO>
<YR>2005</YR>
<VL>130</VL>
<NO>3</NO>
<PG>394-403</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1153"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Przepiorka-1995" MODIFIED="2008-05-14 11:50:54 +0200" MODIFIED_BY="[Empty name]" NAME="Przepiorka 1995" TYPE="JOURNAL_ARTICLE">
<AU>Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al</AU>
<TI>1994 Consensus Conference on Acute GVHD Grading</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>6</NO>
<PG>825-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="80"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Przepiorka-2000" NAME="Przepiorka 2000" TYPE="BOOK_SECTION">
<AU>Przepiorka D</AU>
<TI>Prevention of Acute Graft-Versus-Host Disease</TI>
<SO>Hematopoietic stem cell therapy</SO>
<YR>2000</YR>
<PG>452-69</PG>
<EN>1st</EN>
<ED>Ball ED, Lister J, Law P</ED>
<PB>Churchill Livingstone</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1193"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ringden-1996" MODIFIED="2008-05-14 11:51:03 +0200" MODIFIED_BY="[Empty name]" NAME="Ringden 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ringden O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, et al</AU>
<TI>Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>5</NO>
<PG>921-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1182"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" MODIFIED="2008-05-14 11:51:08 +0200" MODIFIED_BY="[Empty name]" NAME="Robinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KA, Dickersin K</AU>
<TI>Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>150-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rowlings-1997" MODIFIED="2008-05-14 11:51:13 +0200" MODIFIED_BY="[Empty name]" NAME="Rowlings 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ,</AU>
<TI>IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade</TI>
<SO>British Journal of Haematology</SO>
<YR>1997</YR>
<VL>97</VL>
<NO>4</NO>
<PG>855-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1165"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sandmaier-2004" NAME="Sandmaier 2004" TYPE="BOOK_SECTION">
<AU>Sandmaier B, Storb R</AU>
<TI>Nonmyeloablative Therapy and Hematopoietic Cell Transplantation for Hematologic Disorders</TI>
<SO>Thomas' Hematopoietic Cell Transplantation</SO>
<YR>2004</YR>
<PG>1164-76</PG>
<EN>3rd</EN>
<ED>Blume KG, Forman J, Appelbaum FR</ED>
<PB>Blackwell Science</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1173"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sawyers-1999" MODIFIED="2008-05-14 11:51:22 +0200" MODIFIED_BY="[Empty name]" NAME="Sawyers 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sawyers C</AU>
<TI>Chronic myeloid leukemia</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>17</NO>
<PG>1330-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1178"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2001" MODIFIED="2008-05-14 11:51:27 +0200" MODIFIED_BY="[Empty name]" NAME="Simpson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Simpson D</AU>
<TI>New developments in the prophylaxis and treatment of graft versus host disease</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>7</NO>
<PG>1109-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1189"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Socie-1999" MODIFIED="2008-05-14 11:51:32 +0200" MODIFIED_BY="[Empty name]" NAME="Socie 1999" NOTES="&lt;p&gt;DA - 19990701&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:51:32 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al</AU>
<TI>Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>1</NO>
<PG>14-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1176"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stem-Cell-Trialists_x0027_-Collaborative-Group-2005" MODIFIED="2008-05-14 11:51:37 +0200" MODIFIED_BY="[Empty name]" NAME="Stem Cell Trialists' Collaborative Group 2005" TYPE="OTHER">
<AU>Stem Cell Trialists' Collaborative Group</AU>
<TI>Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>22</NO>
<PG>5074-87</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1157"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Storb-1986a" MODIFIED="2008-05-14 11:51:43 +0200" MODIFIED_BY="[Empty name]" NAME="Storb 1986a" TYPE="JOURNAL_ARTICLE">
<AU>Storb R, Deeg H, Farewell V, Doney K, Appelbaum F, Beatty P, et al</AU>
<TI>Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease</TI>
<SO>Blood</SO>
<YR>1986</YR>
<VL>68</VL>
<NO>1</NO>
<PG>119-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Storb-1986b" MODIFIED="2008-05-14 11:51:48 +0200" MODIFIED_BY="[Empty name]" NAME="Storb 1986b" TYPE="JOURNAL_ARTICLE">
<AU>Storb R, Deeg H, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al</AU>
<TI>Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<NO>12</NO>
<PG>729-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="22"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sullivan-2004" NAME="Sullivan 2004" TYPE="BOOK_SECTION">
<AU>Sullivan K</AU>
<TI>Graft-Versus-Host Disease</TI>
<SO>Thomas' Hematopoietic Cell Transplantation</SO>
<YR>2004</YR>
<PG>635-64</PG>
<EN>3rd</EN>
<ED>Blume KG, Forman J, Appelbaum FR</ED>
<PB>Blackwell Science</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1159"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Syrjala-2005" MODIFIED="2008-05-14 11:51:56 +0200" MODIFIED_BY="[Empty name]" NAME="Syrjala 2005" NOTES="&lt;p&gt;DA - 20050919&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:51:56 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ</AU>
<TI>Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>27</NO>
<PG>6596-606</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1243"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomas-1975" MODIFIED="2008-05-14 11:52:02 +0200" MODIFIED_BY="[Empty name]" NAME="Thomas 1975" NOTES="&lt;p&gt;DA - 19750529&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:52:02 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Thomas E, Storb R, Clift R, Fefer A, Johnson L, Neiman P, et al</AU>
<TI>Bone-marrow transplantation (second of two parts)</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1975</YR>
<VL>292</VL>
<NO>17</NO>
<PG>895-902</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Toze-2005" MODIFIED="2008-05-14 11:52:07 +0200" MODIFIED_BY="[Empty name]" NAME="Toze 2005" TYPE="JOURNAL_ARTICLE">
<AU>Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, et al</AU>
<TI>Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>9</NO>
<PG>825-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1181"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vargas_x002d_Diez-2005" MODIFIED="2008-05-14 11:52:13 +0200" MODIFIED_BY="[Empty name]" NAME="Vargas-Diez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vargas-Diez E, Garcia-Diez A, Marin A, Fernandez-Herrera J</AU>
<TI>Life-threatening graft-vs-host disease</TI>
<SO>Clinics in Dermatology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>3</NO>
<PG>285-300</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1154"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Verhagen-1998" MODIFIED="2008-05-14 11:52:19 +0200" MODIFIED_BY="[Empty name]" NAME="Verhagen 1998" NOTES="&lt;p&gt;DA - 19990407&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 11:52:19 +0200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al</AU>
<TI>The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>12</NO>
<PG>1235-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vogelsang-2003" MODIFIED="2008-05-14 11:52:27 +0200" MODIFIED_BY="[Empty name]" NAME="Vogelsang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Vogelsang G, Lee L, Bensen-Kennedy D</AU>
<TI>Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant</TI>
<SO>Annual Review ofMedicine</SO>
<YR>2003</YR>
<VL>54</VL>
<PG>29-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wheatley-2004" NAME="Wheatley 2004" TYPE="CORRESPONDENCE">
<AU>Wheatley K</AU>
<TI>Comments on title registration</TI>
<SO>Personal communication</SO>
<YR>March 9 2004</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1146"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wheatley-2005" NAME="Wheatley 2005" TYPE="CORRESPONDENCE">
<AU>Wheatley K</AU>
<TI>Expert opinion on in- or exclusion of a study</TI>
<SO>Personal communication</SO>
<YR>January 27 2005</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1162"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wingard-2002" MODIFIED="2008-05-14 11:52:37 +0200" MODIFIED_BY="[Empty name]" NAME="Wingard 2002" TYPE="OTHER">
<AU>Wingard JR, Vogelsang GB, Deeg HJ</AU>
<TI>Stem cell transplantation: supportive care and long-term complications</TI>
<SO>Hematology (the education program of the American Society of Hematology)</SO>
<YR>2002</YR>
<PG>422-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-06 10:55:36 +0100" MODIFIED_BY="Nicole Skoetz">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-06 10:55:23 +0100" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-06 10:54:52 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Atkinson-1991">
<CHAR_METHODS>
<P>unblinded randomised-controlled trial<BR/>median follow-up: 0.8 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 10:54:52 +0100" MODIFIED_BY="Nicole Skoetz">
<P>N = 41; all BMT; all HLA-identical sibling</P>
<P>steroid group: N = 21 (ALL = 4, ANL = 8, CML = 9); high risk participants = 13; median age = 36 [15-52]; sex mismatch = 4<BR/>control group: N = 20 (ALL = 2, ANL = 8, CML = 9, lymphoma = 1); high risk participants = 8; median age = 32 [15-50]; sex mismatch = 10</P>
<P>conditioning regimen:<BR/>acute leukaemia: BU + CY<BR/>CML: CY + fTBI (12 Gy total dose)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 01:13:58 +0200" MODIFIED_BY="[Empty name]">
<P>GvHD prophylaxis regimen:<BR/>steroid group: MTX + CSP+steroids<BR/>control group: MTX + CSP<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>primary outcome: acute GvHD</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>full-text publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 01:16:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chao-2000">
<CHAR_METHODS MODIFIED="2008-05-07 01:14:09 +0200" MODIFIED_BY="[Empty name]">
<P>double-blind randomised-controlled trial<BR/>median follow up: 2.1 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 01:16:02 +0200" MODIFIED_BY="[Empty name]">
<P>N = 186; all BMT; all HLA-identical sibling</P>
<P>steroid group: N = 90 (ALL = 19, AML = 28, CML = 43); high risk participants = 25; median age = 35 [2-49]; sex mismatch = 45<BR/>control group: N = 96 (ALL = 21, AML = 31, CML = 44); high risk participants = 22; median age = 35 [1-50]; sex mismatch = 45</P>
<P>conditioning regimen:<BR/>a) fTBI (13.20 Gy total dose) + VP16: 83 participants in steroid group, 90 participants in control group<BR/>b) fTBI (13.20 Gy total dose) + CY: 7 participants in steroid group, 6 participants in control group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 01:16:09 +0200" MODIFIED_BY="[Empty name]">
<P>GvHD prophylaxis regimen:<BR/>steroid group: MTX + CSP + steroids<BR/>control group: MTX + CSP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>primary and secondary outcomes not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 00:37:33 +0200" MODIFIED_BY="[Empty name]">
<P>full-text publication<BR/>steroid group did not receive last dose of MTX<BR/>one treatment arm consisted of 23% paediatric participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 01:18:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deeg-1997">
<CHAR_METHODS>
<P>unblinded randomised-controlled trial<BR/>median follow-up: 3.4 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 01:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>N = 122; all BMT; all HLA-identical sibling</P>
<P>steroid group: N = 62 (ALL = 13, ANL = 9, CML = 2, lymphoma = 20, MDS = 15, other = 3); median age = 39 [12-59]<BR/>control group: N = 60 (ALL = 15, ANL = 9, CML = 2, lymphoma = 21, MDS = 11, other = 2); median age = 36 [0.9-57]</P>
<P>conditioning regimen:<BR/>a) fTBI (12.00-15.75 Gy total dose) + chemotherapy (CY or CY + BU): 50 participants in steroid group, 51 participants in control group<BR/>b) only chemotherapy (BU + CY, ATG + BU + CY, ATG + CY, BCNU + CY + VP16): 12 participants in steroid group, 9 participants in control group<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 01:18:12 +0200" MODIFIED_BY="[Empty name]">
<P>GvHD prophylaxis regimen:<BR/>steroid group: CSP + steroids<BR/>control group: CSP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>primary outcomes: acute GvHD grade II-IV<BR/>secondary outcomes: chronic GvHD, infections, relapse, survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 00:37:34 +0200" MODIFIED_BY="[Empty name]">
<P>full-text publication<BR/>all participants included were deemed as high-risk participants<BR/>sex mismatch was not reported<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 01:18:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deeg-2000">
<CHAR_METHODS MODIFIED="2008-05-07 01:18:20 +0200" MODIFIED_BY="[Empty name]">
<P>median follow up: 6.1 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2008-05-07 01:18:24 +0200" MODIFIED_BY="[Empty name]">
<P>long-term follow up of Deeg 1997<BR/>published as letter to the editor</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 10:55:02 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Ruutu-2000">
<CHAR_METHODS>
<P>unblinded randomised-controlled trial<BR/>median follow-up: 6.4 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 10:55:02 +0100" MODIFIED_BY="Nicole Skoetz">
<P>N = 108; all BMT; all HLA-identical sibling</P>
<P>steroid group: N = 53 (ALL = 5, AML = 22, CML = 15, CLL = 2, MDS = 3, MM = 4, NHL = 2); high risk participants = 20; median age = 42 [18-54]; sex mismatch = 26<BR/>control group: N = 55 (ALL = 10, AML = 21, CML = 13, MDS = 6; MM = 4; NHL = 1); high risk participants = 18; median age = 41 [17-52]; sex mismatch = 25</P>
<P>conditioning regimen:<BR/>a) fTBI (12 Gy total dose) + CY: 34 participants in steroid group, 34 participants in control group<BR/>b) BU + CY: 19 participants in steroid group, 21 participants in control group<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 01:19:48 +0200" MODIFIED_BY="[Empty name]">
<P>GvHD prophylaxis regimen:<BR/>steroid group: MTX + CSP+steroids<BR/>control group: MTX + CSP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>primary and secondary outcomes not stated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>full-text publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 01:20:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruutu-2003">
<CHAR_METHODS MODIFIED="2008-05-07 01:19:57 +0200" MODIFIED_BY="[Empty name]">
<P>median follow up: 10.0 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2008-05-07 01:20:06 +0200" MODIFIED_BY="[Empty name]">
<P>long-term follow up of Ruutu 2000<BR/>published as an abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 10:55:17 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Storb-1990">
<CHAR_METHODS>
<P>unblinded randomised-controlled trial<BR/>median follow-up: 2.3 years in steroid group, 2.6 years in control group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 10:55:10 +0100" MODIFIED_BY="Nicole Skoetz">
<P>N = 147; all BMT; all HLA-identical sibling except for 25 participants (HLA-nonidentical relative differing no more than one HLA-locus)</P>
<P>steroid group: N = 73 (ANL = 31, CML = 27, MDS = 8, aplastic anaemia = 7); high risk participants = 27 (or 28); median age = 32 [5-53]; sex mismatch = 29<BR/>control group:<BR/>N = 74 (ANL = 32, CML = 30, MDS = 6; aplastic anaemia = 6); high risk participants = 26 (or 27); median age = 28 [1 to 55]; sex mismatch = 31</P>
<P>conditioning regimen:<BR/>a) AML/CML: fTBI (12.00-15.75 Gy total dose) + CY<BR/>b) MDS: fTBI (12 Gy total dose) + CY<BR/>c) aplastic anaemia: CY</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 01:21:48 +0200" MODIFIED_BY="[Empty name]">
<P>GvHD prophylaxis regimen:<BR/>steroid group: MTX + CSP + steroids<BR/>control group: MTX + CSP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>primary outcome: acute GvHD</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-06 10:55:17 +0100" MODIFIED_BY="Nicole Skoetz">
<P>full-text publication<BR/>randomisation was stratified for HLA-matching criteria<BR/>of one patient with CML in 2nd chronic phase the study arm was unknown<BR/>data of infections were published separately of Sayer 1994</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>participants deemed as low-risk participants: acute leukaemia in first remission or CML in first chronic phase; all others deemed as high-risk participants<BR/>ALL: acute lymphoblastic leukaemia<BR/>AML: acute myeloid leukaemia<BR/>ANL: acute non-lymphoblastic leukaemia<BR/>BCNU: carmustine<BR/>BMT: bone marrow transplantation<BR/>BU: busulfan<BR/>CLL: chronic lymphocytic leukaemia<BR/>CSP: cyclosporine A<BR/>CY: cyclophosphamide<BR/>fTBI: fractionated total body irradiation<BR/>HLA: human leukocyte antigen<BR/>MDS: myelodysplastic syndrome<BR/>MM: multiple myeloma<BR/>MTX: Methotrexate<BR/>NHL: non-Hodgkin lymphoma<BR/>VP16: etoposide<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-06 10:55:36 +0100" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Basara-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment arms did not differ with respect to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 00:37:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bauser-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 00:37:37 +0200" MODIFIED_BY="[Empty name]">
<P>participants were not randomised to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-06 10:55:36 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Buckner-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-06 10:55:36 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Study evaluating different conditioning regimens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elfenbein-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>A non-randomised consecutive study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamazaki-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A retrospective study analysing the effect of FK506.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 00:37:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Helenglass-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 00:37:37 +0200" MODIFIED_BY="[Empty name]">
<P>participants were not randomised to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kraut-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment arms differed with respect to the use of MMF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leelasiri-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>A non-randomised sequential study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 00:37:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linck-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 00:37:37 +0200" MODIFIED_BY="[Empty name]">
<P>participants were not randomised to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lowenberg-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study evaluating two different methods of reducing the number of T-lymphocytes in the graft.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Macedo-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract did not provide sufficient data; the authors were contacted, but did not reply; a full-text publication was not identified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Michallet-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study evaluating different doses of steroids in the treatment of GvHD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Michallet-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>A non-randomised retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mohty-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study compared PBSCT versus BMT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 00:37:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nandi-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 00:37:37 +0200" MODIFIED_BY="[Empty name]">
<P>Study did not seem to be randomised ("A control group of 23 participants matched for age, disease and conditioning regime was also studied."). Authors were contacted to clarify, but did not reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nash-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study focused on the pharmacokinetics of tacrolimus; no separate outcome analysis of the randomised groups was available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 01:23:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Przepiorka-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 01:23:16 +0200" MODIFIED_BY="[Empty name]">
<P>Participants were not randomised to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ramsay-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment and control group did not differ only with respect to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 01:23:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruutu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 01:23:28 +0200" MODIFIED_BY="[Empty name]">
<P>Participants were not randomised to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sayer-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective analysis of the infection data of the study of Storb 1990.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 01:23:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidt-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 01:23:35 +0200" MODIFIED_BY="[Empty name]">
<P>Participants were not randomised to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 01:23:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sullivan-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 01:23:41 +0200" MODIFIED_BY="[Empty name]">
<P>Participants were not randomised to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 01:23:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tollemar-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 01:23:45 +0200" MODIFIED_BY="[Empty name]">
<P>Participants were not randomised to the use of corticosteroids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Atkinson-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chao-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Deeg-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Deeg-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ruutu-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ruutu-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Storb-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-06 10:58:07 +0100" MODIFIED_BY="Nicole Skoetz">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-06 10:55:51 +0100" MODIFIED_BY="Nicole Skoetz" NO="1">
<TITLE>Criteria defining HSCT-relevant time-to-event-outcomes</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Definition</P>
</TH>
<TH>
<P>Relevant event</P>
</TH>
<TH>
<P>Censored cases</P>
</TH>
<TH>
<P>Competing risk</P>
</TH>
<TH>
<P>Population</P>
</TH>
</TR>
<TR>
<TD>
<P>Overall survival (OS)</P>
</TD>
<TD>
<P>Probability of being alive irrespective of disease state at any point of time</P>
</TD>
<TD>
<P>Death regardless of cause</P>
</TD>
<TD>
<P>Participants alive at last follow up</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>All participants</P>
</TD>
</TR>
<TR>
<TD>
<P>Disease-free survival (DFS)</P>
</TD>
<TD>
<P>Probability of being alive and free of disease at any point of time</P>
</TD>
<TD>
<P>Relapse of the disease or death regardless of cause</P>
</TD>
<TD>
<P>Participants alive and free of relapse at last follow up</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>All participants</P>
</TD>
</TR>
<TR>
<TD>
<P>Relapse incidence (RI)</P>
</TD>
<TD>
<P>Probability of having had a relapse before time t</P>
</TD>
<TD>
<P>Relapse</P>
</TD>
<TD>
<P>Participants alive and without relapse at last follow up</P>
</TD>
<TD>
<P>Death without relapse ("non-relapse mortality")</P>
</TD>
<TD>
<P>All participants</P>
</TD>
</TR>
<TR>
<TD>
<P>Non-relapse mortality (NRM)</P>
</TD>
<TD>
<P>Probability of dying without previous occurrence of relapse</P>
</TD>
<TD>
<P>Death without previous relapse</P>
</TD>
<TD>
<P>Participants alive and without relapse at last follow up</P>
</TD>
<TD>
<P>Relapse ("relapse incidence")</P>
</TD>
<TD>
<P>All participants</P>
</TD>
</TR>
<TR>
<TD>
<P>Acute GvHD (grade I-II, II-IV, III-IV)</P>
</TD>
<TD>
<P>Probability of acute GvHD</P>
</TD>
<TD>
<P>Acute GvHD within 100 days post-transplant</P>
</TD>
<TD>
<P>Participants alive at day 100 without having experienced acute GvHD</P>
</TD>
<TD>
<P>Death without acute GvHD within 100 days post-transplant</P>
</TD>
<TD>
<P>All participants</P>
</TD>
</TR>
<TR>
<TD>
<P>Chronic GvHD</P>
</TD>
<TD>
<P>Probability of chronic GvHD</P>
</TD>
<TD>
<P>Chronic GvHD after 100 days post-transplant</P>
</TD>
<TD>
<P>Participants alive without episodes of chronic GvHD at last follow-up</P>
</TD>
<TD>
<P>Death without chronic GvHD</P>
</TD>
<TD>
<P>Participants surviving 100 days</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>adopted by the statistical guidelines of the EBMT, Labopin 2005</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-11-06 10:56:03 +0100" MODIFIED_BY="Nicole Skoetz" NO="2">
<TITLE>Regimens used for GvHD prophylaxis in the included studies</TITLE>
<TABLE COLS="4" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>CSP</P>
</TH>
<TH>
<P>MTX</P>
</TH>
<TH>
<P>Steroids</P>
</TH>
</TR>
<TR>
<TD>
<P>Atkinson 1991</P>
</TD>
<TD>
<P>day 1-4: 3mg/kg iv over 24 hours, day 5-NR: 6.25 mg/kg po bid</P>
</TD>
<TD>
<P>day 1,3,6,11: 7.5 mg/sqm</P>
</TD>
<TD>
<P>day 0-19 MP on alternate days: 0.5 mg/k iv bid, day 20-30 prednisolone on alternate days: 0.5 mg/kg po bid</P>
</TD>
</TR>
<TR>
<TD>
<P>Chao 2000</P>
</TD>
<TD>
<P>day -2-3: 5mg/kg iv over 20 hours, day 4-14: 3 mg/kg iv over 20 hours, day 15-35 3.75 mg/kg iv over 20 hours, day 36-83: 5 mg/kg po bid, day 84-97: 4 mg/kg po bid, day 98-199: 3 mg/kg po bid, day 120-180: 2 mg/kg po bid</P>
</TD>
<TD>
<P>day 1: 15 mg/sqm, day 3,6,11: 10 mg/sqm (MTX dose on day 11 was only given to control group)</P>
</TD>
<TD>
<P>day 7-14 MP: 0.25 mg/kg iv bid, day 15-28 MP: 0.5 mg/kg iv bid, day 29-42 PSE: 0.4 mg/kg po bid, day 43-56 PSE: 0.25 mg/kg po bid, day 57-119 PSE: 0.1 mg/kg po bid, day 120-180 PSE: 0.1 mg/kg po qd</P>
</TD>
</TR>
<TR>
<TD>
<P>Deeg 1997</P>
</TD>
<TD>
<P>see Chao et al. (only difference: start on day -1 instead of day -2 of transplant)</P>
</TD>
<TD>
<P>./.</P>
</TD>
<TD>
<P>day 7-14 MP: 0.25 mg/kg iv bid, day 15-28 MP: 0.5 mg/kg iv bid, day 29-42 MP: 0.25 mg/kg po bid, day 43-56 MP: 0.15 mg/kg po bid, day 57-72 MP: 0.1 mg po bid</P>
</TD>
</TR>
<TR>
<TD>
<P>Rutuu 2000</P>
</TD>
<TD>
<P>day -1-13: 3 mg/kg/day iv, day 14-365: 1.5 mg po bid, day 366-407: tapering off</P>
</TD>
<TD>
<P>day 1: 15 mg/sqm, day 3,6,11: 10 mg/sqm (six hours after each dose the same milligram dose of calcium folinate was given iv)</P>
</TD>
<TD>
<P>day 14-20 MP: 0.25 mg/kg po bid, day 21-34: 0.5 mg/kg po bid, day 35-48 MP: 0.25 mg/kg po bid, day 49-69 MP: 0.12 mg/kg po bid, day 70-89 MP: 0.12 mg/kg po qd, day 90-99 MP on alternate days: 0.12 mg/kg po qd, day 100-110 MP on alternate days: 0.06 mg/kg po qd</P>
</TD>
</TR>
<TR>
<TD>
<P>Storb 1990</P>
</TD>
<TD>
<P>day -1-NR: 1.5 mg/kg iv bid, day NR-60: 6.25 mg/kg po bid (iv administration until patient recovered from conditioning-induced toxicity), day 60-180: -5% each week (participants with no acute GvHD were randomised to stop CSP after 60 days)</P>
</TD>
<TD>
<P>day 1: 15 mg/sqm, day 3,6,11: 10 mg/sqm</P>
</TD>
<TD>
<P>day 0-21 MP: 0.5 mg/kg po bid, day 22-35 MP: 0.25 mg/kg po bid</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>iv:intravenously; po:by mouth; bid:twice daily; qd:once daily; NR:not reported; MP: methylprednisolone; PSE: prednisone</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-11-06 10:56:23 +0100" MODIFIED_BY="Nicole Skoetz" NO="3">
<TITLE>Regimens used for GvHD treatment in the included studies</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>acute GvHD</P>
</TH>
<TH>
<P>chronic GvHD</P>
</TH>
</TR>
<TR>
<TD>
<P>Atkinson 1991</P>
</TD>
<TD>
<P>Prednisolone 2 mg/kg/day for 1 week, then reducing dosage; no differentiation between the 2 groups</P>
</TD>
<TD>
<P>Prednisolone 1 mg/kg on alternate days and CSP 6.25-12.5 mg/kg/day on alternate days for 9 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Chao 2000</P>
</TD>
<TD>
<P>Prednisolone 1 mg/kg/day for 3 days; if biopsy confirmed diagnosis, code was broken; patients in control group continued at 1 mg/kg/day, patients in steroid group continued at 2 mg/kg/day</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Deeg 1997</P>
</TD>
<TD>
<P>MP 2 mg/kg/day for 14 days, then tapering off; patients not responding ot MP were treated with ATG</P>
</TD>
<TD>
<P>Treatment with "continued immunosuppression"</P>
</TD>
</TR>
<TR>
<TD>
<P>Ruutu 2000</P>
</TD>
<TD>
<P>MP iv 10 mg/kg/day divided into 4 doses; dose was halved every 3 days; second-line treatment ATG</P>
</TD>
<TD>
<P>MP plus -according to personal judgment - with CSP, thalidomide, psoralen plus UV and low-dose irradiation of lymph nodes</P>
</TD>
</TR>
<TR>
<TD>
<P>Storb 1990</P>
</TD>
<TD>
<P>Treatment as "previously reported" by Thomas 1975 (ATG)</P>
</TD>
<TD>
<P>Treatment as "previously reported" by Thomas 1975 (ATG)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2008-05-12 13:31:22 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE>Internal validity of the included trials</TITLE>
<TABLE COLS="6" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Randomisation</P>
</TH>
<TH>
<P>Allocation</P>
</TH>
<TH>
<P>Blinding</P>
</TH>
<TH>
<P>Drop-outs</P>
</TH>
<TH>
<P>Intention-to-treat</P>
</TH>
</TR>
<TR>
<TD>
<P>Atkinson 1991</P>
</TD>
<TD>
<P>method of randomisation not reported</P>
</TD>
<TD>
<P>concealment of allocation not reported</P>
</TD>
<TD>
<P>unblinded</P>
</TD>
<TD>
<P>stated for each group</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Chao 2000</P>
</TD>
<TD>
<P>method of randomisation not reported</P>
</TD>
<TD>
<P>concealment of allocation adequate</P>
</TD>
<TD>
<P>participants and clinicians blinded</P>
</TD>
<TD>
<P>stated for each group</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Deeg 1997</P>
</TD>
<TD>
<P>method of randomisation not reported</P>
</TD>
<TD>
<P>concealment of allocation not reported</P>
</TD>
<TD>
<P>unblinded</P>
</TD>
<TD>
<P>not stated for each group</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Rutuu 2000</P>
</TD>
<TD>
<P>method of randomisation not reported</P>
</TD>
<TD>
<P>concealment of allocation adequate</P>
</TD>
<TD>
<P>unblinded</P>
</TD>
<TD>
<P>not stated for each group</P>
</TD>
<TD>
<P>yes, except for chronic GvHD</P>
</TD>
</TR>
<TR>
<TD>
<P>Storb 1990</P>
</TD>
<TD>
<P>truly randomised</P>
</TD>
<TD>
<P>concealment of allocation not reported</P>
</TD>
<TD>
<P>unblinded</P>
</TD>
<TD>
<P>not stated for each group</P>
</TD>
<TD>
<P>yes, except for chronic GvHD</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2008-11-06 10:57:20 +0100" MODIFIED_BY="Nicole Skoetz" NO="5">
<TITLE>Prophylactic use of antiviral and/or antibacterial agents and analysed infection</TITLE>
<TABLE COLS="4" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Prophylaxis</P>
</TH>
<TH>
<P>Analysed infection</P>
</TH>
<TH>
<P>Results/Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Atkinson 1991</P>
</TD>
<TD>
<P>cotrimoxazol (for Pneumocystis carinii prophylaxis)</P>
</TD>
<TD>
<P>rate of interstitial pneumonitis; to be evaluable participants had to develop complication or survive at least until day 180 post-transplant<BR/>
</P>
</TD>
<TD>
<P>uncommon in both treatment arms (11%, respectively)</P>
</TD>
</TR>
<TR>
<TD>
<P>Chao 2000</P>
</TD>
<TD>
<P>hospitalisation in rooms with high-efficiency particulate air filtration systems; Ig iv (500 mg/kg) every other week; low dose amphotericin B (0.15 mg/kg) beginning day 1 post-transplant (as prophylaxis for fungal infections)<BR/>
</P>
</TD>
<TD>
<P>any infection; classified in three main categories (bacterial, viral, fungal) subdivided into 5 sub-categories, respectively; analysed per overall number of infections and per infected patient</P>
</TD>
<TD>
<P>incidence of infections not significantly different between both treatment arms; steroid group tended to have fewer infections in all three categories</P>
</TD>
</TR>
<TR>
<TD>
<P>Deeg 1997</P>
</TD>
<TD>
<P>systemic antiviral and antibacterial antibiotics (not further specified); trimethroprim-sulfamethoxazole (for Pneumocystis carinii prophylaxis); 10 participants: intermittent Ig iv (all others: only if serum Ig G &lt; 400 mg/dL); 12 participants: hospitalised in laminar air-flow rooms</P>
</TD>
<TD>
<P>infections classified into 8 categories (first infection, all infections, first bacterial/fungal/invasive infection, all bacterial/fungal/invasive infections); Additional analysis: censoring participants of control group at time of treatment with steroids for acute GvHD</P>
</TD>
<TD>
<P>number of fungal infections slightly higher in steroid group (not statistically significant); no statistically significant difference in additional analysis censoring patients at time of treatment for GvHD</P>
</TD>
</TR>
<TR>
<TD>
<P>Ruutu 2000</P>
</TD>
<TD>
<P>cotrimoxazol (for Pneumocystis carinii prophylaxis) for one year; acyclovir (for prophylaxis of Herpes simplex infections) for five weeks post-transplant</P>
</TD>
<TD>
<P>infections classified into various categories; analysed per patient for the first 4 months and for the first year post-transplant</P>
</TD>
<TD>
<P>statistically significant fewer participants with pneumonia in steroid group for both periods; lower rates for the categories other bacterial infections, deep fungal infections, CMV infections and other viruses in steroid group; overall number of infections markedly lower in steroid group</P>
</TD>
</TR>
<TR>
<TD>
<P>Storb 1990 (analysed by Sayer 1994)</P>
</TD>
<TD>
<P>44 participants: Ig (500 mg/kg body weight weekly day -7 to day 90 post-transplant; subsequent monthly until day 360)</P>
</TD>
<TD>
<P>infections; defined as septicaemia, bacteraemia or fungaemia; subdivided according to time of onset (during first 65 days vs. days 65-100 post-transplant); data collected retrospectively from the participants' charts</P>
</TD>
<TD>
<P>71 episodes of first infections in steroid group within the first 65 days vs. 47 in control group; 93 episodes of all infections in steroid group vs. 63 in control group; predominant infections: bacteraemias (caused by Staphylococcus and Streptococcus species); no influence of Ig for first infection within 65 days detected; participants receiving prophylactic methyl-prednisolone higher risk for infection (RR 1.6; P = 0.03); acute GvHD as predominant risk factor for infections detected (RR 2.8; P = 0.005)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Ig=Immunoglobulines</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2008-11-06 10:57:44 +0100" MODIFIED_BY="Nicole Skoetz" NO="6">
<TITLE MODIFIED="2008-11-06 10:57:37 +0100" MODIFIED_BY="Nicole Skoetz">Overview of measures and results for engraftment</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Measures/Definitions</P>
</TH>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Atkinson 1991</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>"All participants showed rapid and sustained haematological engraftment."</P>
</TD>
<TD>
<P>if genetic marker difference between donor and recipient pre-transplant existent, evidence for engraftment was sought</P>
</TD>
</TR>
<TR>
<TD>
<P>Chao 2000 (measure 1)</P>
</TD>
<TD>
<P>median time to myeloid recovery (500 granulocytes/µL)</P>
</TD>
<TD>
<P>statistically significant shorter in steroid group (19 versus 21 days, P = 0.0001)</P>
</TD>
<TD>
<P>5 of 193 participants having entered the trial died before engraftment between day 19 and 29; the remaining 186 participants achieved engraftment</P>
</TD>
</TR>
<TR>
<TD>
<P>Chao 2000 (measure 2)</P>
</TD>
<TD>
<P>time to platelet transfusion independence (&gt; 25.000 platelets/µL sustained for 3 days)</P>
</TD>
<TD>
<P>no statistically significant difference (27 days in steroid group versus 30 days, P = 0.67)</P>
</TD>
<TD>
<P>see row above</P>
</TD>
</TR>
<TR>
<TD>
<P>Deeg 1997</P>
</TD>
<TD>
<P>first of at least 3 consecutive days with neutrophil counts &gt; 0.5 x 109/L</P>
</TD>
<TD>
<P>sustained engraftment in all remaining participants (104)</P>
</TD>
<TD>
<P>18 participants (12 in control group, 6 in steroid group) died before day 28 and were not evaluable for engraftment</P>
</TD>
</TR>
<TR>
<TD>
<P>Ruutu 2000 (measure 1)</P>
</TD>
<TD>
<P>neutrophil recovery: 1.0 x 109 neutrophils/L</P>
</TD>
<TD>
<P>statistically significant faster in steroid group (median days 19 versus 24; P &lt; 0.0001)</P>
</TD>
<TD>
<P>"All participants showed engraftment"; one patient in each group received granulocyte colony-stimulating factor</P>
</TD>
</TR>
<TR>
<TD>
<P>Ruutu 2000 (measure 2)</P>
</TD>
<TD>
<P>platelet recovery: 50 x 109/L</P>
</TD>
<TD>
<P>not statistically significant (median days 20 in steroid group versus 21, P = 0.35)</P>
</TD>
<TD>
<P>see row above</P>
</TD>
</TR>
<TR>
<TD>
<P>Ruutu 2000 (measure 3)</P>
</TD>
<TD>
<P>tranfusion units given within the first year post-transplant</P>
</TD>
<TD>
<P>no statistically significant (median platelets units 28 in steroid group versus 48, p=0.09; median red blood cells units 4 in steroid group versus 8, P = 0.15)</P>
</TD>
<TD>
<P>see row above</P>
</TD>
</TR>
<TR>
<TD>
<P>Storb 1990 (measure 1)</P>
</TD>
<TD>
<P>recovery of granulocyte counts to 1000/mm<SUP>3</SUP>
</P>
</TD>
<TD>
<P>statistically significant faster in steroid group (median days 21 versus 26 days; P = 0.001).</P>
</TD>
<TD>
<P>sustained haematopoietic engraftment in 137 of 147 patients: 7 died before day 19, 1 HLA non-identical rejected graft on day 80, 2 died on days 32 and 42 had only poorly functioning grafts</P>
</TD>
</TR>
<TR>
<TD>
<P>Storb 1990 (measure 2)</P>
</TD>
<TD>
<P>time to discontinuation of transfusion of platelets and red blood cells</P>
</TD>
<TD>
<P>no statistically significant differences (data not reported)</P>
</TD>
<TD>
<P>see row above</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2008-11-06 10:58:07 +0100" MODIFIED_BY="Nicole Skoetz" NO="7">
<TITLE>Causes of deaths</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Total deaths</P>
</TH>
<TH>
<P>Relapse</P>
</TH>
<TH>
<P>GvHD</P>
</TH>
<TH>
<P>VOD*</P>
</TH>
<TH>
<P>Infections related**</P>
</TH>
<TH>
<P>Other</P>
</TH>
</TR>
<TR>
<TD>
<P>Atkinson 1991 (steroid arm; N = 21)</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>1 (haemorrhage; suicide)</P>
</TD>
</TR>
<TR>
<TD>
<P>Atkinson 1991 (control arm; N = 20)</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1 (idiopathic pneumonitis)</P>
</TD>
</TR>
<TR>
<TD>
<P>Deeg 1997 (steroid arm; N = 62)</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>5 (3 with infections)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>11 (pulmonary, hepatic or cardiac failure or undetermined)</P>
</TD>
</TR>
<TR>
<TD>
<P>Deeg 1997 (control arm; N = 60)</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>10 (pulmonary, hepatic or cardiac failure or undetermined)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ruutu 2000 (steroid arm; N = 53)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1 (acute respiratory distress syndrome)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ruutu 2000 (control arm; N = 55)</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>1 (intracerebral haemorrhage)</P>
</TD>
</TR>
<TR>
<TD>
<P>Storb 1990 (steroid arm; N = 73)</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>22 (partly associated with acute or chronic GvHD)</P>
</TD>
<TD>
<P>3 (idiopathic pneumonitis, haemorrhage, cerebrovascular accident or other malignant tumour)</P>
</TD>
</TR>
<TR>
<TD>
<P>Storb 1990 (control arm; N = 74)</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>10 (partly associated with acute or chronic GvHD)</P>
</TD>
<TD>
<P>7 (idiopathic pneumonitis, haemorrhage, cerebrovascular accident or other malignant tumour)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*veno-occlusive disease; **pneumonia, sepsis etc. of fungal, bacterial or viral causes</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-14 15:19:24 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-05-07 01:55:35 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Overall Survival</NAME>
<IPD_OUTCOME CHI2="4.848261527913677" CI_END="1.2506133517738345" CI_START="0.7876866073041394" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.49619988587341" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978788" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="1" P_CHI2="0.30322440069009293" P_Q="1.0" P_Z="0.9492219640195189" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.06368385056955797">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5301" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5302" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5303" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5304" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5305" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.848261527913677" CI_END="1.2506133517738345" CI_START="0.7876866073041393" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.49619988587341" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978794" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="2" P_CHI2="0.30322440069009293" P_Q="0.9745395887036424" P_Z="0.9492219640195189" Q="0.00101858719666037" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.063683850569558">
<NAME>Type of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.5700780860677361" CI_START="0.6192201789111701" DF="0.0" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" NO="1" P_CHI2="1.0" P_Z="0.9526820322811917" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="74" WEIGHT="24.687065368567453" Z="0.05933908290969267">
<NAME>Truly randomised</NAME>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5306" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.847242940717017" CI_END="1.298217475176497" CI_START="0.7620804597818781" DF="3.0" EFFECT_SIZE="0.994658821093632" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="103" I2="38.10914706172676" ID="CMP-001.02.02" LOG_CI_END="0.11334745082933914" LOG_CI_START="-0.11799917381186709" LOG_EFFECT_SIZE="-0.002325861491263944" NO="2" P_CHI2="0.18333076370823131" P_Z="0.9685640619727134" STUDIES="4" TAU2="0.0" TOTAL_1="226" TOTAL_2="231" WEIGHT="75.31293463143254" Z="0.03940930422456676">
<NAME>Type of randomisation not reported</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5307" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5308" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5309" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5310" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.848261527913677" CI_END="1.2506133517738345" CI_START="0.7876866073041394" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.49619988587341" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978788" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="3" P_CHI2="0.30322440069009293" P_Q="0.5237859387018001" P_Z="0.9492219640195189" Q="0.4064322640061375" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.06368385056955794">
<NAME>Concealment of allocation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.9096844123201753" CI_END="1.5723743670512746" CI_START="0.7543183801800546" DF="1.0" EFFECT_SIZE="1.0890688158196231" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="54" I2="74.42248799292328" ID="CMP-001.03.01" LOG_CI_END="0.19655595530899972" LOG_CI_START="-0.12244530987185769" LOG_EFFECT_SIZE="0.03705532271857103" NO="1" P_CHI2="0.04800867198220793" P_Z="0.6488642944661149" STUDIES="2" TAU2="0.0" TOTAL_1="143" TOTAL_2="151" WEIGHT="39.6105702364395" Z="0.45534050106498575">
<NAME>Concealment of allocation adequate</NAME>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5311" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5312" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.5321448515873644" CI_END="1.2573935288788003" CI_START="0.6936108109141412" DF="2.0" EFFECT_SIZE="0.9338852955282133" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="86" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.09947122094222619" LOG_CI_START="-0.15888414637993492" LOG_EFFECT_SIZE="-0.029706462718854378" NO="2" P_CHI2="0.7663836343963574" P_Z="0.6521878436970237" STUDIES="3" TAU2="0.0" TOTAL_1="156" TOTAL_2="154" WEIGHT="60.3894297635605" Z="0.4507248882848516">
<NAME>Concealment of allocation not reported</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5313" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5314" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5315" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.848261527913678" CI_END="1.2506133517738345" CI_START="0.7876866073041393" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.496199885873423" I2_Q="72.47835782767149" ID="CMP-001.04" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978794" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="4" P_CHI2="0.30322440069009293" P_Q="0.056627662293655345" P_Z="0.9492219640195187" Q="3.633504111921943" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.06368385056955805">
<NAME>Blinding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="2.4677672593388946" CI_START="0.9256294766914541" DF="0.0" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" NO="1" P_CHI2="1.0" P_Z="0.09873199643293816" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="22.225312934631432" Z="1.6510322178050578">
<NAME>Patients and clinicians blinded</NAME>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5316" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.2147574159917347" CI_END="1.1438686626433063" CI_START="0.6772052421381072" DF="3.0" EFFECT_SIZE="0.8801328619359425" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="114" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.05837616225094976" LOG_CI_START="-0.1692796887455569" LOG_EFFECT_SIZE="-0.05545176324730364" NO="2" P_CHI2="0.7494671637409005" P_Z="0.3396763904813749" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="77.77468706536857" Z="0.9548048808604936">
<NAME>Patients and clinicians not blinded</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5317" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5318" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5319" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5320" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.848261527913678" CI_END="1.2506133517738345" CI_START="0.7876866073041394" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.496199885873423" I2_Q="74.68950412597697" ID="CMP-001.05" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978788" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="5" P_CHI2="0.30322440069009293" P_Q="0.046845536884278616" P_Z="0.9492219640195189" Q="3.9509301002132142" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.06368385056955794">
<NAME>Statement of withdrawals in each group</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.14516664348954722" CI_END="2.245326479479382" CI_START="0.9341575283808451" DF="1.0" EFFECT_SIZE="1.4482709119769421" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="32" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.35127949809103964" LOG_CI_START="-0.029579881866408683" LOG_EFFECT_SIZE="0.16084980811231547" NO="1" P_CHI2="0.7031978876748104" P_Z="0.0978194136249383" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="116" WEIGHT="27.788595271210013" Z="1.6555182695279265">
<NAME>Withdrawals stated</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5321" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5322" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.7521647842109167" CI_END="1.126459848802062" CI_START="0.6538122818007839" DF="2.0" EFFECT_SIZE="0.8581918690492484" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="108" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.05171571647310301" LOG_CI_START="-0.18454692549898202" LOG_EFFECT_SIZE="-0.0664156045129395" NO="2" P_CHI2="0.6865459168214718" P_Z="0.2704930560730281" STUDIES="3" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="72.21140472878999" Z="1.1019278525819372">
<NAME>Withdrawals not stated</NAME>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5323" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5324" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5325" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.848261527913678" CI_END="1.2506133517738345" CI_START="0.7876866073041393" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.496199885873423" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978794" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="6" P_CHI2="0.30322440069009293" P_Q="0.3882181786655038" P_Z="0.9492219640195189" Q="0.7445157610996134" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.063683850569558">
<NAME>MTX part of prophylaxis regimen</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.103745766814065" CI_END="1.3991606701347135" CI_START="0.8047542362326965" DF="3.0" EFFECT_SIZE="1.061122272153916" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="97" I2="26.896056177255726" ID="CMP-001.06.01" LOG_CI_END="0.14586758879228087" LOG_CI_START="-0.09433672850672681" LOG_EFFECT_SIZE="0.02576543014277707" NO="1" P_CHI2="0.25047728886446663" P_Z="0.6741423821496344" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="69.86091794158554" Z="0.4204696709357129">
<NAME>MTX included</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5326" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5327" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5328" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5329" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2951141969741715" CI_START="0.557957786608402" DF="0.0" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" NO="2" P_CHI2="1.0" P_Z="0.44955379174817" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="30.139082058414466" Z="0.7561591431346929">
<NAME>MTX not included</NAME>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5330" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.848261527913677" CI_END="1.2506133517738345" CI_START="0.7876866073041394" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.49619988587341" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978788" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="7" P_CHI2="0.30322440069009293" P_Q="0.8546816236590675" P_Z="0.9492219640195189" Q="0.03354334037199003" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.06368385056955791">
<NAME>Timing of steroid administration</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.1496130807835519" CI_END="1.5613451845004893" CI_START="0.6736982054044786" DF="1.0" EFFECT_SIZE="1.0256097936422528" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="43" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.1934989281432804" LOG_CI_START="-0.17153460951828836" LOG_EFFECT_SIZE="0.010982159312496069" NO="1" P_CHI2="0.6989055405834764" P_Z="0.906121237678206" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="94" WEIGHT="30.250347705146034" Z="0.11793237883215744">
<NAME>MTX overlapping with steroids</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5331" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5332" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.665105106758135" CI_END="1.2905017951969961" CI_START="0.7419297458143639" DF="2.0" EFFECT_SIZE="0.9784997030574345" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="97" I2="57.128511486210954" ID="CMP-001.07.02" LOG_CI_END="0.11075861302061381" LOG_CI_START="-0.12963721662079497" LOG_EFFECT_SIZE="-0.009439301800090612" NO="2" P_CHI2="0.09704789686794724" P_Z="0.8776739392589049" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="211" WEIGHT="69.74965229485397" Z="0.15391857333780404">
<NAME>MTX not overlapping with steroids</NAME>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5333" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5334" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5335" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.848261527913677" CI_END="1.2506133517738345" CI_START="0.7876866073041393" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.49619988587341" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978794" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="8" P_CHI2="0.30322440069009293" P_Q="0.3882181786655039" P_Z="0.9492219640195189" Q="0.7445157610996125" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.063683850569558">
<NAME>Risk status of patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2951141969741715" CI_START="0.557957786608402" DF="0.0" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" NO="1" P_CHI2="1.0" P_Z="0.44955379174817" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="30.139082058414466" Z="0.7561591431346929">
<NAME>Only high risk patients included in study</NAME>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5336" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.103745766814065" CI_END="1.3991606701347135" CI_START="0.8047542362326965" DF="3.0" EFFECT_SIZE="1.061122272153916" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="97" I2="26.896056177255726" ID="CMP-001.08.02" LOG_CI_END="0.14586758879228087" LOG_CI_START="-0.09433672850672681" LOG_EFFECT_SIZE="0.02576543014277707" NO="2" P_CHI2="0.25047728886446663" P_Z="0.6741423821496344" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="69.86091794158553" Z="0.4204696709357129">
<NAME>High- and low-risk included in study</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5337" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5338" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5339" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5340" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.517278024710551" CI_END="1.119940345338276" CI_START="0.7918016120063497" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.9416849636634297" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="254" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.04919489018768794" LOG_CI_START="-0.10138361841514806" LOG_EFFECT_SIZE="-0.026094364113730045" NO="9" P_CHI2="0.5894918697566334" P_Q="0.500319322189819" P_Z="0.49694760395420057" Q="0.4542590808051381" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="508" TOTAL_2="514" WEIGHT="200.0" Z="0.6793003110062955">
<NAME>Chao sensitivity (different including criteria)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.214757415991735" CI_END="1.1438686626433063" CI_START="0.6772052421381072" DF="3.0" EFFECT_SIZE="0.8801328619359425" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="114" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.05837616225094976" LOG_CI_START="-0.1692796887455569" LOG_EFFECT_SIZE="-0.05545176324730364" NO="1" P_CHI2="0.7494671637409004" P_Z="0.3396763904813749" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.0" Z="0.9548048808604936">
<NAME>without Chao</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5341" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="7.15307582260372"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5342" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="38.75178826895566"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5343" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="22.353361945636625"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5344" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="31.741773962804007"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.848261527913678" CI_END="1.2506133517738345" CI_START="0.7876866073041394" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.496199885873423" ID="CMP-001.09.02" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978788" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="2" P_CHI2="0.30322440069009293" P_Z="0.9492219640195189" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.06368385056955794">
<NAME>All</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5345" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5346" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5347" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5348" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5349" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.519352490286678" CI_END="1.1645303280733865" CI_START="0.8359274775898979" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.9866422349176638" ESTIMABLE="YES" EVENTS_1="284" EVENTS_2="274" I2="15.960670558601436" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.06615080342750977" LOG_CI_START="-0.07783139893506509" LOG_EFFECT_SIZE="-0.005840297753777628" MODIFIED="2008-05-07 01:55:35 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.3003930781874332" P_Q="0.9424111566757678" P_Z="0.8736668145905135" Q="0.005218573359080381" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="577" TOTAL_2="590" WEIGHT="200.0" Z="0.15900261377540498">
<NAME>Atkinson sensitivity (median follow up &lt; 1year)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.665872389013922" CI_END="1.2437370518297932" CI_START="0.7729117462215285" DF="3.0" EFFECT_SIZE="0.9804585542337734" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="134" I2="35.703342271775774" ID="CMP-001.10.01" LOG_CI_END="0.09472857246884295" LOG_CI_START="-0.11187009252039984" LOG_EFFECT_SIZE="-0.008570760025778446" NO="1" P_CHI2="0.197963589324209" P_Z="0.8708188317213503" STUDIES="4" TAU2="0.0" TOTAL_1="278" TOTAL_2="285" WEIGHT="100.0" Z="0.16261848518271915">
<NAME>without Atkinson</NAME>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5350" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="23.53460972017673"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5351" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="31.91458026509573"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5352" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="18.40942562592047"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5353" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="26.14138438880707"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.848261527913677" CI_END="1.2506133517738345" CI_START="0.7876866073041393" DF="4.0" EFFECT_SIZE="0.9925177016597688" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="140" I2="17.49619988587341" ID="CMP-001.10.02" LOG_CI_END="0.09712306097566394" LOG_CI_START="-0.10364653858978794" LOG_EFFECT_SIZE="-0.0032617388070619855" NO="2" P_CHI2="0.30322440069009293" P_Z="0.9492219640195189" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.063683850569558">
<NAME>All</NAME>
<IPD_DATA CI_END="3.2543155995254534" CI_START="0.4584142662312191" EFFECT_SIZE="1.2214027581601699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5124596679880784" LOG_CI_START="-0.33874187522677757" LOG_EFFECT_SIZE="0.08685889638065036" ORDER="5354" O_E="0.8" SE="0.5" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="4.0" WEIGHT="5.563282336578581"/>
<IPD_DATA CI_END="2.4677672593388946" CI_START="0.9256294766914541" EFFECT_SIZE="1.5113696162283285" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" LOG_CI_END="0.392304198006614" LOG_CI_START="-0.03356282371857126" LOG_EFFECT_SIZE="0.17937068714402135" ORDER="5355" O_E="6.6" SE="0.25015639663712996" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="15.98" WEIGHT="22.225312934631432"/>
<IPD_DATA CI_END="1.2951141969741715" CI_START="0.557957786608402" EFFECT_SIZE="0.8500700269676768" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" LOG_CI_END="0.11230806411544703" LOG_CI_START="-0.25339865722107197" LOG_EFFECT_SIZE="-0.0705452965528125" ORDER="5356" O_E="-3.52" SE="0.21481793839053773" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.67" WEIGHT="30.139082058414466"/>
<IPD_DATA CI_END="1.2470260164847293" CI_START="0.41149371608297625" EFFECT_SIZE="0.7163402610320406" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09587551418254665" LOG_CI_START="-0.38563679250839633" LOG_EFFECT_SIZE="-0.14488063916292482" ORDER="5357" O_E="-4.17" SE="0.282842712474619" STUDY_ID="STD-Ruutu-2003" TOTAL_1="53" TOTAL_2="55" VAR="12.5" WEIGHT="17.385257301808068"/>
<IPD_DATA CI_END="1.5700780860677361" CI_START="0.6192201789111701" EFFECT_SIZE="0.986014215597002" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.19592125209396055" LOG_CI_START="-0.20815489947151689" LOG_EFFECT_SIZE="-0.006116823688778171" ORDER="5358" O_E="-0.25" SE="0.23735633163877068" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="17.75" WEIGHT="24.687065368567453"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-05-07 01:57:14 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Disease-free survival</NAME>
<IPD_OUTCOME CHI2="6.618484682541689" CI_END="1.231277963713969" CI_START="0.7395152773502538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.5632052975624" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="1" P_CHI2="0.15747639614571696" P_Q="1.0" P_Z="0.7186548735908092" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.36025710635502567">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5359" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5360" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575103"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5361" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.73274695534506"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5362" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.518944519621108"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5363" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.64614343707713"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.618484682541689" CI_END="1.231277963713969" CI_START="0.7395152773502538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.5632052975624" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="2" P_CHI2="0.15747639614571696" P_Q="0.6374004388911167" P_Z="0.7186548735908092" Q="0.22215814023054037" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="0.36025710635502567">
<NAME>Type of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.5765564385034867" CI_START="0.4344730430053709" DF="0.0" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" NO="1" P_CHI2="1.0" P_Z="0.5650232035311522" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="74" WEIGHT="15.646143437077132" Z="0.5753964555687505">
<NAME>Truly randomised</NAME>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5364" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.646143437077132"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="6.396326542311149" CI_END="1.2931597289704482" CI_START="0.7423050643974463" DF="3.0" EFFECT_SIZE="0.9797545692108778" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="114" I2="53.098079340458014" ID="CMP-002.02.02" LOG_CI_END="0.11165217153630384" LOG_CI_START="-0.12941757645073404" LOG_EFFECT_SIZE="-0.008882702457215091" NO="2" P_CHI2="0.09384215600511026" P_Z="0.8851548687562364" STUDIES="4" TAU2="0.0" TOTAL_1="226" TOTAL_2="231" WEIGHT="84.35385656292289" Z="0.14443767454772577">
<NAME>Type of randomisation not reported</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5365" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5366" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575107"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5367" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.732746955345064"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5368" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.51894451962111"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.618484682541689" CI_END="1.231277963713969" CI_START="0.7395152773502538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.5632052975624" I2_Q="55.221528601684874" ID="CMP-002.03" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="3" P_CHI2="0.15747639614571696" P_Q="0.1350725385827477" P_Z="0.7186548735908092" Q="2.2332160271947714" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.36025710635502556">
<NAME>Concealment of allocation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.0920087081250802" CI_END="1.8072993747901136" CI_START="0.8090924595072594" DF="1.0" EFFECT_SIZE="1.209244514651551" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="57" I2="8.42563868222756" ID="CMP-002.03.01" LOG_CI_END="0.2570300983552241" LOG_CI_START="-0.0920018462995117" LOG_EFFECT_SIZE="0.08251412602785616" NO="1" P_CHI2="0.2960270435793739" P_Z="0.35408005576707" STUDIES="2" TAU2="0.0" TOTAL_1="143" TOTAL_2="151" WEIGHT="40.240189445196215" Z="0.9267043759583447">
<NAME>Concealment of allocation adequate</NAME>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5369" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575107"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5370" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.51894451962111"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.2932599472218382" CI_END="1.1313405999707522" CI_START="0.5850349191083959" DF="2.0" EFFECT_SIZE="0.8135562404578636" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="96" I2="39.26990179784683" ID="CMP-002.03.02" LOG_CI_END="0.053593372758515966" LOG_CI_START="-0.23281821131355168" LOG_EFFECT_SIZE="-0.08961241927751784" NO="2" P_CHI2="0.1926983964313309" P_Z="0.2200231769764327" STUDIES="3" TAU2="0.0" TOTAL_1="156" TOTAL_2="154" WEIGHT="59.75981055480379" Z="1.2264665545597735">
<NAME>Concealment of allocation not reported</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5371" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5372" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.732746955345064"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5373" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.646143437077132"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.618484682541689" CI_END="1.231277963713969" CI_START="0.7395152773502538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.5632052975624" I2_Q="69.7519561048123" ID="CMP-002.04" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="4" P_CHI2="0.15747639614571696" P_Q="0.06902743422381197" P_Z="0.7186548735908089" Q="3.305998905136125" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.3602571063550258">
<NAME>Blinding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="2.228476634629787" CI_START="0.8607392260233568" DF="0.0" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" NO="1" P_CHI2="1.0" P_Z="0.17959221590944457" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="28.721244925575103" Z="1.3420116573915422">
<NAME>Patients and clinicians blinded</NAME>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5374" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575103"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.3124857774055645" CI_END="1.110670304476366" CI_START="0.6072050580368495" DF="3.0" EFFECT_SIZE="0.8212214236668312" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="124" I2="9.43357340692682" ID="CMP-002.04.02" LOG_CI_END="0.04558516047435341" LOG_CI_START="-0.21666461941108758" LOG_EFFECT_SIZE="-0.08553972946836713" NO="2" P_CHI2="0.3459087038725859" P_Z="0.20104199346939355" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="71.2787550744249" Z="1.2785885965550556">
<NAME>Patients and clinicians not blinded</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5375" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5376" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.73274695534506"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5377" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.518944519621108"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5378" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.64614343707713"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.618484682541689" CI_END="1.231277963713969" CI_START="0.7395152773502538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.5632052975624" I2_Q="82.57100629777287" ID="CMP-002.05" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="5" P_CHI2="0.15747639614571696" P_Q="0.016605818043948783" P_Z="0.7186548735908092" Q="5.7375659036024365" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="0.36025710635502567">
<NAME>Statement of withdrawals in each group</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.6347415474258049" CI_END="2.3142004355040364" CI_START="0.9540534055689971" DF="1.0" EFFECT_SIZE="1.485890576947671" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="38" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.36440097097856894" LOG_CI_START="-0.020427313875840118" LOG_EFFECT_SIZE="0.17198682855136443" NO="1" P_CHI2="0.4256216323937313" P_Z="0.07979310177116425" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="116" WEIGHT="33.102165087956706" Z="1.7518878057701444">
<NAME>Withdrawals stated</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5379" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5380" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575107"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.24617723151344778" CI_END="1.0467217343467532" CI_START="0.5612168245357936" DF="2.0" EFFECT_SIZE="0.7664449412206223" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="115" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.019831242041915085" LOG_CI_START="-0.25086931787616074" LOG_EFFECT_SIZE="-0.11551903791712285" NO="2" P_CHI2="0.8841853106862274" P_Z="0.09436783079841168" STUDIES="3" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="66.89783491204331" Z="1.6727941302729394">
<NAME>Withdrawals not stated</NAME>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5381" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.732746955345064"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5382" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.51894451962111"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5383" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.646143437077132"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.6184846825416885" CI_END="1.231277963713969" CI_START="0.7395152773502538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.563205297562384" I2_Q="68.07772528398006" ID="CMP-002.06" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="6" P_CHI2="0.15747639614571696" P_Q="0.07674114696458922" P_Z="0.7186548735908092" Q="3.1326088409926443" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.36025710635502567">
<NAME>MTX part of prophylaxis regimen</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.4858758415490443" CI_END="1.5974408944011556" CI_START="0.8283646116208014" DF="3.0" EFFECT_SIZE="1.1503319112663957" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="105" I2="13.938415010591198" ID="CMP-002.06.01" LOG_CI_END="0.20342479815419048" LOG_CI_START="-0.0817784627796619" LOG_EFFECT_SIZE="0.06082316768726427" NO="1" P_CHI2="0.3225987240293926" P_Z="0.40316968549828247" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="60.26725304465494" Z="0.8359737381847624">
<NAME>MTX included</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5384" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5385" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575103"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5386" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.518944519621108"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5387" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.64614343707713"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.076852471760719" CI_START="0.4796257859390433" DF="0.0" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" NO="2" P_CHI2="1.0" P_Z="0.10935333913272684" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="39.73274695534506" Z="1.6011064713932472">
<NAME>MTX not included</NAME>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5388" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.73274695534506"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.6184846825416885" CI_END="1.231277963713969" CI_START="0.7395152773502538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.563205297562384" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="7" P_CHI2="0.15747639614571696" P_Q="0.7391191720318595" P_Z="0.7186548735908092" Q="0.11090236876809101" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="0.3602571063550256">
<NAME>Timing of steroid administration</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="2.21528112934363" CI_END="1.8391415411172667" CI_START="0.5886597024091675" DF="1.0" EFFECT_SIZE="1.040494359563005" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="48" I2="54.8590024645634" ID="CMP-002.07.01" LOG_CI_END="0.2646151540128092" LOG_CI_START="-0.23013569345630103" LOG_EFFECT_SIZE="0.01723973027825407" NO="1" P_CHI2="0.13665025720023682" P_Z="0.8913541101608716" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="94" WEIGHT="20.027063599458728" Z="0.1365909755239877">
<NAME>MTX overlapping with steroids</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5389" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5390" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.64614343707713"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.292301184429967" CI_END="1.241740978355156" CI_START="0.7021766648577181" DF="2.0" EFFECT_SIZE="0.9337673900916563" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="105" I2="53.40494727502197" ID="CMP-002.07.02" LOG_CI_END="0.09403101339058986" LOG_CI_START="-0.1535536073570254" LOG_EFFECT_SIZE="-0.02976129698321775" NO="2" P_CHI2="0.11693348565681994" P_Z="0.6374971498253479" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="211" WEIGHT="79.97293640054127" Z="0.47120107900215147">
<NAME>MTX not overlapping with steroids</NAME>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5391" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575103"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5392" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.73274695534506"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5393" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.518944519621108"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.618484682541689" CI_END="1.231277963713969" CI_START="0.7395152773502538" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.5632052975624" I2_Q="68.07772528398007" ID="CMP-002.08" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="8" P_CHI2="0.15747639614571696" P_Q="0.07674114696458922" P_Z="0.718654873590809" Q="3.1326088409926456" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="0.3602571063550257">
<NAME>Risk status of patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.076852471760719" CI_START="0.4796257859390433" DF="0.0" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" NO="1" P_CHI2="1.0" P_Z="0.10935333913272684" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="39.732746955345064" Z="1.6011064713932472">
<NAME>Only high risk patients included in study</NAME>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5394" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.732746955345064"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.485875841549044" CI_END="1.5974408944011556" CI_START="0.8283646116208014" DF="3.0" EFFECT_SIZE="1.1503319112663957" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="105" I2="13.93841501059119" ID="CMP-002.08.02" LOG_CI_END="0.20342479815419048" LOG_CI_START="-0.0817784627796619" LOG_EFFECT_SIZE="0.06082316768726427" NO="2" P_CHI2="0.3225987240293926" P_Z="0.40316968549828236" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="60.26725304465495" Z="0.8359737381847625">
<NAME>High- and low-risk included in study</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5395" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5396" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575107"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5397" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.51894451962111"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5398" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.646143437077132"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="10.485343967839919" CI_END="1.089207788614843" CI_START="0.7377902531136705" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.8964412362534012" ESTIMABLE="YES" EVENTS_1="279" EVENTS_2="277" I2="23.703027535032057" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.03711073819524437" LOG_CI_START="-0.1320670864999846" LOG_EFFECT_SIZE="-0.04747817415237013" NO="9" P_CHI2="0.23259876941053448" P_Q="0.45653626754268994" P_Z="0.2712924394965359" Q="0.5543735078926648" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="508" TOTAL_2="514" WEIGHT="200.0" Z="1.1000911207837543">
<NAME>Chao sensitivity (differing including criteria)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.3124857774055654" CI_END="1.110670304476366" CI_START="0.6072050580368495" DF="3.0" EFFECT_SIZE="0.8212214236668312" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="124" I2="9.433573406926845" ID="CMP-002.09.01" LOG_CI_END="0.04558516047435341" LOG_CI_START="-0.21666461941108758" LOG_EFFECT_SIZE="-0.08553972946836713" NO="1" P_CHI2="0.34590870387258565" P_Z="0.20104199346939378" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.0" Z="1.2785885965550554">
<NAME>without Chao</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5399" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="6.146179401993355"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5400" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="55.74276222116753"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5401" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="16.160417655434266"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5402" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="21.95064072140484"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="6.6184846825416885" CI_END="1.231277963713969" CI_START="0.7395152773502538" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.563205297562384" ID="CMP-002.09.02" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="2" P_CHI2="0.15747639614571696" P_Z="0.718654873590809" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="0.3602571063550257">
<NAME>All</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5403" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5404" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575107"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5405" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.732746955345064"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5406" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.51894451962111"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5407" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.646143437077132"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="11.072994303970471" CI_END="1.122046489317482" CI_START="0.7793054132862701" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.9351026163389603" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="297" I2="27.752152846936625" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.050010851247932926" LOG_CI_START="-0.10829230701220852" LOG_EFFECT_SIZE="-0.029140727882137788" MODIFIED="2008-05-07 01:57:14 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.19759755139302826" P_Q="0.8238083915771514" P_Z="0.47054823278517055" Q="0.049572752594039926" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="577" TOTAL_2="590" WEIGHT="200.0" Z="0.7215873360961607">
<NAME>Atkinson sensitivity (median follow up &lt; 1year)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.404936868834742" CI_END="1.1881634761460316" CI_START="0.7054268164705139" DF="3.0" EFFECT_SIZE="0.9155120853512718" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="144" I2="31.894597145643004" ID="CMP-002.10.01" LOG_CI_END="0.07487619813995072" LOG_CI_START="-0.15154803485310217" LOG_EFFECT_SIZE="-0.03833591835657571" NO="1" P_CHI2="0.22092830099300587" P_Z="0.506892874754541" STUDIES="4" TAU2="0.0" TOTAL_1="278" TOTAL_2="285" WEIGHT="99.99999999999999" Z="0.6636835492379628">
<NAME>without Atkinson</NAME>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5408" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="30.037148416769856"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5409" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="41.553157615425434"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5410" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="12.04670086679639"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5411" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="16.362993101008314"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="6.618484682541689" CI_END="1.231277963713969" CI_START="0.7395152773502538" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.5632052975624" ID="CMP-002.10.02" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="2" P_CHI2="0.15747639614571696" P_Z="0.7186548735908092" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="0.36025710635502567">
<NAME>All</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5412" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5413" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575107"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5414" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.732746955345064"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5415" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.51894451962111"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5416" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.646143437077132"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="10.86177786673193" CI_END="1.1574202277114525" CI_START="0.7814490903255489" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.9510336398201191" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="230" I2="44.76042436499148" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.06349106806269407" LOG_CI_START="-0.10709931004514729" LOG_EFFECT_SIZE="-0.021804120991226635" NO="11" P_CHI2="0.09274352680439435" P_Q="0.9677497911260532" P_Z="0.6163513046491758" Q="0.0016346384402581293" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="451" TOTAL_2="461" WEIGHT="200.0" Z="0.5010281626826826">
<NAME>Type of data sensitivity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.241658545749984" CI_END="1.2878706712309926" CI_START="0.6954505971365696" DF="1.0" EFFECT_SIZE="0.9463880955201563" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="77" I2="76.42431635611096" ID="CMP-002.11.01" LOG_CI_END="0.10987225309305745" LOG_CI_START="-0.15773371564033942" LOG_EFFECT_SIZE="-0.023930731273640996" NO="1" P_CHI2="0.03944377203010596" P_Z="0.7259330661059142" STUDIES="2" TAU2="0.0" TOTAL_1="152" TOTAL_2="156" WEIGHT="100.0" Z="0.3505405476719416">
<NAME>Data derived from Kaplan-Meier</NAME>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5417" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="41.95700518902891"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5418" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="58.04299481097109"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="6.618484682541689" CI_END="1.231277963713969" CI_START="0.7395152773502538" DF="4.0" EFFECT_SIZE="0.9542268413910769" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="153" I2="39.5632052975624" ID="CMP-002.11.02" LOG_CI_END="0.09035610693613451" LOG_CI_START="-0.13105284965846226" LOG_EFFECT_SIZE="-0.020348371361163863" NO="2" P_CHI2="0.15747639614571696" P_Z="0.7186548735908092" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="0.3602571063550256">
<NAME>All</NAME>
<IPD_DATA CI_END="7.964588030788738" CI_START="0.6971745248016237" EFFECT_SIZE="2.356418442383661" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.9011633167872056" LOG_CI_START="-0.1566584906673453" LOG_EFFECT_SIZE="0.3722524130599302" ORDER="5419" O_E="2.22" SE="0.6213697660012001" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.59" WEIGHT="4.380920162381597"/>
<IPD_DATA CI_END="2.228476634629787" CI_START="0.8607392260233568" EFFECT_SIZE="1.3849683222739708" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.3480080849088236" LOG_CI_START="-0.06512840470564547" LOG_EFFECT_SIZE="0.14143984010158903" ORDER="5420" O_E="5.53" SE="0.24267841905814505" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="16.98" WEIGHT="28.721244925575103"/>
<IPD_DATA CI_END="1.076852471760719" CI_START="0.4796257859390433" EFFECT_SIZE="0.71866975246537" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="48" LOG_CI_END="0.03215620925074777" LOG_CI_START="-0.31909747613616574" LOG_EFFECT_SIZE="-0.14347063344270905" ORDER="5421" O_E="-7.76" SE="0.20632815353005762" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="23.49" WEIGHT="39.73274695534506"/>
<IPD_DATA CI_END="1.8271338262252337" CI_START="0.40682541648873966" EFFECT_SIZE="0.8621626759694165" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.26177035789585273" LOG_CI_START="-0.39059192227831513" LOG_EFFECT_SIZE="-0.0644107821912312" ORDER="5422" O_E="-1.01" SE="0.3832008326196737" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.81" WEIGHT="11.518944519621108"/>
<IPD_DATA CI_END="1.5765564385034867" CI_START="0.4344730430053709" EFFECT_SIZE="0.8276299132500708" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.19770952249394408" LOG_CI_START="-0.3620371642951745" LOG_EFFECT_SIZE="-0.08216382090061519" ORDER="5423" O_E="-1.75" SE="0.3287979746107146" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.25" WEIGHT="15.64614343707713"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-05-07 02:02:18 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Relapse incidence</NAME>
<IPD_OUTCOME CHI2="4.807390311322744" CI_END="1.178987557360506" CI_START="0.5737989629952593" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.794773443319446" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="1" P_CHI2="0.30763765204011206" P_Q="1.0" P_Z="0.2874717672324787" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="1.063684272797665">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5424" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5425" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5426" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218698"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5427" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.843401957475532"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5428" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" I2_Q="45.968333686511784" ID="CMP-003.02" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="2" P_CHI2="0.3076376520401122" P_Q="0.17369445124692573" P_Z="0.2874717672324787" Q="1.8507665379003213" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="1.063684272797665">
<NAME>Type of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.1261433291492196" CI_START="0.2081214050220163" DF="0.0" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.05159366857679031" LOG_CI_START="-0.6816832508557198" LOG_EFFECT_SIZE="-0.3150447911394647" NO="1" P_CHI2="1.0" P_Z="0.09215148073421767" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="74" WEIGHT="18.191022612217346" Z="1.6841562247129371">
<NAME>Truly randomised</NAME>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5429" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.956623773422424" CI_END="1.3778615781808483" CI_START="0.6214820638818587" DF="3.0" EFFECT_SIZE="0.9253735771845599" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="50" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.13920558995782617" LOG_CI_START="-0.20657140068209295" LOG_EFFECT_SIZE="-0.03368290536213336" NO="2" P_CHI2="0.39836156983113613" P_Z="0.7025734475101654" STUDIES="4" TAU2="0.0" TOTAL_1="226" TOTAL_2="231" WEIGHT="81.80897738778265" Z="0.38184889794012217">
<NAME>Type of randomisation not reported</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5430" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5431" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5432" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218694"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5433" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.84340195747553"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" I2_Q="0.0321468687738005" ID="CMP-003.03" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="3" P_CHI2="0.3076376520401122" P_Q="0.3172329634875275" P_Z="0.2874717672324787" Q="1.0003215720630871" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="1.063684272797665">
<NAME>Concealment of allocation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.08585435209710392" CI_END="1.7005278370637185" CI_START="0.5906262389561876" DF="1.0" EFFECT_SIZE="1.0021857914804244" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.23058374558024602" LOG_CI_START="-0.22868726312652005" LOG_EFFECT_SIZE="9.482412268630063E-4" NO="1" P_CHI2="0.7695151836767539" P_Z="0.9935425179340356" STUDIES="2" TAU2="0.0" TOTAL_1="143" TOTAL_2="151" WEIGHT="46.37192035099561" Z="0.008093341918275395">
<NAME>Concealment of allocation adequate</NAME>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5434" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5435" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.84340195747553"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.7212143871625543" CI_END="1.1336199204822954" CI_START="0.4240295349471357" DF="2.0" EFFECT_SIZE="0.6933169027861045" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" I2="46.25410438862109" ID="CMP-003.03.02" LOG_CI_END="0.05446746892564652" LOG_CI_START="-0.37260389242179826" LOG_EFFECT_SIZE="-0.1590682117480759" NO="2" P_CHI2="0.15557822777911534" P_Z="0.14428251604800882" STUDIES="3" TAU2="0.0" TOTAL_1="156" TOTAL_2="154" WEIGHT="53.628079649004384" Z="1.4600275004522272">
<NAME>Concealment of allocation not reported</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5436" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5437" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218694"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5438" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="4" P_CHI2="0.3076376520401122" P_Q="0.7937959304809191" P_Z="0.2874717672324787" Q="0.06832191316322422" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999997" Z="1.0636842727976652">
<NAME>Blinding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="2.0996582135894744" CI_START="0.39407662337304866" DF="0.0" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" NO="1" P_CHI2="1.0" P_Z="0.8243679155853467" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="18.52851839352008" Z="0.22193059188368636">
<NAME>Patients and clinicians blinded</NAME>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5439" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.739068398159521" CI_END="1.1979410674835067" CI_START="0.5394398328709703" DF="3.0" EFFECT_SIZE="0.8038763146358864" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="56" I2="36.69641904377052" ID="CMP-003.04.02" LOG_CI_END="0.0784354535322113" LOG_CI_START="-0.2680569878843353" LOG_EFFECT_SIZE="-0.09481076717606202" NO="2" P_CHI2="0.1919318336043614" P_Z="0.28344599628475775" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="81.4714816064799" Z="1.0726103475850302">
<NAME>Patients and clinicians not blinded</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5440" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5441" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218694"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5442" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.84340195747553"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5443" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" I2_Q="27.71800281023252" ID="CMP-003.05" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="5" P_CHI2="0.3076376520401122" P_Q="0.23951110103311446" P_Z="0.2874717672324787" Q="1.383470350680299" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.0636842727976652">
<NAME>Statement of withdrawals in each group</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.1401968672133427" CI_END="2.348051097536888" CI_START="0.5867331493652141" DF="1.0" EFFECT_SIZE="1.1737458904414813" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" I2="12.295847431679567" ID="CMP-003.05.01" LOG_CI_END="0.37070754365600556" LOG_CI_START="-0.23155937423518896" LOG_EFFECT_SIZE="0.0695740847104083" NO="1" P_CHI2="0.2856107748031439" P_Z="0.6506701180415403" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="116" WEIGHT="26.96591292608842" Z="0.4528314481134239">
<NAME>Withdrawals stated</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5444" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5445" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.2837230934291037" CI_END="1.0992381731285197" CI_START="0.4732947363371138" DF="2.0" EFFECT_SIZE="0.7212930342950452" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="50" I2="12.423708208996647" ID="CMP-003.05.02" LOG_CI_END="0.04109180167618476" LOG_CI_START="-0.32486832543367006" LOG_EFFECT_SIZE="-0.14188826187874265" NO="2" P_CHI2="0.3192245870518593" P_Z="0.12855742612573087" STUDIES="3" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="73.03408707391156" Z="1.5198152066869497">
<NAME>Withdrawals not stated</NAME>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5446" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218694"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5447" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.84340195747553"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5448" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="6" P_CHI2="0.3076376520401122" P_Q="0.3743704052490411" P_Z="0.2874717672324787" Q="0.7891067606369297" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="1.063684272797665">
<NAME>MTX part of prophylaxis regimen</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.018283550685815" CI_END="1.3843930501231736" CI_START="0.5959566875169621" DF="3.0" EFFECT_SIZE="0.9083161874440586" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="50" I2="25.341256729182817" ID="CMP-003.06.01" LOG_CI_END="0.14125941039908246" LOG_CI_START="-0.22478530243410458" LOG_EFFECT_SIZE="-0.04176294601751104" NO="1" P_CHI2="0.25949667590475745" P_Z="0.6547059208979263" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="73.0003374957813" Z="0.4472342706390318">
<NAME>MTX included</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5449" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5450" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5451" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.843401957475532"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5452" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2575959373071681" CI_START="0.31452179266971514" DF="0.0" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" NO="2" P_CHI2="1.0" P_Z="0.18962708833329142" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="26.999662504218698" Z="1.3116830791010459">
<NAME>MTX not included</NAME>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5453" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218698"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="7" P_CHI2="0.3076376520401122" P_Q="0.8133069835844142" P_Z="0.2874717672324787" Q="0.05577248018789316" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="1.0636842727976652">
<NAME>Timing of steroid administration</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.568110959835023" CI_END="1.5377780234865814" CI_START="0.3809097614424029" DF="1.0" EFFECT_SIZE="0.7653461047641411" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="71.97396574106999" ID="CMP-003.07.01" LOG_CI_END="0.18689365007373504" LOG_CI_START="-0.41917789768231845" LOG_EFFECT_SIZE="-0.11614212380429167" NO="1" P_CHI2="0.05889943562114375" P_Z="0.4525444062830196" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="94" WEIGHT="26.628417144785686" Z="0.7511798915068942">
<NAME>MTX overlapping with steroids</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5454" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5455" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.1835068712998291" CI_END="1.2854178067908701" CI_START="0.5545322767643301" DF="2.0" EFFECT_SIZE="0.8442781905232143" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="44" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.10904431186304622" LOG_CI_START="-0.25607317050186557" LOG_EFFECT_SIZE="-0.0735144293194097" NO="2" P_CHI2="0.5533563799326034" P_Z="0.42996223819093726" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="211" WEIGHT="73.37158285521431" Z="0.7892562847267551">
<NAME>MTX not overlapping with steroids</NAME>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5456" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5457" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218694"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5458" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.84340195747553"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="8" P_CHI2="0.3076376520401122" P_Q="0.3743704052490411" P_Z="0.2874717672324787" Q="0.7891067606369297" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.0636842727976652">
<NAME>Risk status of patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2575959373071681" CI_START="0.31452179266971514" DF="0.0" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" NO="1" P_CHI2="1.0" P_Z="0.18962708833329142" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="26.999662504218694" Z="1.3116830791010459">
<NAME>Only high risk patients included in study</NAME>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5459" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218694"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.018283550685815" CI_END="1.3843930501231734" CI_START="0.5959566875169622" DF="3.0" EFFECT_SIZE="0.9083161874440586" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="50" I2="25.341256729182817" ID="CMP-003.08.02" LOG_CI_END="0.1412594103990824" LOG_CI_START="-0.22478530243410452" LOG_EFFECT_SIZE="-0.04176294601751104" NO="2" P_CHI2="0.25949667590475745" P_Z="0.6547059208979262" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="73.0003374957813" Z="0.44723427063903204">
<NAME>High- and low-risk included in study</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5460" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5461" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5462" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.84340195747553"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5463" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.553434482278734" CI_END="1.0635328456633073" CI_START="0.6231437483486544" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.8140846663207361" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="123" I2="16.260481873406857" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.026750906998554508" LOG_CI_START="-0.20541175765319333" LOG_EFFECT_SIZE="-0.08933042532731943" NO="9" P_CHI2="0.2977772862919613" P_Q="0.9334372072668585" P_Z="0.13148009307811057" Q="0.006975772796467439" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="508" TOTAL_2="514" WEIGHT="199.99999999999997" Z="1.5082908927481822">
<NAME>Chao sensitivity (differing including criteria)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.73906839815952" CI_END="1.1979410674835067" CI_START="0.5394398328709703" DF="3.0" EFFECT_SIZE="0.8038763146358864" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="56" I2="36.696419043770504" ID="CMP-003.09.01" LOG_CI_END="0.0784354535322113" LOG_CI_START="-0.2680569878843353" LOG_EFFECT_SIZE="-0.09481076717606202" NO="1" P_CHI2="0.1919318336043615" P_Z="0.28344599628475775" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.0" Z="1.0726103475850302">
<NAME>without Chao</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5464" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="10.35625517812759"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5465" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="33.140016570008285"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5466" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="34.175642087821046"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5467" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="22.328086164043082"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" ID="CMP-003.09.02" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="2" P_CHI2="0.3076376520401122" P_Z="0.2874717672324787" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999997" Z="1.0636842727976652">
<NAME>all</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5468" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5469" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5470" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218694"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5471" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.84340195747553"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5472" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="7.427569890422348" CI_END="1.024723121298908" CI_START="0.609033975200249" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.7899944278564761" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="128" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.010606535503143133" LOG_CI_START="-0.21535847940256214" LOG_EFFECT_SIZE="-0.10237597194970947" MODIFIED="2008-05-07 02:02:18 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.4912799022764339" P_Q="0.75090214836833" P_Z="0.07573833738771586" Q="0.10077454534754526" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="577" TOTAL_2="590" WEIGHT="200.0" Z="1.7759671158603518">
<NAME>Atkinson sensitivity (median follow up &lt; 1year)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="2.519405033752058" CI_END="1.1013386002578083" CI_START="0.5188945753157348" DF="3.0" EFFECT_SIZE="0.7559620527907478" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="61" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="0.0419208608573443" LOG_CI_START="-0.2849208695300816" LOG_EFFECT_SIZE="-0.12150000433636861" NO="1" P_CHI2="0.47179466674849335" P_Z="0.14506329502759005" STUDIES="4" TAU2="0.0" TOTAL_1="278" TOTAL_2="285" WEIGHT="100.0" Z="1.4571923379457443">
<NAME>without Atkinson</NAME>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5473" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="20.235901216365644"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5474" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="29.487652045705858"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5475" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="30.409141172134166"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5476" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="19.86730556579432"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" ID="CMP-003.10.02" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="2" P_CHI2="0.3076376520401122" P_Z="0.2874717672324787" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="1.0636842727976652">
<NAME>all</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5477" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5478" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5479" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218694"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5480" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.84340195747553"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5481" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="5.999463366556435" CI_END="1.0932018229532479" CI_START="0.632668604147083" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="0.8316456405097533" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="111" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.038700347222851594" LOG_CI_START="-0.1988237166456195" LOG_EFFECT_SIZE="-0.08006168471138399" NO="11" P_CHI2="0.5398120640530977" P_Q="0.9262581430850557" P_Z="0.18640768045929976" Q="0.008566183933861105" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="504" TOTAL_2="516" WEIGHT="200.0" Z="1.3212810190280933">
<NAME>Type of data sensitivity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.1835068712998291" CI_END="1.2854178067908701" CI_START="0.5545322767643301" DF="2.0" EFFECT_SIZE="0.8442781905232143" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="44" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.10904431186304622" LOG_CI_START="-0.25607317050186557" LOG_EFFECT_SIZE="-0.0735144293194097" NO="1" P_CHI2="0.5533563799326034" P_Z="0.42996223819093726" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="211" WEIGHT="100.0" Z="0.7892562847267551">
<NAME>Data derived from Kaplan-Meier</NAME>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5482" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="25.252989880404783"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5483" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="36.79852805887764"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5484" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="37.948482060717566"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.807390311322745" CI_END="1.178987557360506" CI_START="0.5737989629952593" DF="4.0" EFFECT_SIZE="0.8224973178058226" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="67" I2="16.79477344331946" ID="CMP-003.11.02" LOG_CI_END="0.07150922172088452" LOG_CI_START="-0.2412402409729823" LOG_EFFECT_SIZE="-0.08486550962604884" NO="2" P_CHI2="0.3076376520401122" P_Z="0.2874717672324787" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="1.063684272797665">
<NAME>all</NAME>
<IPD_DATA CI_END="7.09641739617011" CI_START="0.5947643129439419" EFFECT_SIZE="2.0544332106438876" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.851039151852179" LOG_CI_START="-0.22565509791149638" LOG_EFFECT_SIZE="0.31269202697034126" ORDER="5485" O_E="1.8" SE="0.6324555320336759" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5" WEIGHT="8.437394532568343"/>
<IPD_DATA CI_END="2.0996582135894744" CI_START="0.39407662337304866" EFFECT_SIZE="0.9096297153506077" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3221486051945047" LOG_CI_START="-0.40441932672080383" LOG_EFFECT_SIZE="-0.04113536076314952" ORDER="5486" O_E="-0.52" SE="0.4267895997763199" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="5.49" WEIGHT="18.52851839352008"/>
<IPD_DATA CI_END="1.2575959373071681" CI_START="0.3145217926697151" EFFECT_SIZE="0.6289207650062137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.0995411256992063" LOG_CI_START="-0.5023492576644724" LOG_EFFECT_SIZE="-0.20140406598263305" ORDER="5487" O_E="-3.71" SE="0.3535533905932738" STUDY_ID="STD-Deeg-2000" TOTAL_1="62" TOTAL_2="60" VAR="8.0" WEIGHT="26.999662504218698"/>
<IPD_DATA CI_END="2.114965581914414" CI_START="0.5402597666679009" EFFECT_SIZE="1.0689391057472464" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3253033042376463" LOG_CI_START="-0.26739737331721275" LOG_EFFECT_SIZE="0.028952965460216817" ORDER="5488" O_E="0.55" SE="0.3481553119113957" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="8.25" WEIGHT="27.843401957475532"/>
<IPD_DATA CI_END="1.1261433291492198" CI_START="0.20812140502201626" EFFECT_SIZE="0.4841224348434046" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.0515936685767904" LOG_CI_START="-0.6816832508557199" LOG_EFFECT_SIZE="-0.3150447911394647" ORDER="5489" O_E="-3.91" SE="0.43073049225394805" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="5.39" WEIGHT="18.191022612217346"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-05-14 15:19:24 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Non-relapse mortality</NAME>
<IPD_OUTCOME CHI2="1.9672364685415995" CI_END="1.2644849310921344" CI_START="0.6148102963908073" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="0.8817133067309719" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.10191365820985912" LOG_CI_START="-0.21125886786671857" LOG_EFFECT_SIZE="-0.05467260482842965" NO="1" P_CHI2="0.579234698832914" P_Q="1.0" P_Z="0.4937681866130017" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.00000000000001" Z="0.684327822412562">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="4.399951460098166" CI_START="0.2272752345267212" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.643447885411688" LOG_CI_START="-0.6434478854116878" LOG_EFFECT_SIZE="0.0" ORDER="5490" O_E="0.0" SE="0.7559289460184544" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.75" WEIGHT="5.922165820642978"/>
<IPD_DATA CI_END="1.265280705485035" CI_START="0.46824357083841084" EFFECT_SIZE="0.7697139440397689" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" LOG_CI_END="0.10218688544804976" LOG_CI_START="-0.3295281769395269" LOG_EFFECT_SIZE="-0.11367064574573855" ORDER="5491" O_E="-4.07" SE="0.2535915646704869" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="15.55" WEIGHT="52.62267343485618"/>
<IPD_DATA CI_END="1.6928096154449566" CI_START="0.2448356201758299" EFFECT_SIZE="0.6437857501040809" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.22860811722821653" LOG_CI_START="-0.6111253981259712" LOG_EFFECT_SIZE="-0.19125864044887733" ORDER="5492" O_E="-1.81" SE="0.49326362366699006" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="4.11" WEIGHT="13.908629441624367"/>
<IPD_DATA CI_END="2.5917239872829843" CI_START="0.6559893297996272" EFFECT_SIZE="1.303895425808137" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.4135887482854799" LOG_CI_START="-0.18310322472011786" LOG_EFFECT_SIZE="0.11524276178268111" ORDER="5493" O_E="2.16" SE="0.3504998186163908" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.14" WEIGHT="27.546531302876485"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.9058928849498478" CI_END="1.1377816723417586" CI_START="0.678046150560254" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.8783327860835766" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="133" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.056058933769116366" LOG_CI_START="-0.16874074528996016" LOG_EFFECT_SIZE="-0.05634090576042183" MODIFIED="2008-05-07 01:57:51 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6894102106570745" P_Q="0.9760730100540032" P_Z="0.32588293175520777" Q="8.995520006007673E-4" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="398" WEIGHT="200.0" Z="0.9824404252621068">
<NAME>Atkinson sensitivity (median follow up &lt; 1year)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.9377568644076477" CI_END="1.2686018748755534" CI_START="0.6031789817910717" DF="2.0" EFFECT_SIZE="0.8747536722904802" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="65" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.1033253489087612" LOG_CI_START="-0.2195538001807106" LOG_EFFECT_SIZE="-0.05811422563597471" NO="1" P_CHI2="0.37950852748187947" P_Z="0.4804753638810494" STUDIES="3" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.0" Z="0.7055382148841199">
<NAME>without Atkinson</NAME>
<IPD_DATA CI_END="1.265280705485035" CI_START="0.46824357083841084" EFFECT_SIZE="0.7697139440397689" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" LOG_CI_END="0.10218688544804976" LOG_CI_START="-0.3295281769395269" LOG_EFFECT_SIZE="-0.11367064574573855" ORDER="5494" O_E="-4.07" SE="0.2535915646704869" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="15.55" WEIGHT="55.935251798561154"/>
<IPD_DATA CI_END="1.6928096154449566" CI_START="0.2448356201758299" EFFECT_SIZE="0.6437857501040809" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.22860811722821653" LOG_CI_START="-0.6111253981259712" LOG_EFFECT_SIZE="-0.19125864044887733" ORDER="5495" O_E="-1.81" SE="0.49326362366699006" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="4.11" WEIGHT="14.784172661870505"/>
<IPD_DATA CI_END="2.5917239872829843" CI_START="0.6559893297996272" EFFECT_SIZE="1.303895425808137" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.4135887482854799" LOG_CI_START="-0.18310322472011786" LOG_EFFECT_SIZE="0.11524276178268111" ORDER="5496" O_E="2.16" SE="0.3504998186163908" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.14" WEIGHT="29.280575539568346"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.9672364685415995" CI_END="1.2644849310921344" CI_START="0.6148102963908073" DF="3.0" EFFECT_SIZE="0.8817133067309719" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="68" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.10191365820985912" LOG_CI_START="-0.21125886786671857" LOG_EFFECT_SIZE="-0.05467260482842965" NO="2" P_CHI2="0.579234698832914" P_Z="0.4937681866130017" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.00000000000001" Z="0.684327822412562">
<NAME>all</NAME>
<IPD_DATA CI_END="4.399951460098166" CI_START="0.2272752345267212" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.643447885411688" LOG_CI_START="-0.6434478854116878" LOG_EFFECT_SIZE="0.0" ORDER="5497" O_E="0.0" SE="0.7559289460184544" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.75" WEIGHT="5.922165820642978"/>
<IPD_DATA CI_END="1.265280705485035" CI_START="0.46824357083841084" EFFECT_SIZE="0.7697139440397689" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" LOG_CI_END="0.10218688544804976" LOG_CI_START="-0.3295281769395269" LOG_EFFECT_SIZE="-0.11367064574573855" ORDER="5498" O_E="-4.07" SE="0.2535915646704869" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="15.55" WEIGHT="52.62267343485618"/>
<IPD_DATA CI_END="1.6928096154449566" CI_START="0.2448356201758299" EFFECT_SIZE="0.6437857501040809" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.22860811722821653" LOG_CI_START="-0.6111253981259712" LOG_EFFECT_SIZE="-0.19125864044887733" ORDER="5499" O_E="-1.81" SE="0.49326362366699006" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="4.11" WEIGHT="13.908629441624367"/>
<IPD_DATA CI_END="2.5917239872829843" CI_START="0.6559893297996272" EFFECT_SIZE="1.303895425808137" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.4135887482854799" LOG_CI_START="-0.18310322472011786" LOG_EFFECT_SIZE="0.11524276178268111" ORDER="5500" O_E="2.16" SE="0.3504998186163908" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.14" WEIGHT="27.546531302876485"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="2.2055229661240703" CI_END="1.1275781308437027" CI_START="0.635957984872316" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_SIZE="0.8468130347824446" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="102" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.05214664422510059" LOG_CI_START="-0.19657157545354587" LOG_EFFECT_SIZE="-0.07221246561422268" MODIFIED="2008-05-14 15:19:24 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8200378976844346" P_Q="0.7178850044206515" P_Z="0.2550762998468823" Q="0.13052828707376296" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="292" TOTAL_2="289" WEIGHT="200.0" Z="1.1381058614972452">
<NAME>Type of data sensitivity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.1077582105087079" CI_END="1.2661253374252694" CI_START="0.49337706835968986" DF="1.0" EFFECT_SIZE="0.7903652365551022" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="34" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.10247669988182898" LOG_CI_START="-0.30682103992185616" LOG_EFFECT_SIZE="-0.10217217002001358" NO="1" P_CHI2="0.7427109951438171" P_Z="0.3278153782621981" STUDIES="2" TAU2="0.0" TOTAL_1="83" TOTAL_2="80" WEIGHT="100.0" Z="0.978523719957892">
<NAME>Data derived from Kaplan-Meier</NAME>
<IPD_DATA CI_END="4.399951460098166" CI_START="0.2272752345267212" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.643447885411688" LOG_CI_START="-0.6434478854116878" LOG_EFFECT_SIZE="0.0" ORDER="5501" O_E="0.0" SE="0.7559289460184544" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.75" WEIGHT="10.115606936416183"/>
<IPD_DATA CI_END="1.265280705485035" CI_START="0.46824357083841084" EFFECT_SIZE="0.7697139440397689" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" LOG_CI_END="0.10218688544804976" LOG_CI_START="-0.3295281769395269" LOG_EFFECT_SIZE="-0.11367064574573855" ORDER="5502" O_E="-4.07" SE="0.2535915646704869" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="15.55" WEIGHT="89.88439306358381"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.9672364685415993" CI_END="1.2644849310921344" CI_START="0.6148102963908073" DF="3.0" EFFECT_SIZE="0.8817133067309719" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="68" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.10191365820985912" LOG_CI_START="-0.21125886786671857" LOG_EFFECT_SIZE="-0.05467260482842965" NO="2" P_CHI2="0.579234698832914" P_Z="0.4937681866130017" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.00000000000001" Z="0.684327822412562">
<NAME>all</NAME>
<IPD_DATA CI_END="4.399951460098166" CI_START="0.2272752345267212" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.643447885411688" LOG_CI_START="-0.6434478854116878" LOG_EFFECT_SIZE="0.0" ORDER="5503" O_E="0.0" SE="0.7559289460184544" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.75" WEIGHT="5.922165820642978"/>
<IPD_DATA CI_END="1.265280705485035" CI_START="0.46824357083841084" EFFECT_SIZE="0.7697139440397689" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" LOG_CI_END="0.10218688544804976" LOG_CI_START="-0.3295281769395269" LOG_EFFECT_SIZE="-0.11367064574573855" ORDER="5504" O_E="-4.07" SE="0.2535915646704869" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="15.55" WEIGHT="52.62267343485618"/>
<IPD_DATA CI_END="1.6928096154449566" CI_START="0.2448356201758299" EFFECT_SIZE="0.6437857501040809" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.22860811722821653" LOG_CI_START="-0.6111253981259712" LOG_EFFECT_SIZE="-0.19125864044887733" ORDER="5505" O_E="-1.81" SE="0.49326362366699006" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="4.11" WEIGHT="13.908629441624367"/>
<IPD_DATA CI_END="2.5917239872829843" CI_START="0.6559893297996272" EFFECT_SIZE="1.303895425808137" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.4135887482854799" LOG_CI_START="-0.18310322472011786" LOG_EFFECT_SIZE="0.11524276178268111" ORDER="5506" O_E="2.16" SE="0.3504998186163908" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.14" WEIGHT="27.546531302876485"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-05-07 01:58:12 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Acute GvHD grade I-IV</NAME>
<IPD_OUTCOME CHI2="12.204109554202525" CI_END="0.7625953472334666" CI_START="0.44540936282707316" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.2241552549601" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="1" P_CHI2="0.015896306292073392" P_Q="1.0" P_Z="8.296147680509575E-5" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="3.9356799400026485">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5507" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5508" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5509" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5510" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5511" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.204109554202525" CI_END="0.7625953472334666" CI_START="0.44540936282707316" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.2241552549601" I2_Q="76.87767107139678" ID="CMP-005.02" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="2" P_CHI2="0.015896306292073392" P_Q="0.037560495525779336" P_Z="8.296147680509575E-5" Q="4.324823866522204" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="3.9356799400026485">
<NAME>Type of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="2.06983770057962" CI_START="0.5696177206629731" DF="0.0" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" NO="1" P_CHI2="1.0" P_Z="0.8024659010443028" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="74" WEIGHT="17.369213398569816" Z="0.2501570470971206">
<NAME>Truly randomised</NAME>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5512" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="7.879285687680321" CI_END="0.6873499661932424" CI_START="0.38042417781674276" DF="3.0" EFFECT_SIZE="0.5113555961964532" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="133" I2="61.92548260192344" ID="CMP-005.02.02" LOG_CI_END="-0.16282208435624376" LOG_CI_START="-0.4197318893194914" LOG_EFFECT_SIZE="-0.2912769868378676" NO="2" P_CHI2="0.048573601508157704" P_Z="8.817759590569709E-6" STUDIES="4" TAU2="0.0" TOTAL_1="226" TOTAL_2="231" WEIGHT="82.63078660143019" Z="4.444302184645988">
<NAME>Type of randomisation not reported</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5513" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5514" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5515" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5516" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.204109554202518" CI_END="0.7625953472334664" CI_START="0.4454093628270731" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5828096667919543" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.22415525496008" I2_Q="22.808428751074764" ID="CMP-005.03" LOG_CI_END="-0.11770584878303449" LOG_CI_START="-0.3512406580217941" LOG_EFFECT_SIZE="-0.2344732534024143" NO="3" P_CHI2="0.015896306292073392" P_Q="0.25504094932759813" P_Z="8.296147680509544E-5" Q="1.2954782288019864" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="3.9356799400026494">
<NAME>Concealment of allocation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="4.809171834526964" CI_END="0.7367099957591503" CI_START="0.3136948193523475" DF="1.0" EFFECT_SIZE="0.4807308072453183" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="69" I2="79.20639905564195" ID="CMP-005.03.01" LOG_CI_END="-0.13270343755167077" LOG_CI_START="-0.5034926535855407" LOG_EFFECT_SIZE="-0.3180980455686057" NO="1" P_CHI2="0.02830875344919348" P_Z="7.713253882403502E-4" STUDIES="2" TAU2="0.0" TOTAL_1="143" TOTAL_2="151" WEIGHT="39.66879939781709" Z="3.362884819228928">
<NAME>Concealment of allocation adequate</NAME>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5517" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5518" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="6.099459490873566" CI_END="0.9350680282712363" CI_START="0.4679287787878825" DF="2.0" EFFECT_SIZE="0.6614720255253073" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="102" I2="67.2102093145706" ID="CMP-005.03.02" LOG_CI_END="-0.029156792092104145" LOG_CI_START="-0.329820243791744" LOG_EFFECT_SIZE="-0.1794885179419241" NO="2" P_CHI2="0.047371879203061074" P_Z="0.01927865988504161" STUDIES="3" TAU2="0.0" TOTAL_1="156" TOTAL_2="154" WEIGHT="60.33120060218292" Z="2.340098397833061">
<NAME>Concealment of allocation not reported</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5519" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5520" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5521" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.204109554202525" CI_END="0.7625953472334666" CI_START="0.44540936282707316" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.2241552549601" I2_Q="0.7175797665063713" ID="CMP-005.04" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="4" P_CHI2="0.015896306292073392" P_Q="0.31556818948729215" P_Z="8.296147680509575E-5" Q="1.0072276619044818" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="3.9356799400026485">
<NAME>Blinding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.3879068363960585" CI_START="0.4217484895729547" DF="0.0" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.14236031496823498" LOG_CI_START="-0.3749464640946302" LOG_EFFECT_SIZE="-0.11629307456319762" NO="1" P_CHI2="1.0" P_Z="0.3781993978371496" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="20.380127963869025" Z="0.8812188319210076">
<NAME>Patients and clinicians blinded</NAME>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5522" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="11.196881892298043" CI_END="0.7347466538534675" CI_START="0.40217514050894776" DF="3.0" EFFECT_SIZE="0.5435962092877372" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="133" I2="73.20682642849346" ID="CMP-005.04.02" LOG_CI_END="-0.1338623830930957" LOG_CI_START="-0.39558477778068646" LOG_EFFECT_SIZE="-0.26472358043689115" NO="2" P_CHI2="0.010707548789437138" P_Z="7.343349225874033E-5" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="79.61987203613097" Z="3.9648780085031">
<NAME>Patients and clinicians not blinded</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5523" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5524" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5525" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5526" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.204109554202518" CI_END="0.7625953472334664" CI_START="0.4454093628270731" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5828096667919543" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.22415525496008" I2_Q="60.83677060678807" ID="CMP-005.05" LOG_CI_END="-0.11770584878303449" LOG_CI_START="-0.3512406580217941" LOG_EFFECT_SIZE="-0.2344732534024143" NO="5" P_CHI2="0.015896306292073392" P_Q="0.11005644109394208" P_Z="8.296147680509544E-5" Q="2.5534155775553273" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="3.9356799400026494">
<NAME>Statement of withdrawals in each group</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.250264578450174" CI_END="1.5076841267583387" CI_START="0.4970640832324289" DF="1.0" EFFECT_SIZE="0.865687950864062" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="53" I2="20.016929437479675" ID="CMP-005.05.01" LOG_CI_END="0.17831036250507062" LOG_CI_START="-0.3035876169002394" LOG_EFFECT_SIZE="-0.06263862719758442" NO="1" P_CHI2="0.2635020387682122" P_Z="0.6103845158445755" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="116" WEIGHT="23.485133609333836" Z="0.509524665365068">
<NAME>Withdrawals stated</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5527" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5528" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="8.400429398197016" CI_END="0.7018989347956706" CI_START="0.379572372424809" DF="2.0" EFFECT_SIZE="0.5161602889440827" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="118" I2="76.19169324333278" ID="CMP-005.05.02" LOG_CI_END="-0.153725416674143" LOG_CI_START="-0.42070540567600173" LOG_EFFECT_SIZE="-0.2872154111750724" NO="2" P_CHI2="0.014992380063624466" P_Z="2.4753653049722177E-5" STUDIES="3" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="76.51486639066617" Z="4.217034121640374">
<NAME>Withdrawals not stated</NAME>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5529" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5530" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5531" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.204109554202525" CI_END="0.7625953472334666" CI_START="0.44540936282707316" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.2241552549601" I2_Q="5.683228028404843" ID="CMP-005.06" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="6" P_CHI2="0.015896306292073392" P_Q="0.3031570023363478" P_Z="8.296147680509575E-5" Q="1.0602568123314953" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="3.9356799400026485">
<NAME>MTX part of prophylaxis regimen</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="11.14385274187103" CI_END="0.9247670362608508" CI_START="0.46227337623340187" DF="3.0" EFFECT_SIZE="0.6538311556370346" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="122" I2="73.07932840203426" ID="CMP-005.06.01" LOG_CI_END="-0.0339676592708234" LOG_CI_START="-0.3351011182164207" LOG_EFFECT_SIZE="-0.18453438874362205" NO="1" P_CHI2="0.010972919145203153" P_Z="0.016299944844378737" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="60.14301844185171" Z="2.402129322414179">
<NAME>MTX included</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5532" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5533" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5534" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5535" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="0.750113337470516" CI_START="0.320047202787619" DF="0.0" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" NO="2" P_CHI2="1.0" P_Z="0.001026244061581845" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="39.85698155814829" Z="3.2832313535400983">
<NAME>MTX not included</NAME>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5536" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.204109554202523" CI_END="0.7625953472334666" CI_START="0.44540936282707316" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.22415525496011" I2_Q="85.53486469292156" ID="CMP-005.07" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="7" P_CHI2="0.015896306292073614" P_Q="0.008556365256657261" P_Z="8.296147680509575E-5" Q="6.913174185869214" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="3.9356799400026485">
<NAME>Timing of steroid administration</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.4779339403692139" CI_END="2.1493323196340963" CI_START="0.6549178440166553" DF="1.0" EFFECT_SIZE="1.186438404996264" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="53" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="0.3323035692491667" LOG_CI_START="-0.18381317653959894" LOG_EFFECT_SIZE="0.07424519635478385" NO="1" P_CHI2="0.48935968966995236" P_Z="0.5728253723180509" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="94" WEIGHT="20.474219044034626" Z="0.5638953282094742">
<NAME>MTX overlapping with steroids</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5537" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5538" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.813001427964095" CI_END="0.6561219693424328" CI_START="0.359010707953613" DF="2.0" EFFECT_SIZE="0.48533989400990474" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="118" I2="58.44588808181587" ID="CMP-005.07.02" LOG_CI_END="-0.18301542024536557" LOG_CI_START="-0.4448925978400269" LOG_EFFECT_SIZE="-0.3139540090426962" NO="2" P_CHI2="0.0901301770905657" P_Z="2.6087088759794397E-6" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="211" WEIGHT="79.52578095596539" Z="4.699443885698816">
<NAME>MTX not overlapping with steroids</NAME>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5539" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5540" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5541" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.204109554202525" CI_END="0.7625953472334666" CI_START="0.44540936282707316" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.2241552549601" I2_Q="5.6832280284046846" ID="CMP-005.08" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="8" P_CHI2="0.015896306292073392" P_Q="0.30315700233634824" P_Z="8.296147680509575E-5" Q="1.0602568123314935" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="3.9356799400026485">
<NAME>Risk status of patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="0.750113337470516" CI_START="0.320047202787619" DF="0.0" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" I2="0.0" ID="CMP-005.08.01" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" NO="1" P_CHI2="1.0" P_Z="0.001026244061581845" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="39.85698155814829" Z="3.2832313535400983">
<NAME>Only high risk patients included in study</NAME>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5542" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="11.143852741871031" CI_END="0.9247670362608509" CI_START="0.4622733762334019" DF="3.0" EFFECT_SIZE="0.6538311556370348" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="122" I2="73.07932840203428" ID="CMP-005.08.02" LOG_CI_END="-0.03396765927082335" LOG_CI_START="-0.33510111821642063" LOG_EFFECT_SIZE="-0.184534388743622" NO="2" P_CHI2="0.010972919145203375" P_Z="0.01629994484437875" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="60.14301844185171" Z="2.4021293224141784">
<NAME>High- and low-risk included in study</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5543" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5544" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5545" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5546" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="23.515274061256207" CI_END="0.690626204201116" CI_START="0.4623729221518088" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.5650901309977744" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="304" I2="65.97955873633296" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="-0.1607569473823879" LOG_CI_START="-0.33500760733922874" LOG_EFFECT_SIZE="-0.2478822773608083" NO="9" P_CHI2="0.002762013804975094" P_Q="0.7353201916920151" P_Z="2.456336735524563E-8" Q="0.11428261475564128" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="508" TOTAL_2="514" WEIGHT="200.0" Z="5.576338547622007">
<NAME>Chao sensitivity (differing including criteria)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="11.196881892298041" CI_END="0.7347466538534675" CI_START="0.40217514050894776" DF="3.0" EFFECT_SIZE="0.5435962092877372" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="133" I2="73.20682642849347" ID="CMP-005.09.01" LOG_CI_END="-0.1338623830930957" LOG_CI_START="-0.39558477778068646" LOG_EFFECT_SIZE="-0.26472358043689115" NO="1" P_CHI2="0.01070754878943736" P_Z="7.343349225874033E-5" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.0" Z="3.9648780085031">
<NAME>without Chao</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5547" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.8997872843299453"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5548" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="50.059087686126205"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5549" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="24.22595131174663"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5550" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="21.81517371779721"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="12.204109554202525" CI_END="0.7625953472334666" CI_START="0.44540936282707316" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.2241552549601" ID="CMP-005.09.02" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="2" P_CHI2="0.015896306292073392" P_Z="8.296147680509575E-5" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="3.9356799400026485">
<NAME>All</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5551" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5552" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5553" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5554" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5555" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="21.96828534739839" CI_END="0.6925941331163689" CI_START="0.4721149840540654" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.5718252076571771" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="327" I2="63.58386704519292" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="-0.15952119162857162" LOG_CI_START="-0.3259522156485414" LOG_EFFECT_SIZE="-0.24273670363855648" MODIFIED="2008-05-07 01:58:12 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.00497496486931448" P_Q="0.8432628241006107" P_Z="1.0832830424634802E-8" Q="0.039093908580898784" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="577" TOTAL_2="590" WEIGHT="200.0" Z="5.717145582189755">
<NAME>Atkinson sensitivity (median follow up &lt; 1year)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="9.725081884614966" CI_END="0.736815247012912" CI_START="0.42668903502524597" DF="3.0" EFFECT_SIZE="0.5607057933888571" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="156" I2="69.15193069226505" ID="CMP-005.10.01" LOG_CI_END="-0.13264139580651021" LOG_CI_START="-0.36988851741539197" LOG_EFFECT_SIZE="-0.2512649566109511" NO="1" P_CHI2="0.02105360356741537" P_Z="3.3024786665254484E-5" STUDIES="4" TAU2="0.0" TOTAL_1="278" TOTAL_2="285" WEIGHT="100.0" Z="4.151538380696182">
<NAME>without Atkinson</NAME>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5556" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="21.03321033210332"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5557" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="41.13420081569237"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5558" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.90677801514857"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5559" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.92581083705574"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="12.204109554202525" CI_END="0.7625953472334666" CI_START="0.44540936282707316" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.2241552549601" ID="CMP-005.10.02" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="2" P_CHI2="0.015896306292073392" P_Z="8.296147680509575E-5" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="3.9356799400026485">
<NAME>All</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5560" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5561" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5562" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5563" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5564" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="16.281561524833805" CI_END="0.6356761952836523" CI_START="0.41506447922050815" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.5136600129933059" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="251" I2="63.148497821610235" I2_Q="56.15639960705801" ID="CMP-005.11" LOG_CI_END="-0.1967640516661664" LOG_CI_START="-0.38188443149403717" LOG_EFFECT_SIZE="-0.2893242415801018" NO="11" P_CHI2="0.012319916187672697" P_Q="0.13098149259752212" P_Z="8.986314838258642E-10" Q="2.2808345825562757" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="414" TOTAL_2="420" WEIGHT="200.0" Z="6.126446951747139">
<NAME>Type of data sensitivity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.7966173880750045" CI_END="0.5885289645810046" CI_START="0.29248662408239745" DF="1.0" EFFECT_SIZE="0.4148937816176652" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="80" I2="44.33984627792925" ID="CMP-005.11.01" LOG_CI_END="-0.2302321583971772" LOG_CI_START="-0.5338939901631099" LOG_EFFECT_SIZE="-0.3820630742801436" NO="1" P_CHI2="0.18012211647486776" P_Z="8.139249803395505E-7" STUDIES="2" TAU2="0.0" TOTAL_1="115" TOTAL_2="115" WEIGHT="100.0" Z="4.931998605533954">
<NAME>Data derived from Kaplan-Meier</NAME>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5565" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="67.38784600699968"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5566" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="32.61215399300032"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="12.204109554202525" CI_END="0.7625953472334666" CI_START="0.44540936282707316" DF="4.0" EFFECT_SIZE="0.5828096667919545" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="171" I2="67.2241552549601" ID="CMP-005.11.02" LOG_CI_END="-0.11770584878303443" LOG_CI_START="-0.35124065802179405" LOG_EFFECT_SIZE="-0.23447325340241423" NO="2" P_CHI2="0.015896306292073392" P_Z="8.296147680509575E-5" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="3.9356799400026485">
<NAME>all</NAME>
<IPD_DATA CI_END="8.957548272354996" CI_START="0.42351632158001173" EFFECT_SIZE="1.947734041054676" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.9521891572635922" LOG_CI_START="-0.3731298480592565" LOG_EFFECT_SIZE="0.2895296546021679" ORDER="5567" O_E="1.1" SE="0.778498944161523" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.65" WEIGHT="3.10500564546481"/>
<IPD_DATA CI_END="1.3879068363960583" CI_START="0.42174848957295474" EFFECT_SIZE="0.765080134311443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" LOG_CI_END="0.14236031496823495" LOG_CI_START="-0.37494646409463017" LOG_EFFECT_SIZE="-0.11629307456319762" ORDER="5568" O_E="-2.9" SE="0.30386856273138196" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.83" WEIGHT="20.380127963869025"/>
<IPD_DATA CI_END="0.750113337470516" CI_START="0.320047202787619" EFFECT_SIZE="0.4899710965262379" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="-0.1248731124492419" LOG_CI_START="-0.4947859641851428" LOG_EFFECT_SIZE="-0.30982953831719234" ORDER="5569" O_E="-15.11" SE="0.21728864020781588" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="21.18" WEIGHT="39.85698155814829"/>
<IPD_DATA CI_END="0.5426858145664001" CI_START="0.159517039553005" EFFECT_SIZE="0.2942237831091212" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="31" LOG_CI_END="-0.2654515304309399" LOG_CI_START="-0.7971929189479436" LOG_EFFECT_SIZE="-0.5313222246894418" ORDER="5570" O_E="-12.54" SE="0.31234752377721214" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="10.25" WEIGHT="19.288671433948064"/>
<IPD_DATA CI_END="2.06983770057962" CI_START="0.5696177206629731" EFFECT_SIZE="1.0858251393048757" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="0.31593629303852777" LOG_CI_START="-0.2444165083697366" LOG_EFFECT_SIZE="0.035759892334395624" ORDER="5571" O_E="0.76" SE="0.3291540093383166" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="9.23" WEIGHT="17.369213398569816"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-05-07 01:59:11 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Acute GvHD grade II-IV</NAME>
<IPD_OUTCOME CHI2="9.308392059592826" CI_END="0.9213978833078346" CI_START="0.514647261764042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.035552789770319" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="1" P_CHI2="0.05383691023198223" P_Q="1.0" P_Z="0.012040765930146885" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="2.5109473336056416">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5572" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.030905077262693"/>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5573" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399558"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5574" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933774"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5575" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.900662251655627"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5576" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.73509933774834"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.308392059592824" CI_END="0.9213978833078345" CI_START="0.514647261764042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" I2_Q="83.1987652343927" ID="CMP-006.02" LOG_CI_END="-0.03555278977031905" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="2" P_CHI2="0.053836910231982005" P_Q="0.014701116153268634" P_Z="0.012040765930146873" Q="5.951943496718666" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="2.510947333605642">
<NAME>Type of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="2.755094793808866" CI_START="0.7426219487688149" DF="0.0" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" NO="1" P_CHI2="1.0" P_Z="0.2845112652100106" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="74" WEIGHT="19.735099337748345" Z="1.0702400993450418">
<NAME>Truly randomised</NAME>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5577" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.735099337748345"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.356448562874158" CI_END="0.7963107569222103" CI_START="0.4156778200233334" DF="3.0" EFFECT_SIZE="0.5753335723721977" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="85" I2="10.619813061247322" ID="CMP-006.02.02" LOG_CI_END="-0.09891741758982633" LOG_CI_START="-0.3812431482107987" LOG_EFFECT_SIZE="-0.24008028290031255" NO="2" P_CHI2="0.33986309455988717" P_Z="8.579934252142578E-4" STUDIES="4" TAU2="0.0" TOTAL_1="226" TOTAL_2="231" WEIGHT="80.26490066225165" Z="3.333374587203464">
<NAME>Type of randomisation not reported</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5578" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.0309050772626933"/>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5579" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399559"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5580" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933775"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5581" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.90066225165563"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.308392059592826" CI_END="0.9213978833078346" CI_START="0.514647261764042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.035552789770319" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="3" P_CHI2="0.05383691023198223" P_Q="0.3376576198140734" P_Z="0.012040765930146885" Q="0.9193051625407875" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999997" Z="2.5109473336056416">
<NAME>Concealment of allocation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.12125853801115" CI_END="0.9298809146216005" CI_START="0.3434606305172465" DF="1.0" EFFECT_SIZE="0.5651349265811562" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="39" I2="67.96164150384047" ID="CMP-006.03.01" LOG_CI_END="-0.0315726658914612" LOG_CI_START="-0.46412303714594944" LOG_EFFECT_SIZE="-0.2478478515187053" NO="1" P_CHI2="0.07727737000204604" P_Z="0.024698441859513094" STUDIES="2" TAU2="0.0" TOTAL_1="143" TOTAL_2="151" WEIGHT="34.194260485651206" Z="2.246086906426406">
<NAME>Concealment of allocation adequate</NAME>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5582" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399558"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5583" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.900662251655627"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="5.267828359040889" CI_END="1.0926416853275671" CI_START="0.5329346535671333" DF="2.0" EFFECT_SIZE="0.7630901768749587" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="73" I2="62.03369085540709" ID="CMP-006.03.02" LOG_CI_END="0.038477765245374405" LOG_CI_START="-0.27332603925679416" LOG_EFFECT_SIZE="-0.11742413700570983" NO="2" P_CHI2="0.07179701922597548" P_Z="0.1398821339215438" STUDIES="3" TAU2="0.0" TOTAL_1="156" TOTAL_2="154" WEIGHT="65.80573951434877" Z="1.4762300916394864">
<NAME>Concealment of allocation not reported</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5584" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.030905077262693"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5585" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933774"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5586" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.73509933774834"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.308392059592826" CI_END="0.9213978833078346" CI_START="0.514647261764042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-0.035552789770319" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="4" P_CHI2="0.05383691023198223" P_Q="0.517081685474429" P_Z="0.012040765930146885" Q="0.41971023247213246" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="2.5109473336056416">
<NAME>Blinding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.6270463799494725" CI_START="0.4320693893036239" DF="0.0" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" NO="1" P_CHI2="1.0" P_Z="0.6024275409046803" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="19.29359823399558" Z="0.5209127704486385">
<NAME>Patients and clinicians blinded</NAME>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5587" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399558"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="8.888681827120694" CI_END="0.9084803152904704" CI_START="0.47507598305598336" DF="3.0" EFFECT_SIZE="0.6569605611249658" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="93" I2="66.24921379403465" ID="CMP-006.04.02" LOG_CI_END="-0.04168447843117443" LOG_CI_START="-0.32323692430591244" LOG_EFFECT_SIZE="-0.18246070136854342" NO="2" P_CHI2="0.030808151549283846" P_Z="0.011075165106455537" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="80.7064017660044" Z="2.540318214357591">
<NAME>Patients and clinicians not blinded</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5588" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.030905077262693"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5589" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933774"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5590" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.900662251655627"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5591" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.73509933774834"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.308392059592824" CI_END="0.9213978833078345" CI_START="0.514647261764042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-0.03555278977031905" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="5" P_CHI2="0.053836910231982005" P_Q="0.4650881236245007" P_Z="0.012040765930146873" Q="0.5336220449966973" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="2.510947333605642">
<NAME>Statement of withdrawals in each group</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.01235943118666226" CI_END="1.5936258071611678" CI_START="0.45148896437837166" DF="1.0" EFFECT_SIZE="0.8482360905324898" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.2023863540972803" LOG_CI_START="-0.34535286056232595" LOG_EFFECT_SIZE="-0.07148325323252282" NO="1" P_CHI2="0.9114791802665905" P_Z="0.6089491077999375" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="116" WEIGHT="21.324503311258283" Z="0.5115741144097906">
<NAME>Withdrawals stated</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5592" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.0309050772626933"/>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5593" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399559"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="8.762410583409466" CI_END="0.9036915408071073" CI_START="0.46865900974912533" DF="2.0" EFFECT_SIZE="0.6507865876255596" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="91" I2="77.17523070892442" ID="CMP-006.05.02" LOG_CI_END="-0.04397978300425058" LOG_CI_START="-0.3291430294502268" LOG_EFFECT_SIZE="-0.18656140622723869" NO="2" P_CHI2="0.012510314992054683" P_Z="0.010331818052344172" STUDIES="3" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="78.67549668874172" Z="2.564521491936423">
<NAME>Withdrawals not stated</NAME>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5594" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933775"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5595" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.90066225165563"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5596" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.735099337748345"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.308392059592826" CI_END="0.9213978833078345" CI_START="0.514647261764042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" I2_Q="21.33785906728908" ID="CMP-006.06" LOG_CI_END="-0.03555278977031905" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="6" P_CHI2="0.05383691023198223" P_Q="0.2595306181131247" P_Z="0.012040765930146873" Q="1.2712595768978865" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="2.510947333605642">
<NAME>MTX part of prophylaxis regimen</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="8.03713248269494" CI_END="1.1791805322662219" CI_START="0.5413252818759053" DF="3.0" EFFECT_SIZE="0.7989494564811924" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="68" I2="62.67325434214982" ID="CMP-006.06.01" LOG_CI_END="0.07158030056997415" LOG_CI_START="-0.26654168929025057" LOG_EFFECT_SIZE="-0.09748069436013815" NO="1" P_CHI2="0.045250612391980694" P_Z="0.25842708120305824" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="55.96026490066226" Z="1.1301166789702664">
<NAME>MTX included</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5597" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.0309050772626933"/>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5598" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399559"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5599" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.90066225165563"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5600" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.735099337748345"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="0.8841799836016373" CI_START="0.36761654251932085" DF="0.0" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" I2="0.0" ID="CMP-006.06.02" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" NO="2" P_CHI2="1.0" P_Z="0.012080934763099897" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="44.03973509933775" Z="2.5097713802162107">
<NAME>MTX not included (nur Deeg)</NAME>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5601" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933775"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.308392059592826" CI_END="0.9213978833078346" CI_START="0.514647261764042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" I2_Q="83.45649393518867" ID="CMP-006.07" LOG_CI_END="-0.035552789770319" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="7" P_CHI2="0.05383691023198223" P_Q="0.013948414260913866" P_Z="0.012040765930146885" Q="6.044667896166453" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="2.5109473336056416">
<NAME>Timing of steroid administration</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.14179251915692348" CI_END="2.5693483518559272" CI_START="0.7373393286942411" DF="1.0" EFFECT_SIZE="1.3764016815374442" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="29" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="0.40982298983760845" LOG_CI_START="-0.13233260079192005" LOG_EFFECT_SIZE="0.13874519452284417" NO="1" P_CHI2="0.7065055900424597" P_Z="0.3157815770875969" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="94" WEIGHT="21.76600441501104" Z="1.0031643645951092">
<NAME>MTX overlapping with steroids</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5602" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.0309050772626933"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5603" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.735099337748345"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.1219316442694502" CI_END="0.7893752005042878" CI_START="0.40861727862339065" DF="2.0" EFFECT_SIZE="0.5679369210069508" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="83" I2="35.93709831311789" ID="CMP-006.07.02" LOG_CI_END="-0.10271652178813832" LOG_CI_START="-0.3886832729161619" LOG_EFFECT_SIZE="-0.24569989735215006" NO="2" P_CHI2="0.20993331921199132" P_Z="7.572531372155175E-4" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="211" WEIGHT="78.23399558498897" Z="3.3679646176755216">
<NAME>MTX not overlapping with steroids</NAME>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5604" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399559"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5605" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933775"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5606" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.90066225165563"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="9.308392059592824" CI_END="0.9213978833078345" CI_START="0.514647261764042" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" I2_Q="21.33785906728897" ID="CMP-006.08" LOG_CI_END="-0.03555278977031905" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="8" P_CHI2="0.053836910231982005" P_Q="0.25953061811312483" P_Z="0.012040765930146873" Q="1.2712595768978847" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="2.510947333605642">
<NAME>Risk status of patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="0.8841799836016373" CI_START="0.36761654251932085" DF="0.0" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" NO="1" P_CHI2="1.0" P_Z="0.012080934763099897" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="44.03973509933775" Z="2.5097713802162107">
<NAME>Only high risk patients included in study</NAME>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5607" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933775"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="8.03713248269494" CI_END="1.1791805322662219" CI_START="0.5413252818759053" DF="3.0" EFFECT_SIZE="0.7989494564811924" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="68" I2="62.67325434214982" ID="CMP-006.08.02" LOG_CI_END="0.07158030056997415" LOG_CI_START="-0.26654168929025057" LOG_EFFECT_SIZE="-0.09748069436013815" NO="2" P_CHI2="0.045250612391980694" P_Z="0.25842708120305824" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="55.96026490066226" Z="1.1301166789702664">
<NAME>High- and low-risk included in study</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5608" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.0309050772626933"/>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5609" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399559"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5610" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.90066225165563"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5611" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.735099337748345"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="18.24188536279227" CI_END="0.8373939516383486" CI_START="0.5429629004916385" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.674295075494188" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="205" I2="56.14488392566322" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="-0.07707018027256012" LOG_CI_START="-0.2652298438222091" LOG_EFFECT_SIZE="-0.17115001204738461" NO="9" P_CHI2="0.019484408346169158" P_Q="0.8323512069582841" P_Z="3.6307162600991325E-4" Q="0.04481147607875258" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="508" TOTAL_2="514" WEIGHT="200.0" Z="3.5655661074027885">
<NAME>Chao sensitivity (differing including criteria)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="8.888681827120696" CI_END="0.9084803152904704" CI_START="0.47507598305598336" DF="3.0" EFFECT_SIZE="0.6569605611249658" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="93" I2="66.24921379403466" ID="CMP-006.09.01" LOG_CI_END="-0.04168447843117443" LOG_CI_START="-0.32323692430591244" LOG_EFFECT_SIZE="-0.18246070136854342" NO="1" P_CHI2="0.030808151549283846" P_Z="0.011075165106455537" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.0" Z="2.540318214357591">
<NAME>without Chao</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5612" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.516411378555799"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5613" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="54.56783369803063"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5614" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="18.462800875273523"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5615" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="24.452954048140043"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="9.308392059592824" CI_END="0.9213978833078345" CI_START="0.514647261764042" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" ID="CMP-006.09.02" LOG_CI_END="-0.03555278977031905" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="2" P_CHI2="0.053836910231982005" P_Z="0.012040765930146873" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="2.510947333605642">
<NAME>All</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5616" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.0309050772626933"/>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5617" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399559"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5618" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933775"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5619" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.90066225165563"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5620" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.735099337748345"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="18.522369181245036" CI_END="0.8441952446604553" CI_START="0.5580511225205897" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.6863702382164534" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="222" I2="56.80898095854573" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="-0.07355709854922558" LOG_CI_START="-0.25332601394485893" LOG_EFFECT_SIZE="-0.16344155624704224" MODIFIED="2008-05-07 01:59:11 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.01763365049444454" P_Q="0.9750440086247771" P_Z="3.653798559409323E-4" Q="9.786135974003685E-4" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="577" TOTAL_2="590" WEIGHT="200.0" Z="3.5639038386183803">
<NAME>Atkinson sensitivity (median follow up &lt; 1year)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="9.212998508054813" CI_END="0.9180829309865287" CI_START="0.509725208487845" DF="3.0" EFFECT_SIZE="0.6840833380562927" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="110" I2="67.43731156173382" ID="CMP-006.10.01" LOG_CI_END="-0.037118086943545715" LOG_CI_START="-0.29266388782300656" LOG_EFFECT_SIZE="-0.16489098738327615" NO="1" P_CHI2="0.02658903461280615" P_Z="0.011427907752917674" STUDIES="4" TAU2="0.0" TOTAL_1="278" TOTAL_2="285" WEIGHT="100.0" Z="2.529334432686778">
<NAME>without Atkinson</NAME>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5621" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.693555655700766"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5622" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.95268138801262"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5623" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="15.209553853086977"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5624" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="20.14420910319964"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="9.308392059592824" CI_END="0.9213978833078345" CI_START="0.514647261764042" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" ID="CMP-006.10.02" LOG_CI_END="-0.03555278977031905" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="2" P_CHI2="0.053836910231982005" P_Z="0.012040765930146873" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="2.510947333605642">
<NAME>All</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5625" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.0309050772626933"/>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5626" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399559"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5627" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933775"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5628" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.90066225165563"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5629" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.735099337748345"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="13.168500883156325" CI_END="0.7870073589119132" CI_START="0.5087665833792313" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="0.6327740869282863" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="195" I2="46.84284823222651" I2_Q="0.0" ID="CMP-006.11" LOG_CI_END="-0.10402120675161539" LOG_CI_START="-0.2934814215943137" LOG_EFFECT_SIZE="-0.1987513141729646" NO="11" P_CHI2="0.06810785324339041" P_Q="0.3902454481425017" P_Z="3.919734243146621E-5" Q="0.7381771792940501" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="504" TOTAL_2="516" WEIGHT="200.0" Z="4.112160624144132">
<NAME>Type of data sensitivity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.1219316442694502" CI_END="0.7893752005042878" CI_START="0.40861727862339065" DF="2.0" EFFECT_SIZE="0.5679369210069508" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="83" I2="35.93709831311789" ID="CMP-006.11.01" LOG_CI_END="-0.10271652178813832" LOG_CI_START="-0.3886832729161619" LOG_EFFECT_SIZE="-0.24569989735215006" NO="1" P_CHI2="0.20993331921199132" P_Z="7.572531372155175E-4" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="211" WEIGHT="100.0" Z="3.3679646176755216">
<NAME>Data derived from Kaplan-Meier</NAME>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5630" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="24.661399548532735"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5631" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="56.29232505643341"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5632" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="19.046275395033863"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="9.308392059592824" CI_END="0.9213978833078345" CI_START="0.514647261764042" DF="4.0" EFFECT_SIZE="0.6886181072550746" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="112" I2="57.0280240197041" ID="CMP-006.11.02" LOG_CI_END="-0.03555278977031905" LOG_CI_START="-0.28849033359237225" LOG_EFFECT_SIZE="-0.1620215616813456" NO="2" P_CHI2="0.053836910231982005" P_Z="0.012040765930146873" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.0" Z="2.510947333605642">
<NAME>All</NAME>
<IPD_DATA CI_END="7.308630301576205" CI_START="0.12273207700670571" EFFECT_SIZE="0.9471026222044756" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8638359941666147" LOG_CI_START="-0.9110419161126203" LOG_EFFECT_SIZE="-0.023602960973002796" ORDER="5633" O_E="-0.05" SE="1.0425720702853738" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.92" WEIGHT="2.0309050772626933"/>
<IPD_DATA CI_END="1.6270463799494725" CI_START="0.4320693893036239" EFFECT_SIZE="0.8384491253221275" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.21139993294241272" LOG_CI_START="-0.36444650093577835" LOG_EFFECT_SIZE="-0.0765232839966828" ORDER="5634" O_E="-1.54" SE="0.3382550457458692" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="8.74" WEIGHT="19.29359823399559"/>
<IPD_DATA CI_END="0.8841799836016373" CI_START="0.36761654251932085" EFFECT_SIZE="0.5701220821336634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="44" LOG_CI_END="-0.05345932104036147" LOG_CI_START="-0.4346049538604359" LOG_EFFECT_SIZE="-0.2440321374503987" ORDER="5635" O_E="-11.21" SE="0.22388683141982252" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="19.95" WEIGHT="44.03973509933775"/>
<IPD_DATA CI_END="0.72101813308949" CI_START="0.15947438410690884" EFFECT_SIZE="0.33909279364852274" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.14205381294814656" LOG_CI_START="-0.7973090664277759" LOG_EFFECT_SIZE="-0.4696814396879613" ORDER="5636" O_E="-7.3" SE="0.3849001794597505" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="6.75" WEIGHT="14.90066225165563"/>
<IPD_DATA CI_END="2.755094793808866" CI_START="0.7426219487688149" EFFECT_SIZE="1.4303824190827976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="27" LOG_CI_END="0.4401365460988258" LOG_CI_START="-0.1292322190092495" LOG_EFFECT_SIZE="0.1554521635447881" ORDER="5637" O_E="3.2" SE="0.3344500310453256" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="8.94" WEIGHT="19.735099337748345"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2008-05-07 01:59:30 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Acute GvHD grade III-IV</NAME>
<IPD_OUTCOME CHI2="3.4490417804974745" CI_END="1.1499272972469035" CI_START="0.5239635175986266" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.776221586692981" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.1100142837149371" NO="1" P_CHI2="0.48566913095548514" P_Q="1.0" P_Z="0.20648542323681107" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174924">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5638" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5639" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5640" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5641" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5642" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.4490417804974745" CI_END="1.1499272972469035" CI_START="0.5239635175986266" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.776221586692981" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" I2_Q="54.576556658881735" ID="CMP-007.02" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.1100142837149371" NO="2" P_CHI2="0.48566913095548514" P_Q="0.13787602853048353" P_Z="0.20648542323681107" Q="2.2015063730203357" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174924">
<NAME>Type of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="2.7796749767655395" CI_START="0.5931345515145797" DF="0.0" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" NO="1" P_CHI2="1.0" P_Z="0.5258009727135036" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="74" WEIGHT="25.894652191395252" Z="0.6344288770224761">
<NAME>Truly randomised</NAME>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5643" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.247535407477139" CI_END="1.0277329848583163" CI_START="0.412409512041963" DF="3.0" EFFECT_SIZE="0.6510352208558676" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="44" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="0.011880295334836774" LOG_CI_START="-0.3846713264639438" LOG_EFFECT_SIZE="-0.18639551556455355" NO="2" P_CHI2="0.7416274528521605" P_Z="0.06539812860175338" STUDIES="4" TAU2="0.0" TOTAL_1="226" TOTAL_2="231" WEIGHT="74.10534780860473" Z="1.842526810149707">
<NAME>Type of randomisation not reported</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5644" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5645" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5646" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5647" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.449041780497474" CI_END="1.1499272972469035" CI_START="0.5239635175986266" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7762215866929809" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" I2_Q="21.455424751187195" ID="CMP-007.03" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.11001428371493716" NO="3" P_CHI2="0.48566913095548525" P_Q="0.2591743552060769" P_Z="0.20648542323681107" Q="1.273162400881549" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000003" Z="1.2632888320174924">
<NAME>Concealment of allocation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.8124901222728362" CI_END="1.1366021225705116" CI_START="0.2550194887238515" DF="1.0" EFFECT_SIZE="0.5383824775941136" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="0.055608462741440656" LOG_CI_START="-0.593426629284421" LOG_EFFECT_SIZE="-0.2689090832714902" NO="1" P_CHI2="0.36738512595280615" P_Z="0.10435238233323792" STUDIES="2" TAU2="0.0" TOTAL_1="143" TOTAL_2="151" WEIGHT="27.663852030558907" Z="1.6241097740422397">
<NAME>Concealment of allocation adequate</NAME>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5648" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443104"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5649" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.062726176115802"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.3633892573430888" CI_END="1.4172239424740045" CI_START="0.5624277201526269" DF="2.0" EFFECT_SIZE="0.8927967466962299" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" I2="0.0" ID="CMP-007.03.02" LOG_CI_END="0.15143848066121762" LOG_CI_START="-0.24993328256034317" LOG_EFFECT_SIZE="-0.04924740094956274" NO="2" P_CHI2="0.5057592392445777" P_Z="0.6305405006490552" STUDIES="3" TAU2="0.0" TOTAL_1="156" TOTAL_2="154" WEIGHT="72.33614796944111" Z="0.4809662314987763">
<NAME>Concealment of allocation not reported</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5650" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.970245275432248"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5651" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.4712505026136"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5652" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.89465219139526"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.4490417804974745" CI_END="1.1499272972469035" CI_START="0.5239635175986266" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.776221586692981" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.1100142837149371" NO="4" P_CHI2="0.48566913095548514" P_Q="0.8913745906238821" P_Z="0.20648542323681107" Q="0.018650019699101517" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174924">
<NAME>Blinding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.9699548987908446" CI_START="0.26927253606843476" DF="0.0" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" NO="1" P_CHI2="1.0" P_Z="0.5323400505431943" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="15.601125854443103" Z="0.6244378915571757">
<NAME>Patients and clinicians blinded</NAME>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5653" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.430391760798373" CI_END="1.2047324185458157" CI_START="0.5120440270235376" DF="3.0" EFFECT_SIZE="0.7854145651043183" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" I2="12.546431743358829" ID="CMP-007.04.02" LOG_CI_END="0.08089059707388857" LOG_CI_START="-0.29069269552548327" LOG_EFFECT_SIZE="-0.10490104922579735" NO="2" P_CHI2="0.32990302548345574" P_Z="0.26845471970470325" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="84.39887414555689" Z="1.10662821777996">
<NAME>Patients and clinicians not blinded</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5654" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5655" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5656" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5657" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.4490417804974736" CI_END="1.1499272972469035" CI_START="0.5239635175986266" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7762215866929809" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.11001428371493716" NO="5" P_CHI2="0.48566913095548536" P_Q="0.9399384469488165" P_Z="0.20648542323681107" Q="0.005677204557969606" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174926">
<NAME>Statement of withdrawals in each group</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.03318751952879577" CI_END="1.9184867669488732" CI_START="0.2941636267351813" DF="1.0" EFFECT_SIZE="0.7512316721286005" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-007.05.01" LOG_CI_END="0.28295880793313444" LOG_CI_START="-0.5314110287015852" LOG_EFFECT_SIZE="-0.12422611038422533" NO="1" P_CHI2="0.8554458964165619" P_Z="0.5498692344325675" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="116" WEIGHT="17.57137112987535" Z="0.5979560915436747">
<NAME>Withdrawals stated</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5658" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5659" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.410177056410708" CI_END="1.205075432193848" CI_START="0.5070097265066936" DF="2.0" EFFECT_SIZE="0.7816552726723837" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="48" I2="41.35201876863698" ID="CMP-007.05.02" LOG_CI_END="0.08101423260401455" LOG_CI_START="-0.29498370905390936" LOG_EFFECT_SIZE="-0.1069847382249474" NO="2" P_CHI2="0.18175655823331527" P_Z="0.2646968809580603" STUDIES="3" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="82.42862887012464" Z="1.1153584133559502">
<NAME>Withdrawals not stated</NAME>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5660" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5661" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5662" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.4490417804974736" CI_END="1.1499272972469035" CI_START="0.5239635175986266" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7762215866929809" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-007.06" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.11001428371493716" NO="6" P_CHI2="0.48566913095548536" P_Q="0.7381993111252736" P_Z="0.20648542323681107" Q="0.11171566276520695" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174926">
<NAME>MTX part of prophylaxis regimen</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.3373261177322666" CI_END="1.3966483784357842" CI_START="0.48638651515674053" DF="3.0" EFFECT_SIZE="0.8242032138293891" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" I2="10.107676200415254" ID="CMP-007.06.01" LOG_CI_END="0.14508708147115074" LOG_CI_START="-0.31301847418392154" LOG_EFFECT_SIZE="-0.08396569635638537" NO="1" P_CHI2="0.3424813161031496" P_Z="0.4724616470938865" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="55.5287494973864" Z="0.7184795677058026">
<NAME>MTX included</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5663" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5664" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5665" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5666" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2984048716399474" CI_START="0.3994942051723288" DF="0.0" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" I2="0.0" ID="CMP-007.06.02" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429194" LOG_EFFECT_SIZE="-0.1425396898109226" NO="2" P_CHI2="1.0" P_Z="0.27504706705683324" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="44.471250502613586" Z="1.0915133744735386">
<NAME>MTX not included (nur Deeg)</NAME>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5667" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.4490417804974727" CI_END="1.1499272972469032" CI_START="0.5239635175986266" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.7762215866929809" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" I2_Q="55.335672956661455" ID="CMP-007.07" LOG_CI_END="0.060670383481790206" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.11001428371493716" NO="7" P_CHI2="0.4856691309554855" P_Q="0.1345747628437367" P_Z="0.20648542323681085" Q="2.2389232441131" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174929">
<NAME>Timing of steroid administration</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.038511131725417425" CI_END="2.6484272709704775" CI_START="0.5974459124976081" DF="1.0" EFFECT_SIZE="1.2578919061622533" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" I2="0.0" ID="CMP-007.07.01" LOG_CI_END="0.42298805118142047" LOG_CI_START="-0.22370140580590228" LOG_EFFECT_SIZE="0.09964332268775909" NO="1" P_CHI2="0.8444204226808739" P_Z="0.5458495923062909" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="94" WEIGHT="27.8648974668275" Z="0.6039910552360811">
<NAME>MTX overlapping with steroids</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5668" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5669" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="1.171607404658955" CI_END="1.023205643845274" CI_START="0.40553862817820774" DF="2.0" EFFECT_SIZE="0.6441656721288493" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="43" I2="0.0" ID="CMP-007.07.02" LOG_CI_END="0.009962926978904036" LOG_CI_START="-0.3919677722650419" LOG_EFFECT_SIZE="-0.1910024226430689" NO="2" P_CHI2="0.5566584991090339" P_Z="0.06249067894010864" STUDIES="3" TAU2="0.0" TOTAL_1="205" TOTAL_2="211" WEIGHT="72.13510253317249" Z="1.8627980895437986">
<NAME>MTX not overlapping with steroids</NAME>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5670" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5671" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5672" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.4490417804974745" CI_END="1.1499272972469035" CI_START="0.5239635175986266" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="0.776221586692981" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-007.08" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.1100142837149371" NO="8" P_CHI2="0.48566913095548514" P_Q="0.7381993111252727" P_Z="0.20648542323681107" Q="0.11171566276520783" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174924">
<NAME>Risk status of patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.2984048716399474" CI_START="0.3994942051723288" DF="0.0" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" I2="0.0" ID="CMP-007.08.01" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429194" LOG_EFFECT_SIZE="-0.1425396898109226" NO="1" P_CHI2="1.0" P_Z="0.27504706705683324" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="44.471250502613586" Z="1.0915133744735386">
<NAME>Only high risk patients included in study</NAME>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5673" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.3373261177322666" CI_END="1.3966483784357844" CI_START="0.48638651515674053" DF="3.0" EFFECT_SIZE="0.8242032138293891" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" I2="10.107676200415254" ID="CMP-007.08.02" LOG_CI_END="0.14508708147115082" LOG_CI_START="-0.31301847418392154" LOG_EFFECT_SIZE="-0.08396569635638537" NO="2" P_CHI2="0.3424813161031496" P_Z="0.4724616470938866" STUDIES="4" TAU2="0.0" TOTAL_1="237" TOTAL_2="245" WEIGHT="55.5287494973864" Z="0.7184795677058023">
<NAME>High- and low-risk included in study</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5674" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5675" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5676" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5677" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.881011432190582" CI_END="1.0423660797994998" CI_START="0.5842944887060957" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.780415758196249" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-007.09" LOG_CI_END="0.018020270321959" LOG_CI_START="-0.2333682101056474" LOG_EFFECT_SIZE="-0.10767396989184416" NO="9" P_CHI2="0.5495236459392678" P_Q="0.9683142293081786" P_Z="0.09315751142484116" Q="0.0015778908947359227" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="508" TOTAL_2="514" WEIGHT="200.0" Z="1.6789719457430599">
<NAME>Chao sensitivity (differing including criteria)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.430391760798372" CI_END="1.2047324185458157" CI_START="0.5120440270235375" DF="3.0" EFFECT_SIZE="0.7854145651043182" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" I2="12.546431743358806" ID="CMP-007.09.01" LOG_CI_END="0.08089059707388857" LOG_CI_START="-0.2906926955254834" LOG_EFFECT_SIZE="-0.1049010492257974" NO="1" P_CHI2="0.32990302548345596" P_Z="0.26845471970470314" STUDIES="4" TAU2="0.0" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.00000000000001" Z="1.1066282177799602">
<NAME>without Chao</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5678" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="2.3344449737970465"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5679" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="52.69175797999048"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5680" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="14.29252024773702"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5681" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="30.68127679847547"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.4490417804974745" CI_END="1.1499272972469035" CI_START="0.5239635175986266" DF="4.0" EFFECT_SIZE="0.776221586692981" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" ID="CMP-007.09.02" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.1100142837149371" NO="2" P_CHI2="0.48566913095548514" P_Z="0.20648542323681107" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174924">
<NAME>All</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5682" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5683" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5684" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5685" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5686" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="6.875736661882849" CI_END="1.024138561963716" CI_START="0.5858363608822176" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="0.7745822152489501" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="117" I2="0.0" I2_Q="0.0" ID="CMP-007.10" LOG_CI_END="0.010358718969131748" LOG_CI_START="-0.232223676627727" LOG_EFFECT_SIZE="-0.11093247882929763" MODIFIED="2008-05-07 01:59:30 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.5500974565012187" P_Q="0.988043649685936" P_Z="0.0730407823984726" Q="2.2456892052602484E-4" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="577" TOTAL_2="590" WEIGHT="200.0" Z="1.7925757776958067">
<NAME>Atkinson sensitivity (median follow up &lt; 1year)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="3.42647031246485" CI_END="1.1495351458990923" CI_START="0.5196841718379704" DF="3.0" EFFECT_SIZE="0.7729134623586332" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="58" I2="12.446344884805566" ID="CMP-007.10.01" LOG_CI_END="0.06052225393213487" LOG_CI_START="-0.2842605104007502" LOG_EFFECT_SIZE="-0.11186912823430765" NO="1" P_CHI2="0.330424735167812" P_Z="0.2034192655870708" STUDIES="4" TAU2="0.0" TOTAL_1="278" TOTAL_2="285" WEIGHT="99.99999999999999" Z="1.2718702035200498">
<NAME>without Atkinson</NAME>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5687" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.914684167350284"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5688" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="45.3650533223954"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5689" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.305168170631664"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5690" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="26.415094339622637"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.4490417804974722" CI_END="1.1499272972469035" CI_START="0.5239635175986265" DF="4.0" EFFECT_SIZE="0.7762215866929809" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" ID="CMP-007.10.02" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116646" LOG_EFFECT_SIZE="-0.11001428371493716" NO="2" P_CHI2="0.4856691309554856" P_Z="0.20648542323681107" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="1.2632888320174926">
<NAME>All</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5691" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.970245275432248"/>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5692" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443104"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5693" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.4712505026136"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5694" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.062726176115802"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5695" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.89465219139526"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="4.982190320493664" CI_END="0.9813974395987038" CI_START="0.5235971622152754" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="0.7168381368058053" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-007.11" LOG_CI_END="-0.00815507939933085" LOG_CI_START="-0.28100271589818493" LOG_EFFECT_SIZE="-0.1445788976487579" NO="11" P_CHI2="0.5460994380609618" P_Q="0.5089701036075376" P_Z="0.037789950123584284" Q="0.43618393544684153" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="414" TOTAL_2="420" WEIGHT="200.0" Z="2.0771257977692494">
<NAME>Type of data sensitivity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.0969646045493484" CI_END="1.0502406376419575" CI_START="0.36921072123712473" DF="1.0" EFFECT_SIZE="0.6227038648477501" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" I2="8.83935581396294" ID="CMP-007.11.01" LOG_CI_END="0.021288818714139426" LOG_CI_START="-0.43272569630669383" LOG_EFFECT_SIZE="-0.20571843879627713" NO="1" P_CHI2="0.2949336995447086" P_Z="0.07570689716974562" STUDIES="2" TAU2="0.0" TOTAL_1="115" TOTAL_2="115" WEIGHT="100.0" Z="1.776157887718674">
<NAME>Data derived from Kaplan-Meier</NAME>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5696" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="78.66287339971551"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5697" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="21.337126600284495"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.4490417804974736" CI_END="1.1499272972469035" CI_START="0.5239635175986266" DF="4.0" EFFECT_SIZE="0.7762215866929809" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.0" ID="CMP-007.11.02" LOG_CI_END="0.06067038348179029" LOG_CI_START="-0.2806989509116645" LOG_EFFECT_SIZE="-0.11001428371493716" NO="2" P_CHI2="0.48566913095548536" P_Z="0.20648542323681107" STUDIES="5" TAU2="0.0" TOTAL_1="299" TOTAL_2="305" WEIGHT="99.99999999999999" Z="1.2632888320174926">
<NAME>All</NAME>
<IPD_DATA CI_END="15.786138152195722" CI_START="0.058380994668384825" EFFECT_SIZE="0.9600054412854777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982758992088451" LOG_CI_START="-1.2337285099764577" LOG_EFFECT_SIZE="-0.017726305383806203" ORDER="5698" O_E="-0.02" SE="1.4285714285714286" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.49" WEIGHT="1.9702452754322475"/>
<IPD_DATA CI_END="1.9699548987908446" CI_START="0.26927253606843476" EFFECT_SIZE="0.7283232465999196" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2944562833034804" LOG_CI_START="-0.5698079393555422" LOG_EFFECT_SIZE="-0.1376758280260309" ORDER="5699" O_E="-1.23" SE="0.5076730825668095" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="3.88" WEIGHT="15.601125854443103"/>
<IPD_DATA CI_END="1.2984048716399474" CI_START="0.3994942051723287" EFFECT_SIZE="0.7202119286624461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.11341013630244676" LOG_CI_START="-0.39848951592429205" LOG_EFFECT_SIZE="-0.1425396898109226" ORDER="5700" O_E="-3.63" SE="0.30069238966213185" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="11.06" WEIGHT="44.471250502613586"/>
<IPD_DATA CI_END="1.129286180082345" CI_START="0.11746842157445761" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05280401338743755" LOG_CI_START="-0.9300788668320061" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="5701" O_E="-3.03" SE="0.5773502691896257" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="3.0" WEIGHT="12.0627261761158"/>
<IPD_DATA CI_END="2.7796749767655395" CI_START="0.5931345515145797" EFFECT_SIZE="1.2840254166877414" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.4439940174830177" LOG_CI_START="-0.22684677653139174" LOG_EFFECT_SIZE="0.10857362047581293" ORDER="5702" O_E="1.61" SE="0.3940552031195503" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="6.44" WEIGHT="25.894652191395252"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2008-05-07 01:59:48 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Chronic GvHD (all grades)</NAME>
<IPD_OUTCOME CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="1" P_CHI2="0.012289606391364227" P_Q="0.7315192576393998" P_Z="0.23160966074352107" Q="0.1177212828666736" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="276" TOTAL_2="288" WEIGHT="200.0" Z="1.1962227656709636">
<NAME>All (in subsets)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="8.098111172291182" CI_END="1.8103482450652113" CI_START="0.7156596190144945" DF="1.0" EFFECT_SIZE="1.1382412465496619" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="49" I2="87.65144144449832" ID="CMP-008.01.01" LOG_CI_END="0.2577621253457686" LOG_CI_START="-0.14529348709503861" LOG_EFFECT_SIZE="0.05623431912536505" NO="1" P_CHI2="0.0044311690860272535" P_Z="0.5844417005651803" STUDIES="2" TAU2="0.0" TOTAL_1="103" TOTAL_2="112" WEIGHT="100.0" Z="0.5469083510009869">
<NAME>Subset with patients surviving &gt;100days</NAME>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5703" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="60.25784753363229"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5704" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="39.74215246636771"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="4.585284544343104" CI_END="1.9306103681999827" CI_START="0.8352765247441671" DF="2.0" EFFECT_SIZE="1.269879332450583" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="64" I2="56.3822052773712" ID="CMP-008.01.02" LOG_CI_END="0.2856946342066976" LOG_CI_START="-0.07816972416978514" LOG_EFFECT_SIZE="0.10376245501845624" NO="2" P_CHI2="0.10099939277937953" P_Z="0.26363627380256505" STUDIES="3" TAU2="0.0" TOTAL_1="173" TOTAL_2="176" WEIGHT="100.0" Z="1.1178378431514762">
<NAME>Subset with all patients</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5705" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="11.649154865235268"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5706" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="52.58108725445409"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5707" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="35.76975788031065"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="2" P_CHI2="0.012289606391364227" P_Q="1.0" P_Z="0.23160966074352096" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999997" Z="1.1962227656709639">
<NAME>All (no subsets)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5708" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5709" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5710" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5711" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5712" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" I2_Q="80.42167726056367" ID="CMP-008.03" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="3" P_CHI2="0.012289606391364227" P_Q="0.023820053643342054" P_Z="0.23160966074352107" Q="5.107689832825741" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999999" Z="1.1962227656709636">
<NAME>Type of randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="5.447611442323186" CI_START="1.2498423147967264" DF="0.0" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" NO="1" P_CHI2="1.0" P_Z="0.0106556398834435" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="17.84545683362698" Z="2.553793605041511">
<NAME>Truly randomised</NAME>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5713" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="7.693427166675217" CI_END="1.4415715681455705" CI_START="0.7258653512232822" DF="3.0" EFFECT_SIZE="1.0229305218955402" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="89" I2="61.00567490916436" ID="CMP-008.03.02" LOG_CI_END="0.1588362082082016" LOG_CI_START="-0.13914393390621596" LOG_EFFECT_SIZE="0.009846137150992853" NO="2" P_CHI2="0.0527913882471045" P_Z="0.8969415262081274" STUDIES="4" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="82.154543166373" Z="0.12952590777259093">
<NAME>Type of randomisation not reported</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5714" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5715" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5716" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5717" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" I2_Q="88.90953395859516" ID="CMP-008.04" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="4" P_CHI2="0.012289606391364227" P_Q="0.0026751930638282406" P_Z="0.23160966074352107" Q="9.016753635659926" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="288" WEIGHT="100.0" Z="1.1962227656709636">
<NAME>Concealment of allocation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.7147726921369028" CI_END="1.2010101874884858" CI_START="0.5232618044722711" DF="1.0" EFFECT_SIZE="0.7927438160558591" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="68" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="0.07954669129238902" LOG_CI_START="-0.2812809654558942" LOG_EFFECT_SIZE="-0.10086713708175257" NO="1" P_CHI2="0.39786442119056187" P_Z="0.2731700067580899" STUDIES="2" TAU2="0.0" TOTAL_1="140" TOTAL_2="148" WEIGHT="56.028190284419836" Z="1.0957915902871838">
<NAME>Concealment of allocation adequate</NAME>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5718" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.970551220739996"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5719" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.05763906367984"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="3.0695906717041295" CI_END="3.3083713386253812" CI_START="1.295128349142641" DF="2.0" EFFECT_SIZE="2.0699675142728013" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="45" I2="34.84473293340868" ID="CMP-008.04.02" LOG_CI_END="0.519614249751404" LOG_CI_START="0.11231280977811293" LOG_EFFECT_SIZE="0.3159635297647585" NO="2" P_CHI2="0.21549987878246224" P_Z="0.0023588883334495123" STUDIES="3" TAU2="0.0" TOTAL_1="136" TOTAL_2="140" WEIGHT="43.971809715580164" Z="3.0408787104100847">
<NAME>Concealment of allocation not reported</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5720" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872892"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5721" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.708029197080293"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5722" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.845456833626983"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" I2_Q="0.35565988615874466" ID="CMP-008.05" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="5" P_CHI2="0.012289606391364227" P_Q="0.31644864196672173" P_Z="0.23160966074352107" Q="1.0035692934064535" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999999" Z="1.1962227656709634">
<NAME>Blinding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="1.6797276414141693" CI_START="0.5289878657711257" DF="0.0" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" I2="0.0" ID="CMP-008.05.01" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" NO="1" P_CHI2="1.0" P_Z="0.8411412224424927" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="28.97055122073999" Z="0.20043393411828697">
<NAME>Patients and clinicians blinded</NAME>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5723" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="11.797547706094505" CI_END="1.935246170149894" CI_START="0.925270657318776" DF="3.0" EFFECT_SIZE="1.3381429280642019" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="70" I2="74.57098649026673" ID="CMP-008.05.02" LOG_CI_END="0.2867362166612525" LOG_CI_START="-0.033731210194581356" LOG_EFFECT_SIZE="0.1265025032333355" NO="2" P_CHI2="0.008109890411911569" P_Z="0.1217747892701844" STUDIES="4" TAU2="0.0" TOTAL_1="186" TOTAL_2="192" WEIGHT="71.02944877926" Z="1.5473669366280927">
<NAME>Patients and clinicians not blinded</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5724" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5725" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5726" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5727" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.80111699950096" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160608" I2_Q="44.843106567644014" ID="CMP-008.06" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="6" P_CHI2="0.012289606391364227" P_Q="0.17814772554889846" P_Z="0.23160966074352107" Q="1.8130100115707073" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999999" Z="1.1962227656709634">
<NAME>Statement of withdrawals in each group</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.10044182877457213" CI_END="1.5278194262611853" CI_START="0.5371029191524086" DF="1.0" EFFECT_SIZE="0.905867691102095" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="52" I2="0.0" ID="CMP-008.06.01" LOG_CI_END="0.1840720277916741" LOG_CI_START="-0.2699424872291591" LOG_EFFECT_SIZE="-0.04293522971874255" NO="1" P_CHI2="0.7513000912890999" P_Z="0.7108612747600784" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="116" WEIGHT="35.38887490561288" Z="0.3706996192085522">
<NAME>Withdrawals stated</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5728" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5729" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="10.88766515915568" CI_END="2.084898697890405" CI_START="0.961782957458825" DF="2.0" EFFECT_SIZE="1.4160579210113855" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="61" I2="81.63058864537035" ID="CMP-008.06.02" LOG_CI_END="0.3190849581030572" LOG_CI_START="-0.016922922778083518" LOG_EFFECT_SIZE="0.15108101766248688" NO="2" P_CHI2="0.0043229018571734334" P_Z="0.07797841759700966" STUDIES="3" TAU2="0.0" TOTAL_1="165" TOTAL_2="172" WEIGHT="64.6111250943871" Z="1.7625381439840757">
<NAME>Withdrawals not stated</NAME>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5730" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5731" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5732" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" I2_Q="76.14828114663548" ID="CMP-008.07" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="7" P_CHI2="0.012289606391364227" P_Q="0.040601639198560746" P_Z="0.23160966074352107" Q="4.19256996171972" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999999" Z="1.1962227656709634">
<NAME>MTX part of prophylaxis regimen</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="8.60854703778124" CI_END="1.4562413848139926" CI_START="0.7274729436238668" DF="3.0" EFFECT_SIZE="1.0292600287767575" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="101" I2="65.15091354169778" ID="CMP-008.07.01" LOG_CI_END="0.16323336907305652" LOG_CI_START="-0.1381831544429004" LOG_EFFECT_SIZE="0.012525107315078126" NO="1" P_CHI2="0.034974766226881004" P_Z="0.870605616744234" STUDIES="4" TAU2="0.0" TOTAL_1="214" TOTAL_2="228" WEIGHT="80.29197080291969" Z="0.16288927331319744">
<NAME>MTX included</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5733" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5734" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5735" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5736" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.0" CI_END="4.692193362422934" CI_START="1.1560767613439566" DF="0.0" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" I2="0.0" ID="CMP-008.07.02" LOG_CI_END="0.671375900822639" LOG_CI_START="0.0629866713866911" LOG_EFFECT_SIZE="0.367181286104665" NO="2" P_CHI2="1.0" P_Z="0.017991403792185983" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="19.70802919708029" Z="2.3657949935420675">
<NAME>MTX not included</NAME>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5737" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.801116999500957" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" I2_Q="59.77859055434877" ID="CMP-008.08" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="8" P_CHI2="0.012289606391364338" P_Q="0.11484620902287723" P_Z="0.23160966074352107" Q="2.4862380850955503" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999999" Z="1.1962227656709636">
<NAME>Timing of steroid administration</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="2.872234773652422" CI_END="3.536030013299485" CI_START="1.0004809601392413" DF="1.0" EFFECT_SIZE="1.8808856166144297" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="33" I2="65.18390456193909" ID="CMP-008.08.01" LOG_CI_END="0.5485159425839743" LOG_CI_START="2.088281195117684E-4" LOG_EFFECT_SIZE="0.2743623853517431" NO="1" P_CHI2="0.09011977889872402" P_Z="0.04982574483805059" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="80" WEIGHT="24.26378051849987" Z="1.96145692739053">
<NAME>MTX overlapping with steroids</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5738" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5739" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="7.442644140752985" CI_END="1.500040401722702" CI_START="0.734096705148299" DF="2.0" EFFECT_SIZE="1.049368722849107" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="80" I2="73.12782981187038" ID="CMP-008.08.02" LOG_CI_END="0.1761029563949703" LOG_CI_START="-0.13424672517132685" LOG_EFFECT_SIZE="0.02092811561182169" NO="2" P_CHI2="0.0242020378059985" P_Z="0.79152074396928" STUDIES="3" TAU2="0.0" TOTAL_1="202" TOTAL_2="208" WEIGHT="75.73621948150011" Z="0.2643363618512276">
<NAME>MTX not overlapping with steroids</NAME>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5740" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5741" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5742" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" I2_Q="76.1482811466355" ID="CMP-008.09" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="9" P_CHI2="0.012289606391364227" P_Q="0.04060163919856086" P_Z="0.23160966074352107" Q="4.192569961719721" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999999" Z="1.1962227656709636">
<NAME>Risk status of patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="0.0" CI_END="4.692193362422934" CI_START="1.1560767613439566" DF="0.0" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" I2="0.0" ID="CMP-008.09.01" LOG_CI_END="0.671375900822639" LOG_CI_START="0.0629866713866911" LOG_EFFECT_SIZE="0.367181286104665" NO="1" P_CHI2="1.0" P_Z="0.017991403792185983" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="19.70802919708029" Z="2.3657949935420675">
<NAME>Only high risk patients included in study</NAME>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5743" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="8.608547037781237" CI_END="1.4562413848139928" CI_START="0.7274729436238669" DF="3.0" EFFECT_SIZE="1.0292600287767575" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="101" I2="65.15091354169776" ID="CMP-008.09.02" LOG_CI_END="0.16323336907305658" LOG_CI_START="-0.13818315444290033" LOG_EFFECT_SIZE="0.012525107315078126" NO="2" P_CHI2="0.034974766226881226" P_Z="0.8706056167442339" STUDIES="4" TAU2="0.0" TOTAL_1="214" TOTAL_2="228" WEIGHT="80.29197080291969" Z="0.16288927331319752">
<NAME>High- and low-risk included in study</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5744" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5745" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5746" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5747" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="24.768658562359377" CI_END="1.5995194210688473" CI_START="0.9941842480547992" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="1.2610380695618906" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="183" I2="67.70111720076153" I2_Q="0.0" ID="CMP-008.10" LOG_CI_END="0.20398951757537934" LOG_CI_START="-0.002533122143583932" LOG_EFFECT_SIZE="0.1007281977158977" NO="10" P_CHI2="0.0017012284126671773" P_Q="0.6801175386257063" P_Z="0.05589110603893371" Q="0.16999385676391654" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="462" TOTAL_2="480" WEIGHT="200.0" Z="1.9118837529816974">
<NAME>Chao sensitivity (differing including criteria)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="11.797547706094505" CI_END="1.935246170149894" CI_START="0.925270657318776" DF="3.0" EFFECT_SIZE="1.338142928064202" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="70" I2="74.57098649026673" ID="CMP-008.10.01" LOG_CI_END="0.2867362166612525" LOG_CI_START="-0.033731210194581356" LOG_EFFECT_SIZE="0.12650250323333556" NO="1" P_CHI2="0.008109890411911569" P_Z="0.12177478927018433" STUDIES="4" TAU2="0.0" TOTAL_1="186" TOTAL_2="192" WEIGHT="100.0" Z="1.5473669366280929">
<NAME>without Chao</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5748" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="9.036144578313253"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5749" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="27.7462792345854"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5750" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="38.093550673281364"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5751" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="25.124025513819987"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="12.801116999500957" CI_END="1.649924892232663" CI_START="0.8858853635843829" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" ID="CMP-008.10.02" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="2" P_CHI2="0.012289606391364338" P_Z="0.23160966074352096" STUDIES="5" TAU2="0.0" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999999" Z="1.1962227656709639">
<NAME>all</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5752" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5753" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5754" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5755" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5756" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="25.0246811347631" CI_END="1.5354049789150408" CI_START="0.9819799655778958" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_SIZE="1.227899396670233" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="217" I2="68.03156069434675" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="0.18622294457604086" LOG_CI_START="-0.007897372628248833" LOG_EFFECT_SIZE="0.0891627859738961" MODIFIED="2008-05-07 01:59:48 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0015396626039788641" P_Q="0.8880807993324112" P_Z="0.07178329418258038" Q="0.0198058069366418" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="531" TOTAL_2="556" WEIGHT="200.0" Z="1.8004900443901353">
<NAME>Atkinson sensitivity (median follow up &lt; 1year)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="12.203758328325499" CI_END="1.7217283907443237" CI_START="0.9052522160294383" DF="3.0" EFFECT_SIZE="1.2484384010122795" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="104" I2="75.41740897116212" ID="CMP-008.11.01" LOG_CI_END="0.23596464090121327" LOG_CI_START="-0.043230403370184314" LOG_EFFECT_SIZE="0.09636711876551442" NO="1" P_CHI2="0.00671680375713013" P_Z="0.1760541780527811" STUDIES="4" TAU2="0.0" TOTAL_1="255" TOTAL_2="268" WEIGHT="100.0" Z="1.353004546102912">
<NAME>without Atkinson</NAME>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5757" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="30.95750403442711"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5758" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="21.05970952124798"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5759" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="28.91339429800968"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5760" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="19.069392146315224"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" ID="CMP-008.11.02" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="2" P_CHI2="0.012289606391364227" P_Z="0.23160966074352107" STUDIES="5" TAU2="0.0" TOTAL_1="276" TOTAL_2="288" WEIGHT="99.99999999999999" Z="1.1962227656709634">
<NAME>all</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5761" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872891"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5762" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.97055122073999"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5763" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.70802919708029"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5764" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.057639063679833"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5765" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.84545683362698"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="20.100758820858424" CI_END="1.525784381528525" CI_START="0.9131701071699017" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_SIZE="1.1803815854199713" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="150" I2="70.15038062257709" I2_Q="0.0" ID="CMP-008.12" LOG_CI_END="0.18349316498936044" LOG_CI_START="-0.039448313677254584" LOG_EFFECT_SIZE="0.07202242565605288" NO="12" P_CHI2="0.002657317784666824" P_Q="0.7891944808753023" P_Z="0.20538657769994473" Q="0.07147964639262128" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="388" TOTAL_2="400" WEIGHT="200.0" Z="1.2663534951804005">
<NAME>Type of data sensitivity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="7.228162174964844" CI_END="1.7670998367287647" CI_START="0.7117269786689018" DF="1.0" EFFECT_SIZE="1.1214689598028442" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="37" I2="86.16522463395249" ID="CMP-008.12.01" LOG_CI_END="0.247261086753819" LOG_CI_START="-0.14768657152734685" LOG_EFFECT_SIZE="0.04978725761323609" NO="1" P_CHI2="0.007176889167912148" P_Z="0.6212018982533178" STUDIES="2" TAU2="0.0" TOTAL_1="112" TOTAL_2="112" WEIGHT="100.00000000000001" Z="0.4941476662281745">
<NAME>Data derived from Kaplan-Meier</NAME>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5766" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="42.14208826695372"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5767" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="57.85791173304629"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="12.801116999500959" CI_END="1.649924892232663" CI_START="0.8858853635843829" DF="4.0" EFFECT_SIZE="1.2089848274657777" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="113" I2="68.75272681160607" ID="CMP-008.12.02" LOG_CI_END="0.21746417474037374" LOG_CI_START="-0.0526224735800154" LOG_EFFECT_SIZE="0.08242085058017917" NO="2" P_CHI2="0.012289606391364227" P_Z="0.23160966074352096" STUDIES="5" TAU2="0.0" TOTAL_1="276" TOTAL_2="288" WEIGHT="100.0" Z="1.1962227656709639">
<NAME>all</NAME>
<IPD_DATA CI_END="2.5829849414336272" CI_START="0.22183788107309843" EFFECT_SIZE="0.7569702149037022" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4121218742835207" LOG_CI_START="-0.6539642916570961" LOG_EFFECT_SIZE="-0.12092120868678774" ORDER="5768" O_E="-0.71" SE="0.6262242910851495" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.55" WEIGHT="6.418323684872892"/>
<IPD_DATA CI_END="1.6797276414141693" CI_START="0.5289878657711257" EFFECT_SIZE="0.9426322401172411" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.22523886897589687" LOG_CI_START="-0.2765542899479579" LOG_EFFECT_SIZE="-0.025657710486030515" ORDER="5769" O_E="-0.68" SE="0.2947557854680691" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="11.51" WEIGHT="28.970551220739996"/>
<IPD_DATA CI_END="4.692193362422934" CI_START="1.1560767613439564" EFFECT_SIZE="2.3290632679318772" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.671375900822639" LOG_CI_START="0.06298667138669102" LOG_EFFECT_SIZE="0.367181286104665" ORDER="5770" O_E="6.62" SE="0.35737084494593163" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="7.83" WEIGHT="19.708029197080293"/>
<IPD_DATA CI_END="1.1973478579308716" CI_START="0.3622365492135873" EFFECT_SIZE="0.6585766138158562" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.07822034157819577" LOG_CI_START="-0.44100773204249355" LOG_EFFECT_SIZE="-0.18139369523214893" ORDER="5771" O_E="-4.49" SE="0.30499714066520933" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="10.75" WEIGHT="27.05763906367984"/>
<IPD_DATA CI_END="5.447611442323186" CI_START="1.2498423147967264" EFFECT_SIZE="2.609340011417896" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.7362061234141092" LOG_CI_START="0.09685522410129617" LOG_EFFECT_SIZE="0.4165306737577027" ORDER="5772" O_E="6.8" SE="0.37555788309433985" STUDY_ID="STD-Storb-1990" TOTAL_1="53" TOTAL_2="60" VAR="7.09" WEIGHT="17.845456833626983"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Chronic GvHD (limited)</NAME>
<IPD_OUTCOME CHI2="0.24297978978817547" CI_END="1.177914380077876" CI_START="0.3237075542106851" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.6174947635766675" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.07111372371839486" LOG_CI_START="-0.489847165553452" LOG_EFFECT_SIZE="-0.20936672091752853" NO="1" P_CHI2="0.6220622177048175" P_Q="1.0" P_Z="0.1434592407917591" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="148" WEIGHT="100.0" Z="1.4630297420280391">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.358133153534006" CI_START="0.19504159254069525" EFFECT_SIZE="0.5146770377116013" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.13294235095347046" LOG_CI_START="-0.7098727656386726" LOG_EFFECT_SIZE="-0.28846520734260106" ORDER="5773" O_E="-2.71" SE="0.49507377148833714" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="4.08" WEIGHT="44.299674267100976"/>
<IPD_DATA CI_END="1.6957299039217881" CI_START="0.3004189713234754" EFFECT_SIZE="0.7137432545240896" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.22935667894797493" LOG_CI_START="-0.5222726452998757" LOG_EFFECT_SIZE="-0.14645798317595035" ORDER="5774" O_E="-1.73" SE="0.44151078568834795" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="5.13" WEIGHT="55.70032573289902"/>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Chronic GvHD (extensive)</NAME>
<IPD_OUTCOME CHI2="0.9216384687560495" CI_END="1.7816888470810135" CI_START="0.6195286866302245" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="1.050622363847172" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.25083186143220465" LOG_CI_START="-0.20793857926892048" LOG_EFFECT_SIZE="0.02144664108164209" NO="1" P_CHI2="0.3370452736423427" P_Q="1.0" P_Z="0.8546025398959677" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="148" WEIGHT="100.0" Z="0.18324913891634037">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.217341173593875" CI_START="0.6629142937159133" EFFECT_SIZE="1.2123972773064933" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="31" LOG_CI_END="0.3458325214453193" LOG_CI_START="-0.178542616651467" LOG_EFFECT_SIZE="0.08364495239692613" ORDER="5775" O_E="2.03" SE="0.30802055181684873" STUDY_ID="STD-Chao-2000" TOTAL_1="90" TOTAL_2="96" VAR="10.54" WEIGHT="76.5432098765432"/>
<IPD_DATA CI_END="1.9593180458376562" CI_START="0.2212394257193501" EFFECT_SIZE="0.6583907648674018" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.29210493846593644" LOG_CI_START="-0.6551374775181903" LOG_EFFECT_SIZE="-0.18151626952612693" ORDER="5776" O_E="-1.35" SE="0.5564148840746572" STUDY_ID="STD-Ruutu-2000" TOTAL_1="50" TOTAL_2="52" VAR="3.23" WEIGHT="23.45679012345679"/>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Deaths due to relapse</NAME>
<DICH_OUTCOME CHI2="2.891873636580482" CI_END="1.2096592114977731" CI_START="0.5736898462301346" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8330481420872526" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.08266303691818595" LOG_CI_START="-0.2413228366527635" LOG_EFFECT_SIZE="-0.07932989986728874" METHOD="MH" NO="1" P_CHI2="0.4085984519266591" P_Q="0.0" P_Z="0.3371468022634131" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.0" Z="0.959818061962541">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.603705054779926" CI_START="0.5494064140866008" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8197876678702763" LOG_CI_START="-0.2601062746821901" LOG_EFFECT_SIZE="0.2798406965940431" ORDER="5777" O_E="0.0" SE="0.6343350474165466" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.4023809523809524" WEIGHT="6.410551874683382"/>
<DICH_DATA CI_END="1.6104245462236746" CI_START="0.43680029880715515" EFFECT_SIZE="0.8387096774193549" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.20694038148333685" LOG_CI_START="-0.35971707321024626" LOG_EFFECT_SIZE="-0.07638834586345469" ORDER="5778" O_E="0.0" SE="0.3328573938866499" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="0.11079404466501241" WEIGHT="31.802542672609597"/>
<DICH_DATA CI_END="1.7051989709866664" CI_START="0.4743542154580623" EFFECT_SIZE="0.89937106918239" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.23177506189736324" LOG_CI_START="-0.3238972356081426" LOG_EFFECT_SIZE="-0.046061086855389656" ORDER="5779" O_E="0.0" SE="0.3264046581769683" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="0.10654000087962351" WEIGHT="30.710161427881367"/>
<DICH_DATA CI_END="1.1970031371365741" CI_START="0.2441855084218787" EFFECT_SIZE="0.5406392694063927" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.07809528861803787" LOG_CI_START="-0.6122801135244724" LOG_EFFECT_SIZE="-0.2670924124532173" ORDER="5780" O_E="0.0" SE="0.4055299286318666" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="0.16445452301616684" WEIGHT="31.076744024825658"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Deaths due to GvHD</NAME>
<DICH_OUTCOME CHI2="0.48393546980280794" CI_END="2.113195210657666" CI_START="0.47552022931313004" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0024305817139367" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.3249396177316798" LOG_CI_START="-0.3228310028229101" LOG_EFFECT_SIZE="0.001054307454384858" METHOD="MH" NO="1" P_CHI2="0.7850815156751525" P_Q="0.0" P_Z="0.9949094907347963" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="135" WEIGHT="100.0" Z="0.006380050510649193">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<DICH_DATA CI_END="66.4433184667098" CI_START="0.12341968180365896" EFFECT_SIZE="2.8636363636363638" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8224513148659036" LOG_CI_START="-0.9086155776031525" LOG_EFFECT_SIZE="0.4569178686313755" ORDER="5781" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.5735930735930737" WEIGHT="4.104856575287141"/>
<DICH_DATA CI_END="3.1736967935419944" CI_START="0.29508945391373176" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5015654330736472" LOG_CI_START="-0.5300463113028677" LOG_EFFECT_SIZE="-0.014240439114610228" ORDER="5782" O_E="0.0" SE="0.6059738452072572" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="0.36720430107526886" WEIGHT="40.77327730892518"/>
<DICH_DATA CI_END="2.4743386382545527" CI_START="0.3197576353324563" EFFECT_SIZE="0.889487870619946" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.39345913695071444" LOG_CI_START="-0.49517907642503134" LOG_EFFECT_SIZE="-0.050859969737158416" ORDER="5783" O_E="0.0" SE="0.5219904853670126" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="0.27247406681368946" WEIGHT="55.12186611578768"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2008-05-14 15:19:18 +0200" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Death due to VOD</NAME>
<DICH_OUTCOME CHI2="0.04237658880312369" CI_END="1.2149296093132504" CI_START="0.04075970837386316" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22253129346314326" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.08455111647555943" LOG_CI_START="-1.389768931929475" LOG_EFFECT_SIZE="-0.6526089077269578" METHOD="MH" MODIFIED="2008-05-14 15:19:18 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8369037104717273" P_Q="0.0" P_Z="0.08271262118944554" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="80" WEIGHT="100.0" Z="1.7351591420310948">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9210092192755392" CI_START="0.020819296384186323" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.5933978634365971" LOG_CI_START="-1.6815339521371484" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="5784" O_E="0.0" SE="1.3363062095621219" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="6" VAR="1.7857142857142856" WEIGHT="23.85257301808067"/>
<DICH_DATA CI_END="1.6933642156143998" CI_START="0.024273216671671927" EFFECT_SIZE="0.20273972602739726" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22875037796698677" LOG_CI_START="-1.6148726674179839" LOG_EFFECT_SIZE="-0.6930611447254985" ORDER="5785" O_E="0.0" SE="1.08295330294039" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="1.1727878563495" WEIGHT="76.14742698191934"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Deaths due to infections</NAME>
<DICH_OUTCOME CHI2="5.017569567437276" CI_END="2.096251752131466" CI_START="0.8687436279447001" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3494833649334563" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" I2="40.21009654815309" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.3214434386150768" LOG_CI_START="-0.06110836785058261" LOG_EFFECT_SIZE="0.1301675353822471" METHOD="MH" NO="1" P_CHI2="0.17051530505002788" P_Q="0.0" P_Z="0.18226961397178543" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.0" Z="1.333799380860847">
<NAME>All</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no steroids</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.218244504526753" CI_START="0.06379335213776025" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1528459783163107" LOG_CI_START="-1.1952245764561868" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="5786" O_E="0.0" SE="1.3792682670100667" STUDY_ID="STD-Atkinson-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.9023809523809523" WEIGHT="3.6461132730650156"/>
<DICH_DATA CI_END="2.0290727696998556" CI_START="0.5352921393022264" EFFECT_SIZE="1.0421836228287842" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.30729762264319527" LOG_CI_START="-0.27140913412961315" LOG_EFFECT_SIZE="0.01794424425679104" ORDER="5787" O_E="0.0" SE="0.33993521357299417" STUDY_ID="STD-Deeg-1997" TOTAL_1="62" TOTAL_2="60" VAR="0.11555594942691716" WEIGHT="47.029453248129"/>
<DICH_DATA CI_END="2.2464115044281754" CI_START="0.029961554525251437" EFFECT_SIZE="0.25943396226415094" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.35148931458471855" LOG_CI_START="-1.5234356574537338" LOG_EFFECT_SIZE="-0.5859731714345076" ORDER="5788" O_E="0.0" SE="1.101340209603681" STUDY_ID="STD-Ruutu-2000" TOTAL_1="53" TOTAL_2="55" VAR="1.21295025728988" WEIGHT="13.973552279312662"/>
<DICH_DATA CI_END="4.375513696379568" CI_START="1.1366690456904727" EFFECT_SIZE="2.23013698630137" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" LOG_CI_END="0.6410290476226793" LOG_CI_START="0.055634033242773724" LOG_EFFECT_SIZE="0.3483315404327265" ORDER="5789" O_E="0.0" SE="0.34386392919881204" STUDY_ID="STD-Storb-1990" TOTAL_1="73" TOTAL_2="74" VAR="0.11824240180404563" WEIGHT="35.35088119949333"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flowchart with numbers of RCTs identified, included and excluded (following the requirements of the QUOROM statement (Moher 1999))</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-05-14 11:37:29 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-05-14 11:37:28 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-04-30 01:11:13 +0200" MODIFIED_BY="[Empty name]">Cochrane Haematological Malignancies Group trials register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-14 11:37:28 +0200" MODIFIED_BY="[Empty name]">
<P>1. Graft-vs-Host-Disease.ME<BR/>2. gvhd*</P>
<P>3. graft*</P>
<P>4. host*</P>
<P>5. #1 or #2 or #3 or #4</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-05-14 11:37:28 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-04-30 01:12:29 +0200" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-14 11:37:28 +0200" MODIFIED_BY="[Empty name]">
<P>1. GRAFT VS HOST DISEASE (MeSH)<BR/>2. GRAFT VS HOST REACTION explode (MeSH)<BR/>3. graft versus host*<BR/>4. graft-versus host*<BR/>5. graft-versus-host*<BR/>6. graft vs host*<BR/>7. graft-vs host*<BR/>8. graft-vs-host*<BR/>9. graft v host*<BR/>10. graft-v host*<BR/>11. graft-v-host*<BR/>12. gvhd<BR/>13. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-05-14 11:37:28 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-04-30 01:14:05 +0200" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-14 11:37:28 +0200" MODIFIED_BY="[Empty name]">
<P>For <B>MEDLINE</B> phase 1 and 2 of the revised version of the original Cochrane methodological search strategy was adapted and applied using the interface OVID (capital letters indicate MeSH terms) (Dickersin 1994; Robinson 2002):<BR/>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. Randomized Controlled Trials/<BR/>4. Random Allocation/<BR/>5. Double Blind Method/<BR/>6. Single Blind Method/<BR/>7. or/1-6<BR/>8. Animals/ not (Animals/ and Human/)<BR/>9. 7 not 8<BR/>10. clinical trial.pt<BR/>11. exp Clinical Trials/<BR/>12. (clinic$ adj25 trial$).tw.<BR/>13. Cross-over Studies/<BR/>14. (crossover or cross over or cross-over).tw.<BR/>15. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.<BR/>16. Placebos/<BR/>17. placebo$.tw.<BR/>18. random$.tw.<BR/>19. Research Design/<BR/>20. (latin adj square).tw.<BR/>21. or/10-20<BR/>22. 21 not 8<BR/>23. 9 or 22</P>
<P>24. Graft vs Host Disease/<BR/>25. graft versus host$.tw.<BR/>26. graft vs host$.tw.<BR/>27. graft v host$.tw.<BR/>28. gvhd.tw.<BR/>29. or/24-28</P>
<P>30. 23 and 29</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-05-14 11:37:29 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-04-30 01:18:40 +0200" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-14 11:37:29 +0200" MODIFIED_BY="[Empty name]">
<P>The database<B> LILACS</B> (http://www.bireme.br/bvs/I/ibd.htm) was kindly searched by Bernardo GO Soares, Co-director of the Brazilian Cochrane Centre, on the basis of the first two stages of the methodological tri-language search developed by Castro et al. (Castro 1997; Castro 1999):<BR/>GvHD OR (Graft AND host) OR GCHD OR DECH$ OR (enxert$ AND hosped$) OR (injert$ AND huesped$) OR DECH OR EICH OR (doenca ENXERTO hospedeiro) [Palavras] and ((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh pro! spective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct animal))) [Palavras]</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>